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Abstract 
 
 Progressive Multifocal Leukoencephalopathy (PML) is caused by lytic infection of 
oligodendrocytes by JC Virus (JCV).  JCV Encephalopathy (JCVE) is a newly identified 
disease characterized by JCV infection of cortical pyramidal neurons.  JCVCPN was 
isolated from the brain of a JCVE patient.  JCVCPN contains a unique 143 base pair 
deletion in the agnogene and has an archetype-like regulatory region (RR), of the type 
typically found in the kidneys.  In this dissertation, we studied the JCVCPN virus to better 
understand the role of the agnogene and the RR in JCV replication.  We used kidney, 
glial and neuronal cell lines to compare the replication of JCVCPN to the prototype virus 
JCVMad-1.  JCVCPN was able to replicate viral DNA in all cell lines tested, but was unable 
to establish the high level of infection seen with JCVMad-1.  Levels of VP1 capsid protein 
were undetectable in JCVCPN transfected cells, and few infectious virions were 
produced. JCVCPN did not have a replication advantage in the neuronal cell line tested.  
To determine if the agnogene deletion or the archetype-like RR was responsible for the 
observed phenotype of JCVCPN, we generated a series of chimeric viruses between 
JCVCPN and JCVMad-1.  We found that the phenotype of JCVCPN was due predominantly 
to the deletion in the agnogene, in particular the loss of the DNA and not the lack of a 
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full length agnoprotein.  To further study the role of the agnogene DNA in JCV 
replication, we introduced a series of small agnogene deletions into a virus with a start 
codon mutation which prevents agnoprotein expression.  We characterized the 
replication of these additional mutants and found that nucleotides 376-396 are crucial 
for the expression of VP1 capsid protein.  Previous studies have provided evidence for 
the binding of host cell proteins to the agnogene DNA.  We used DNA-
Immunoprecipitations with the agnogene to identify candidate binding proteins, but were 
unable to confirm any candidate proteins as binding specifically to the JCV agnogene.  
Studying this naturally occurring pathogenic variant of JCV provided a valuable tool for 
understanding the functions of the agnogene and RR form in JCV replication. 
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CHAPTER 1: INTRODUCTION 
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JC VIRUS 
 The human polyomavirus JC Virus (JCV) is in the polyomaviridae family, and is 
the etiological agent of Progressive Multifocal Leukoencephalopathy (PML).  
Polyomaviruses are small non-enveloped DNA viruses with a circular double stranded 
DNA genome.  This family also includes the human polyomavirus BK Virus (BKV), 
which causes BKV nephropathy, and Simian Virus 40 (SV40).  JCV is 75% homologous 
to BKV and 69% homologous to SV40 (1).  Since 2007, numerous new polyomaviruses 
have been discovered in humans, non-human primates and other species.  In 2007, KI 
polyomavirus (KIPyV) and WU polyomavirus (WUPyV) were isolated from respiratory 
tract samples (2, 3).  In 2008, Merkel cell polyomavirus (MCPyV) was isolated from a 
human Merkel cell carcinoma (4).  Since then, HPyV6, HPyV7, Trichodysplasia 
spinulosa-associated virus (TSPyV), HPyV9, HPyV10, MWPyV, MxPyV, and Saint 
Louis polyomavirus (STLPyV) have been isolated from human samples (5-11).  Some of 
these viruses, such as JCV, BKV, MCPyV and TSPyV, have been associated with 
human diseases (4, 6, 12).  Others have not, and may be non-pathogenic.  This family 
of viruses will certainly continue to grow as new viruses and associated diseases are 
identified. 
 
Genome Organization, Proteins and Virion Structure 
 The first full JCV sequence was published in 1984 (1).  This sequence was 
named Mad-1, after Madison, Wisconsin, where it was isolated.  It is the most 
commonly used prototype JCV strain in in vitro studies.  The genome of JCVMad-1 is 
5,130 nucleotides long, and contains three regions (Figure 1.1).  The early region  
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encodes the early regulatory proteins, Large T Antigen (T Ag) and small t antigen (t ag).  
Three additional T forms, T’135, T’136 and T’165 have been identified as being 
expressed from alternatively spliced early transcripts (13).  The late region encodes the 
structural proteins VP1, VP2 and VP3, as well as the agnoprotein, which was named 
due to the unknown nature of its function.  Finally, the regulatory region (RR) contains 
the origin of replication and the promoters for the early and late transcripts.  The early 
and late coding regions are highly conserved and the RR is hypervariable (14, 15). 
Figure 1.1 Schematic of JCV genome organization.  This diagram shows the 
JCVMad-1 genome.  The early region is transcribed in the counter clockwise direction 
and encodes the Large T Ag, small t ag and T’ proteins T’135, T’136 and T’165.  
The late region is transcribed in the clockwise direction and encodes the structural 
proteins VP1, VP2 and VP3 and the agnoprotein.  The RR contains the origin of 
replication (ORI) and early and late promoters.  The location of the JCV miRNA 
MIR-J1 is indicated.  The unique EcoRI site used for cloning is indicated at 1722.  
(Adapted from Ferenzy et al. 2012 (14)).  
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 Large T Ag is a multifunctional phosphoprotein that is involved in numerous 
processes important for viral replication. Large T Ag is involved in the modulation of 
both viral DNA replication initiation and activation of late gene transcription through 
interactions with host cell proteins (16-19).  Large T Ag can bind to the JCV origin of 
replication, which activates replication of the viral genome (20, 21).  It has a helicase 
domain which acts to unwind the viral genome during replication (20).  Large T Ag 
autoregulates its own expression by binding to the RR and down regulating early gene 
expression (21).  It has the ability to transform cells by altering cell cycle regulation (20).  
Large T Ag can bind to the host cell protein Rb, which induces expression of the S 
phase cellular genes required for viral replication (22).  SV40 Large T Ag can substitute 
for JCV Large T Ag during replication in cell culture.  Many of the JCV-permissive cell 
lines are transformed with SV40 Large T Ag.  Small t ag promotes the expression of 
host cell genes involved in cell survival and promotes entry into S phase of the cell cycle 
(23).   
 The structural proteins VP1, VP2 and VP3 are expressed from the late region of 
the virus, and form the capsid of the viral particle.  VP1 capsid proteins form pentamers, 
each of which is associated with one monomer of either VP2 or VP3 (24).  Seventy-two 
of these pentamers make up the viral capsid, which contains the viral genome 
packaged as a mini-chromosome on host-cell histones (Figure 1.2A) (14, 24).  JCV 
virions have a T=7 icosahedral symmetry and are 42 nm in diameter (Figure 1.2B) (24).  
VP2 and VP3 have been shown to be essential for JCV propagation, and likely play a 
role in virion assembly (25, 26).  In addition to the capsid proteins, the agnoprotein is 
expressed from the leader region of the late transcript (27).  It is a multifunctional, 
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auxiliary protein which plays a role in viral processes, such as regulation of DNA 
replication and gene expression, and alters host cell processes (27).   
 
Replication Cycle 
 JCV infection begins with binding of the virion to receptors on the cell surface 
(Figure 1.3).  The 2,6-linked glycan, lactoseries tetrasaccharide c (LSTc) acts as the 
attachment factor for JCV (28).  The JCV cellular receptor is the serotonin receptor 
5HT-2α, which facilitates JCV entry (29, 30).  Following receptor binding, JCV is 
internalized through clathrin-mediated endocytosis.  The virion is then trafficked to the 
early endosome, the late endosome and finally the endoplasmic reticulum (ER) (14).  
From the ER, the virus enters the cytoplasm and then the nucleus (14, 31).  The virus 
then uncoats, and the early coding region is transcribed leading to the production of 
Large T Ag and small t ag.  Large T Ag activates replication of the viral genomic DNA 
Figure 1.2 The JCV virion. (A) The JCV virion is made up of 72 pentamers of 
VP1, each of which is associated with one monomer of VP2 or VP3.  The DNA 
genome is packaged as a mini-chromosome on host cell histones. (Adapted from 
Flint et al. 2004 (31)).  (B) Negative Stain of JCV virions in primary human fetal glial 
cells.  Bar is 100nm. (Adapted from Padgett et al. 1971 (47)).  
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and transcription of the late coding region, leading to the production of the structural 
proteins VP1, VP2 and VP3 and the agnoprotein.  The structural proteins are 
transported into the nucleus where they encapsidate viral genomes to form mature viral 
particles.  These virions then exit the nucleus and are released from the cell (14).   
 
Figure 1.3 JCV Replication Cycle.  JCV binds to the 5HT-2α receptor and the 
attachment factor LSTc (1) and enters the cell through clathrin-mediated endocytosis 
(2). The virus is trafficked through the early endosome, late endosome and 
endoplasmic reticulum (3).  The virus enters the nucleus (4) and uncoats (5).  Early 
mRNA is transcribed from the viral DNA and transported into the cytoplasm (6).  
Large T Ag and small t ag are translated from the early transcript (7).  Large T Ag is 
transported to the nucleus where it actives viral DNA replication and production of 
the late transcript (9-11).  The late transcript is transported into the cytoplasm and 
VP1, VP2 and VP3 are produced (12).  The capsid proteins are transported into the 
nucleus (13) and viral particles are formed (14).  These virions are released from the 
nucleus and the cell (15).  
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JCV Tropism and RR Variation 
 Polyomaviruses exhibit highly species and tissue-specific patterns of infection.  
Much of this specificity is due to variations in the structure of the RR of the viruses.  JCV 
exhibits tropism for kidney epithelial cells and oligodendrocytes (32).  More recently, 
JCV has been found to also infect neurons (33, 34).   
 The RR of JCV is hypervariable and can display unique changes in each 
individual (35).  The sequence elements which make up different forms of the RR can 
be defined as 6 blocks of sequences, called A-F (Figure 1.4) (35-38).  Analysis of the 
sequence of different forms of the RR from individuals has led to hypotheses on how 
the virus emerges from latency and becomes pathogenic.  The kidneys and urine 
usually contain JCV with a well conserved, non-pathogenic RR which is called the 
“archetype” (Figure 1.4) (39).  This form contains one copy of each of the elements A-F.  
The 23-base pair (bp) B block and 66-bp D block are also referred to as the 23-bp insert 
and 66-bp insert, respectively.   Some forms of the RR may be classified as “archetype-
like” when they have only one copy of the A, C and E blocks, but also have mutations in 
these blocks or the insert blocks B and D.  The JCV RR detected in the brain and the 
cerebrospinal fluid (CSF) of PML patients usually has duplications, tandem repeats, and 
deletions, and has been called “rearranged” compared to the archetype (Figure 1.4).  
The prototype rearranged strain is Mad-1, which contains 2 repeats of a 98-bp element 
made up of the A, C and E blocks followed by one F block (37, 38).    
 The RR controls transcription of both the early and late genes, and contains 
binding sites for host cell transcription factors.  The expression of both the early and late 
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genes is dependent on the interactions between the RR sequence and these 
transcription factors.  Numerous transcription factors have been shown to activate viral 
transcription, including NF-1, Oct-6/tst-1/SCIP, DDX1, NFAT4, EGF-1, YB-1, Pur-α, 
LCP-1, GF-1, Sp1 and Spi-B.  Conversely, AP-1, C/EBPb and NF-1A have been shown 
to repress transcription.  Different forms of the regulatory region have different numbers 
and types of transcription factor binding sites, which is thought to contribute to the 
neurotropism and neurovirulence of JCV (38). 
 Although it is not clear which form of JCV RR is present at the time of primary 
infection, it has been hypothesized that JCV with archetype RR remains confined in the 
kidneys of most healthy individuals.  Rearrangements which confer neurotropism are 
thought to occur prior to viral migration to the brain where glial cells and neurons are 
infected. The RR of JCV, with its transcription control factor binding sites, is closely 
associated with pathogenesis, with rearranged forms correlating with poor clinical 
outcome in PML patients (40). 
 
 
Figure 1.4 Schematic of Mad-1 versus Archetype RR.  The JCV RR can be 
divided into 6 blocks (A-F).  Archetype is usually found in the kidneys and urine, and 
is made up of one copy each of Blocks A-F. Mad-1 is the prototype rearranged form, 
which is generally found in the brain and CSF of PML patients and is made up of 2 
repeats Blocks A,C and E followed by 1 Block F.  TATA boxes and the origin of 
replication (ORI) are labeled.  (Adapted from Marshall et al. 2010 (38)). 
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miRNAs in JCV replication 
The first mirocRNA (miRNA) of a polyomavirus was identified in SV40 by Sullivan 
et al. based on miRNA precursors predicted by a computer algorithm (41).   They 
identified a precursor miRNA located on the late pre-mRNA in the untranslated region 3' 
to the polyadenylation cleavage site, which produces 5 miRNAs.  The miRNAs are 
expressed late in infection, and were found to target the early SV40 mRNA, resulting in 
down regulation of early mRNA expression.  While the loss of these miRNAs did not 
negatively affect virion production, it was found to increase the Cytotoxic T lymphocyte 
(CTL) response against T Ag, indicating that these miRNAs may play a role in immune 
evasion (41).   
These miRNAs were also predicted to be present in JCV and BKV.  A follow up 
study found that both JCV and BKV expressed a pre-miRNA similar to the previously 
studied SV40 pre-miRNA (41, 42).  These are also processed into miRNAs targeting the 
same sequence in the early mRNA (41, 42). The JCV miRNAs downregulate T Ag 
expression, and were shown to be present in the brain tissue of PML patients (42).  
Further study found that the 3p arm miRNA produced by JCV and BKV downregulates 
the expression of UL16 binding protein 3 (ULBP3), a ligand for activation of NK cell 
cytotoxicity (43).  This may function as an immune evasion mechanism during JCV and 
BKV infection (43).  Prevention of the expression of these miRNAs in BKV has also 
been shown to cause an increase in early mRNA and protein levels in archetype BKV, 
but not rearranged BKV (44).  Loss of the miRNA gave archetype BKV the ability to 
replicate in a cell line which normally only replicates rearranged BKV, indicating that this 
miRNA can also regulate viral replication (44). 
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JCV AND HUMAN DISEASE 
Progressive Multifocal Leukoencephalopathy 
 PML was first described in 1958 in patients with hematological malignancies who 
also had multiple sites of demyelinating disease in the brain (45).  In 1965, electron 
microscopy (EM) demonstrated the presence of papovavirus-like particles in PML 
lesions, leading to a hypothesis that PML was caused by a viral infection (46).  JCV was 
first isolated in 1971 from the brain of a patient with PML through inoculation of PML 
brain extract onto primary human fetal glial cells (47).  It was given the name JC after 
the initials of the patient it was isolated from (47).  EM revealed the presence of virions 
in cell nuclei in the pattern of a crystalline array similar to that seen with SV40 and the 
virus was classified as a papovavirus, which is now the polyomavirus family (47).   
 PML is a demyelinating disease of the white matter of the central nervous system 
(CNS) caused by lytic infection of oligodendrocytes and astrocytes by JCV (12).  
Neurological symptoms vary depending on the area of demyelination in the brain, and 
include aphasia, cognitive dysfunction, sensory deficits, weakness and coordination 
difficulties.  18% of PML patients will also develop seizures.  PML is usually diagnosed 
through magnetic resonance imaging (MRI), brain biopsy and/or polymerase chain 
reaction (PCR) for JCV in the CSF.  Brain lesions are detected by MRI as hyperintense 
regions in the white matter on some MRI sequences, and there are often multiple 
lesions present in one patient (Figure 1.5A).  PML diagnosis is confirmed either through 
the detection of JCV by in situ hybridization (ISH) for JCV DNA or 
immunohistochemistry (IHC) staining for JCV proteins on a brain biopsy sample, or 
through a positive JCV PCR in the CSF.  PML is characterized in histological samples  
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Figure 1.5 MRI of PML, JCV GCN and JCVE brains.  (A) Fluid-attenuated inversion 
recovery (FLAIR) MRI of a typical PML brain.  Arrows indicate lesions in the white 
matter. (B and C) T2-weighted MRI images of JCV GCN brain showing (B) 
subcortical hyperintensities and (C) mild cortical atrophy in both cerebellar 
hemispheres.  (Adapted from Du Pasquier et al 2003 (67)). (D and E) FLAIR MRI 
images of JCVE brain at diagnosis (D) and 3 months later (E).  (D) Areas of 
hyperintensity are seen in temporal, parietal and frontal cortex.  (E) Additional cortical 
areas are affected and the hyperintense signal extends into the subcortical white 
matter (Adapted from Wuthrich et al. 2009 (34)). 
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by lytic infection of oligodendrocytes and astrocytes in areas of demyelination, and 
enlarged oligodendrocytes and giant, bizarre multinucleated astrocytes (12, 15).   
 PML primarily occurs in the setting of severe cellular immune suppression, such 
as in patients with hematological malignancies, organ transplants and chronic 
inflammatory conditions.  Before the development of highly active antiretroviral therapy 
(HAART), up to 5% of acquired immunodeficiency syndrome (AIDS) patients developed 
PML (48).  Recently, a new risk group has emerged in patients taking 
immunomodulatory drugs such as natalizumab (49-51), rituximab (52) and efalizumab 
(53, 54).  Up to 3.50 in 1000 patients taking natalizumab for multiple sclerosis (MS) 
develop PML and 437 patients have been diagnosed to date (55).  PML can also occur 
in individuals with occult or minimal immune suppression, such as individuals with 
alcoholic cirrhosis or pregnant women (56).  
 There are currently no known antiviral drugs specific to JCV.  Studies have 
tested cytarabine (57, 58), cidofovir (59), and mefloquine (12), but did not show 
significant benefit with treatment.  Since the identification of the serotonin receptor, 
5HT-2α, as the cellular receptor for JCV, some patients are being treated with the 
serotonin receptor inhibitor mirtazapine, although there is not solid clinical evidence to 
indicate this is efficacious (15, 60).  PML patients are therefore treated with measures to 
restore the function of the immune system in the hopes that the immune system will 
control JCV infection.  Combination antiretroviral therapy (cART) is used with Human 
Immunodeficiency Virus (HIV)-positive PML patients, while HIV-negative patients may 
be treated with the reduction of immunosuppressive medications if possible (19). 
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 PML is a fatal disease, but with improved treatments, more patients are surviving 
for extended periods.  Risk factors that influence survival have been identified, such as 
CD4+ T cell count (61), viral load in the CSF (62, 63), Human Leukocyte Antigen (HLA) 
type (64), and the magnitude of the cellular immune response to JCV (65). 
 
JCV Granule Cell Neuronopathy 
 Recently, two new syndromes caused by JCV infection in the CNS have been 
identified.  The first of these is JCV Granule Cell Neuronopathy (JCV GCN) (66).  With 
PML, demyelination results from lytic infection of oligodendrocytes, whereas JCV GCN 
occurs when JCV infects and destroys the granule cell neurons in the cerebellum (67).   
The first case of JCV GCN was the first time that JCV infection of neurons was 
observed. 
 JCV GCN was first identified in an HIV-1 positive patient who presented with 
cerebellar dysfunction.  They had lesions in the white matter of the frontal lobes and 
cerebellar atrophy identified by MRI (Figure 1.5B and 1.5C).  Disease progressed and 
the patient died after 6 months.  Autopsy revealed both lesions in the white matter 
typical of PML and tissue destruction in the internal granule cell layer (IGCL) of the 
cerebellum.  Granule cell neurons were identified by staining with Map-2 and NeuN, and 
were found to be positive for JCV VP1.  ISH indicated that there were also granule cell 
neurons that were positive for JCV DNA but did not express VP1 protein.  Additionally, 
EM demonstrated the presence of 40 nm polyomavirus particles in these cells (67).  
Sequencing of the DNA extracted from frozen brain samples from this patient indicated 
that both the strains from the white matter (JCVHWM) and the granule cell neurons 
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(JCVGCN1) had a rearranged RR (68).  JCVGCN1, but not JCVHWM, also had a 10 bp 
deletion in the c-terminal region of the VP1 gene, resulting in a frame shift and change 
in amino acid sequence (68).   
 Since the identification of the first case, multiple additional patients, both HIV-
positive and HIV-negative, have been diagnosed with JCV GCN, both with and without 
the presence of classic PML in the patient’s brain (66, 67, 69-75).  To date, there have 
been two cases of JCV GCN diagnosed in MS patients treated with natalizumab (55).  
Patients with JCV GCN present with cerebellar dysfunctions, such as incoordination, 
gait ataxia and dysarthria, due to the area of the brain affected with JCV GCN (12).  A 
retrospective study of archival PML brain samples found that up to 51% have granule 
cell neurons infected by JCV (33).  Sequencing of DNA samples from additional JCV 
GCN patients found that they also contained deletions or mutations in the VP1 c-
terminal region, suggesting that alteration of the C terminus of the VP1 protein is 
somehow involved in JCV infection of granule cell neurons and the development of JCV 
GCN (69).   
 
JCV Encephalopathy 
 JCV Encephalopathy (JCVE) was first identified in a 74-year-old HIV-negative 
woman who presented with progressive aphasia and global cognitive decline, and 
cortical gray matter lesions on MRI (Figure 1.5D) (34).  She had a history of non-small 
cell lung cancer treated with chemotherapy.  A biopsy of the right frontal brain stained 
positive for JCV and PCR of the CSF confirmed the presence of JCV in the CNS.   An 
MRI taken three months later showed new areas with cortical lesions and lesions now 
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extended into the subcortical white matter (Figure 1.5E).  The patient experienced 
worsening of her neurological symptoms and developed seizures.  She passed away 4 
1/2 months after the onset of symptoms.  Autopsy samples were obtained for further 
study (34). 
 Postmortem analysis of the brain found laminar necrosis in both subcortical white 
matter and deep cortical layers.  Giant multinucleated astrocytes and pyramidal neurons 
with enlarged nuclei were seen throughout the cortex and at the gray-white junction 
(GWJ) (Figure 1.6A and 1.6B).  IHC staining demonstrated JCV infection at areas of 
tissue necrosis at the GWJ and areas of cell loss in the cortex (Figure 1.6C and 1.6D).  
JCV infected astrocytes were observed in the cortex and at the GWJ.  Few infected 
oligodendrocytes were seen, and there was limited demyelination present.  Many of the 
JCV positive cells were not oligodendrocytes, and double immunofluorescence (IF) 
staining with the neuronal marker MAP-2 and either JCV T Ag or VP1 showed that JCV 
infected many neurons in the brain, specifically cortical pyramidal neurons (Figure 1.6E 
and 1.6F).   Infection of neurons by JCV was confirmed by staining with NeuN (Figure 
1.7).  JCV proteins were found in the cytoplasm and nucleus, as well as in the axons 
and dendritic processes of the neurons (Figure 1.7B and 1.7C).  This finding was novel 
in that it is the first time JCV has been found to infect cortical pyramidal neurons.  qPCR 
for JCV in frozen cortical samples containing lesions had a high viral load, with a mean 
of 4.6 x 108 copies/µg of brain DNA (34).   
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 Figure 1.6 JCV infection in astrocytes and neurons in the cortex and GWJ in a 
JCVE patient.  (A and B) Hematoxylin and eosin staining.  (A) Giant bizarre 
astrocytes and a neuron with an enlarged nucleus.  (B) Cortical pyramidal neurons 
with enlarged nuclei.  (C and D) Double IHC for JCV T Ag (dark blue) and myelin (C, 
CNPase, brown) or astrocytes (D, glial fibrillary acidic protein, light brown).  (C) Most 
JCV-infected cells located in the cortex and GWJ are not oligodendrocytes.  (D) 
Numerous JCV infected astrocytes are present.  (E and F) Double 
Immunofluorescence (IF) staining for neuronal marker MAP-2 (green) and either JCV 
T Ag or VP1 (red).  Numerous neurons are infected with JCV and express T Ag 
and/or VP1.  GM is gray matter; WM is white matter. (From Wuthrich et al. 2009 
(34)). 
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Figure 1.7 Confirmation of JCV infection in neuronal cells.  (A) Double IF 
staining for NeuN (green) and JCV T Ag (red).  (B,C) Double IHC staining for NeuN 
(brown) and JCV T Ag (B, blue) or VP1 (C, blue).  JCV T Ag and VP1 can be seen in 
numerous neurons, in the cell body, axons and dendritic processes.  (From Wuthrich 
et al. 2009 (34)). 
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JCV CORTICAL PYRAMIDAL NEURON 1 (JCVCPN1) 
Isolation and sequencing 
 JCV DNA was isolated from frozen brain samples of the JCVE patient described 
above, and the full viral genome was amplified, cloned and sequenced (76).  This initial 
strain was named JCV Cortical Pyramidal Neuron 1 (JCVCPN1).  Compared to the 
prototype JCVMad-1, JCVCPN1 has 8 single nucleotide mutations resulting in amino acid 
changes and 15 silent mutations (Table 1.1).  The RR of the virus was found to be 
archetype-like, containing portions of the 23-bp and 66-bp inserts (Figure 1.8A). The 
largest mutation present in the virus is a 143-nucleotide deletion in the agnoprotein 
gene, which results in the encoded agnoprotein being truncated to 10 amino acids 
compared to the 71 amino acid wild type protein (Figure 1.8B).  Further studies found 
that additional forms of JCVCPN1 were present.  JCVCPN1.2 contains an additional 75-bp 
duplication between the agnogene and the VP2 gene, encompassing the start of the 
VP2 gene (Figure 1.9) (76).  The mutations and deletions present in JCVCPN do not 
affect the sequences which produce miRNAs or the target sequence of these miRNAs. 
  
Molecular Biology studies 
 Further studies of the brain of the JCVE patient found that JCVCPN1 coexists with 
a JCV strain with an intact agnogene.  Primers encompassing the agnogene region that 
can amplify both full length and deleted agnogene were used in PCR screening.   It was 
found that JCVCPN1.2 was the predominant strain in the JCVE brain, and the intact 
agnogene strain was the minority species in the brain.  In contrast, PCR screening of 
the blood and CSF found only JCV with a full length agnogene (76). 
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Amino acid mutations 
Position Location Nucleotide Mutation Amino Acid Mutation 
 Mad-1 CPN1 Mad-1 CPN1 
1100 VP2 G A S N192S 
1689 VP1 A G N S74N 
1692 VP1 G A R K75R 
1850 VP1 A G T A128T 
1940 VP1 C G L V158L 
2502 VP1 A G K R345K 
3035 T C T J V545G 
4286 T T C F S128F 
 
Silent Mutations 
  
Position Location Nucleotide Mutation  
1086 VP2 A G 
1843 VP1 G T 
2245 VP1 C T 
2260 VP1 A T 
2311 VP1 G T 
2518 VP1 G A 
2592 Non-coding G T 
2712 T A G 
3131 T T C 
3134 T T C 
3440 T T C 
3545 T T C 
3599 T G A 
4095 T C A 
5019 Early mRNA C T 
 
Table 1.1 Single nucleotide mutations in JCVCPN1. (Adapted from Dang et al. 2012 
(76)). 
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Figure 1.8 JCVCPN1 Genome map and RR. (A) JCVCPN1 RR compared to JCVMad-1 
and Archetype. JCVCPN1 has an archetype-like RR with a 19-bp deletion in the 98-bp 
element, a 3 nt deletion in the 23-bp insert and mutations in the 66-bp insert resulting 
in an 80-bp insert.  (B) JCVCPN1 has a 143-bp deletion in the Agno gene (nt 300-442) 
resulting in a 10 amino acid truncated Agno peptide.  (Adapted from Dang et al. 2012 
(76)). 
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Figure 1.9 Structure of JCVCPN1.1 and JCVCPN1.2.  JCVCPN1.2 contains the same RR 
and agnogene deletion as JCVCPN1.1, and has an additional 75-basepair duplication 
covering the VP2 start codon. 
Histological studies of JCVE brain samples 
 To determine whether JCVCPN1 or the JCV with an intact agnogene was 
responsible for the infection of cortical pyramidal neurons, two different agnoprotein 
antibodies were used to stain formalin fixed paraffin embedded (FFPE) JCVE brain 
samples.  Anti-agno1-71 can recognize the entire agnoprotein including the N terminus of 
the protein.  Anti-agno48-71 recognizes only the C terminus of the protein.  Both 
antibodies will stain a full length agnoprotein but only Anti-agno1-71 can recognize the 
truncated agnoprotein of JCVCPN1.  Control PML brain samples show agnoprotein 
staining with both antibodies (Figure 1.10).  Double staining of the JCVE brain for VP1 
and agnoprotein shows that all the VP1 positive cells stain for agnoprotein when Anti-
agno1-71 is used, while only 1% of VP1 positive cells are agnoprotein positive when Anti-
agno48-71 is used (Figure 1.11).  Double staining with Anti-agno1-71 and MAP-2, a neuron 
marker, indicate that these infected cells are neuronal (Figure 1.12).  No double staining 
with MAP-2 and Anti-agno48-71 was seen (Figure 1.12).  These results indicated that the 
infected cells were primarily infected with JCVCPN1 type virus, and that these infected 
cells were neurons.   
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Figure 1.10 Double IF staining of classic PML patient for JCV VP1 and 
Agnoprotein.  Double IF staining for (A) Anti-Agno 1-71 or (C) Anti-Agno 48-71 and 
(B and D) VP1 in FFPE samples from a patient with classic PML.  Staining for both 
Anti-Agno 1-71 and Anti-Agno 48-71 colocalizes with VP1 staining. (From Dang et al. 
2012 (76)). 
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  Figure 1.11 Double IF staining of JCVE patient for JCV VP1 and Agnoprotein.  
Double IF staining for (A) Anti-Agno 1-71 or (C) Anti-Agno 48-71 and (B and D) VP1 
in FFPE samples from a patient with JCVE.  Staining with Anti-Agno 1-71 colocalizes 
with VP1 positive cells, while very few Anti-Agno 48-71 positive cells are seen. (From 
Dang 2012 (76)). 
24 
 
 
  
Figure 1.12 Double IF of JCV Agnoprotein and neuronal marker in JCVE 
patient.   Double staining with Anti-Agno1-71 (red) and the neuronal marker MAP-2 
(green). Double IF staining for (A) Anti-Agno 1-71 or (C) Anti-Agno 48-71 and (B and 
D) VP1 in FFPE samples from a patient with JCVE.  Staining with Anti-Agno 1-71 
colocalizes with VP1 positive cells, while very few Anti-Agno 48-71 positive cells are 
seen. (From Dang et al. 2012 (76)). 
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AGNOPROTEIN 
Agnoprotein 
 The JCV agnoprotein is a small 71 amino acid highly basic protein encoded in 
the leader region of the late transcript (Figure 1.13A).  It is not incorporated into virions 
(27, 77, 78).  JCV, BKV and SV40 encode agnoproteins, but none of the more recently 
identified polyomaviruses including KIV, WUV and MCPyV encode an agnoprotein (2-
4).  Some polyomaviruses of other mammals also encode agnoproteins (79).  
Agnoprotein expression has been observed both in the brains of PML patients and JCV 
infected cells in culture (77, 80).  The N- and C-terminal regions of the agnoprotein are 
hydrophilic and the center region is hydrophobic (81).  The N-terminal region is highly 
conserved between JCV, BKV and SV40, while more variation is present in the C-
terminal region (27).  The structure of agnoprotein has not been determined, but 
computer models predict the presence of an alpha helix formed from amino acids 17-42, 
which contains an Ile/Leu/Phe-rich domain (Figure 1.13B) (82).  Agnoprotein can form 
both homodimers and oligomers, an interaction which is mediated by the Leu/Ile/Phe 
rich domain of the protein (82, 83).  Agnoprotein is found mainly in the cytoplasm, 
primarily in the perinuclear region, with a small amount detected in the nucleus (77). 
There are 3 phosphorylation sites on the agnoprotein (Ser7, Ser11 and Thr21), which 
can be phosphorylated by Protein Kinase C (PKC) (Figure 1.13A) (84).   Agnoprotein is 
dephosphorylated by Protein Phosphatase 2A (PP2A), a process which can be inhibited 
by small t ag (84, 85).  It has been suggested that the phosphorylation state of 
agnoprotein can influence both the localization and function of agnoprotein during 
infection (77, 84-86).    While agnoprotein is not essential for JCV replication, viruses 
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lacking agnoprotein replicate less efficiently (87, 88).  Studies have implicated 
agnoprotein in a number of viral processes during infection, as well as the alteration of 
host cell functions. 
 
Roles in Viral Replication 
 Agnoprotein has been shown to play a role in the regulation of viral genome 
replication.  Using a reporter assay, Safak et al. demonstrated that agnoprotein inhibits 
Large T Ag activation of DNA replication by interacting with the Large T Ag protein (19).  
In contrast, another study found that JCV that does not express agnoprotein has 
decreased viral DNA replication (88).  It has also been shown that the presence of 
agnoprotein increases the binding of T Ag to the origin of replication, which influences 
the efficiency of DNA replication (83). 
 Agnoprotein has also been implicated in the regulation of transcription from the 
early and late promoters (79).  However, the results of the studies are not all in 
Figure 1.13 Structure of the JCV agnoprotein.  (A) The primary structure of the 
agnoprotein.  P stands for phosphorylation and indicates the previously identified 
sites at Ser7, Ser11 and Ser21. (B) The predicted structure of the agnoprotein. 
(Adapted from et al. Saribas 2013 (82)). 
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agreement.  In one study, cells transfected with a Mad-1 virus in which the agnoprotein 
start codon was mutated had no mRNA detectable by RT-PCR for Large T Ag, 
agnoprotein or VP1 (77).  Agnoprotein has been show to negatively regulate Large T Ag 
activation of the late promoter in a CAT reporter assay (19).  Agnoprotein can interact 
with the transcription factor YB-1 and negatively regulate activation of both the early and 
late promoters in CAT assays (89).  A Mad-1 virus lacking the agnoprotein due to 
deletion of the start codon showed down regulation of both early and late proteins (90).  
Agnoprotein may also influence the splicing of late transcripts (82).  
 Agnoprotein has also been implicated in JCV virion assembly, maturation and 
release.  JCV agnoprotein has been shown to facilitate nuclear accumulation of VP1 
and production of infectious virions (26, 91, 92).  JCV which does not express 
agnoprotein due to a mutated start codon has been shown to release viral particles 
which lack viral DNA and which have an irregular morphology (84, 91, 92).  In vitro 
assays have indicated that JCV agnoprotein can bind to VP1 and facilitate VP1 
pentamer formation (92).  In addition, JCV agnoprotein has been shown to interact with 
the protein HP-1α which destabilizes the nuclear envelope and facilitates release of 
virions from the nucleus (93).  JCV agnoprotein has been demonstrated to have 
properties of a viroporin, a group of viral proteins which help proteins which help 
permeabilize cell membranes (92).   
 
Alterations of Host Cell Processes 
 In addition to its roles in viral processes, agnoprotein has been shown to interact 
with host cell proteins and alter host cell processes (79).  Agnoprotein can dysregulate 
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cell cycle progression through an interaction with p53, which results in the upregulation 
of p21 expression and causes cells to accumulate at the G2/M stage (94).  Binding of 
Ku70 by agnoprotein results in the inhibition of DNA repair and the regulation of cell 
cycle in response to DNA damage (95).  Agnoprotein can inhibit the differentiation of 
oligodendrocytes in vitro and induce apoptosis (96).  An interaction between YB-1 and 
JCV agnoprotein has been shown to negatively regulate the transcriptional activation 
activity of YB-1 on the JCV promoters (89).  Agnoprotein also colocalizes with 
microtubules and dissociates the protein fasciculation and elongation protein zeta 1 
(FEZ1) from the microtubules, which may facilitate JCV infection (97).  Binding of 
agnoprotein to heterochromatin protein 1 alpha (HP1α) causes it to dissociate from the 
lamin B receptor (LBR).  This destabilizes the nuclear membrane and assists with virion 
release from the nucleus (93).  Finally, the agnoprotein has been shown to interact with 
HIV-1 Tat, inhibiting the promoter activity of Tat on HIV-1 (81). 
 
Agnogene Cis-Acting Regulatory Element 
In addition to the agnoprotein itself, the agnoprotein coding region has been 
shown to influence transcription due to the presence of a cis-acting DNA element.  
Deletion of the agnoprotein coding region results in decreased activity of the early 
promoter and increased activity of the late promoter in a CAT assay.  Using nuclease 
protection and gel shift assays, it was demonstrated that the agnogene contains 3 
cellular factor binding sites, although the identity of the proteins which bind to the 
agnogene remain unknown (88).   
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SCOPE OF THE DISSERTATION 
 JCV is known to cause at least 3 fatal human diseases, PML, JCV GCN and 
JCVE.  A better understanding of JCV replication is crucial for the development of 
effective treatments for these diseases.  Additionally, understanding how the changes 
present in the JCV strains isolated from patients with the newly discovered JCV GCN 
and JCVE may add to our knowledge of the pathogenesis of these newly identified 
diseases.  Therefore, we undertook studies of the JCVCPN strain, which was isolated 
from a patient with JCVE.  These studies were done to further our knowledge of the 
pathogenesis of JCVE, and to better understand the role of the agnoprotein and 
agnogene in JCV replication.  JCVCPN is the first naturally occurring isolate with a large 
deletion in the agnogene, giving us a unique tool with which to probe the role of the 
agnoprotein. 
In Chapter 2, we sought to better understand the biology of the JCVCPN virus.  
We studied the replication of the virus compared to the prototype JCVMad-1 in kidney, 
glial and neuronal cell lines to determine if the virus had a replication advantage over 
JCVMad-1 in neuronal cells.  We found that JCVCPN did not have a replication advantage 
in neuronal cells, and was unable to establish the persistent high level infection seen 
with JCVMad-1 in all cell lines tested.  JCVCPN failed to express detectable VP1 protein 
and was impaired for the production of infectious virions.  We generated a series of 
chimeras between JCVCPN and JCVMad-1 to determine whether the archetype-like RR or 
the 143 nucleotide agnogene deletion was responsible for the observed differences in 
phenotypes between JCVCPN and JCVMad-1.  We found that the deletion in the agnogene 
was responsible for the majority of the phenotype of JCVCPN.  Interestingly, this was due 
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to the loss of the agnogene DNA and not the loss of expression of the full length 
agnoprotein. 
In Chapter 3, we sought to further understand the role of the agnogene DNA in 
JCV replication.  Previous studies have indicated that there is a cis-acting DNA 
regulatory element present in the agnogene and three host cell protein binding sites 
have been identified.  To determine which nucleotides of the agnogene are critical for 
viral propagation, we generated a series of additional smaller agnogene deletion 
mutants and tested their replication.  We found that the deletion of nucleotides 376-396 
prevents the expression of VP1 protein.  We also sought to identify the proteins binding 
to the agnogene.  We used biotinylated JCV agnogene DNA probes to 
immunoprecipitate proteins from JCV permissible cells.  We then used mass 
spectrometry (MS) analysis to identify proteins that were binding specifically to the JCV 
agnogene DNA.  This study identified a number of candidate agnogene binding 
proteins.  We were not able to confirm any of these proteins as binding specifically to 
the agnogene DNA.  Further investigation into these binding factors is warranted.  
In summary, we have studied the biology of JCVCPN to better understand the 
broadened pathogenesis of JCV represented by the newly discovered disease JCVE.  
We have used this novel, pathogenic isolate to better understand the biology of JCV, in 
particular the effect of the RR form and agnogene deletion on viral replication.  
Additionally, we have studied the role of the agnogene DNA, and attempted to identify 
host cell proteins that bind the agnogene DNA.  Further studies to identify the host cell 
proteins that bind to the agnogene are needed, and our deletion mutants will be useful 
for identifying specific binding sites for host cell binding proteins. 
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ABSTRACT 
 Infection of glial cells by the human polyomavirus JCV causes PML.  JCVE is a 
newly identified disease characterized by JCV infection of cortical pyramidal neurons.  
The virus JCVCPN associated with JCVE contains a unique 143 nucleotide deletion in 
the agnogene. Contrary to most JCV brain isolates, JCVCPN has an archetype-like RR 
usually found in kidney strains.  This provided us with the unique opportunity to 
determine for the first time how each of these regions contributed to the phenotype of 
JCVCPN. We characterized the replication of JCVCPN compared to the prototype virus 
JCVMad-1 in kidney, glial and neuronal cell lines.  We found that JCVCPN is capable of 
replicating viral DNA in all cell lines tested, but is unable to establish the persistent 
infection seen with JCVMad-1.  JCVCPN does not have an increased ability to replicate in 
the neuronal cell line tested.  To determine whether this phenotype results from the 
archetype-like RR or the agnogene deletion, we generated chimeric viruses between 
JCVCPN and JCVMad-1.  We found that the deletion in the agnogene is the predominant 
cause of the inability of the virus to maintain a persistent infection, with the introduction 
of a full length agnogene, either with or without agnoprotein expression, rescues the 
replication of JCVCPN.  Studying this naturally occurring pathogenic variant of JCV 
provides a valuable tool for understanding the functions of the agnogene and RR form 
in JCV replication. 
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INTRODUCTION 
The human polyomavirus JCV has a circular double stranded DNA genome 
which can be divided into 3 regions.  The early coding region encodes the regulatory 
proteins small t ag and large T Ag.  The late coding region encodes the VP1, VP2 and 
VP3 structural proteins, and the agnoprotein (1).  The RR contains the origin of 
replication, as well as the early and late promoters (2, 3).  While the coding regions are 
well conserved, the RR is hypervariable, with different sequences being isolated from 
individuals (1).  Archetype RR, which has one 98-bp element and contains a 23-bp and 
a 66-bp insert, is generally found in the kidneys or urine of healthy and 
immunosuppressed individuals (4).  RRs from the brain or CSF of PML patients are 
generally of the rearranged type, containing two 98-bp tandem repeats with additional 
mutations, insertions and deletions (1, 2).   
JCV is the etiological agent of PML, an often fatal demyelinating disease caused 
by lytic infection of oligodendrocytes by the virus (5).  Infection with JCV is widespread 
in the population, but remains asymptomatic in healthy people (6, 7).  Development of 
PML is associated with immune suppression, such as in patients with AIDS (8), organ 
transplants (9) or hematological malignancies (10).  We have identified two additional 
syndromes caused by JCV infection in the brain, JCV GCN (11-13) and JCVE (14).  The 
viruses isolated from patients with these syndromes contain previously unreported 
unique mutations.  JCV GCN is associated with deletions in the C-terminus of the VP1 
protein (15, 16) and JCVE with a deletion in the agnogene (17).  These naturally 
occurring pathogenic variants provide a unique tool for studying the basic biology of 
JCV replication and pathogenesis. 
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JCVE was described in an HIV-negative patient with a history of lung cancer 
treated with chemotherapy, who presented with cortical lesions, aphasia and 
progressive cognitive decline.  Post-mortem analysis of the brain showed cortical 
lesions with productive infection of cortical pyramidal neurons (14).  Isolation and 
sequencing of the JCV DNA present in the brain of this patient identified a virus with an 
archetype-like RR and a 143 nucleotide deletion in the agnogene (17).  This virus was 
named JCV Cortical Pyramidal Neuron 1 (JCVCPN1).  The deleted agnogene encodes a 
10 amino acid truncated peptide.  Further analysis found that multiple forms of JCVCPN 
were present, and that these strains co-existed with a virus containing a full length 
agnogene.  Immunostaining analysis indicated that the majority of the cortical cells 
infected with JCV contained the truncated form of the agnoprotein (17). 
JCV agnoprotein is a highly basic, 71 amino acid, non-essential protein that is 
expressed late in infection, but not incorporated into virions (18).  It is primarily 
expressed in the cytoplasm, particularly in the perinuclear region, with a small amount 
found in the nucleus (19).  Agnoprotein has been shown to form homodimers and 
oligimers (20).  Agnoprotein contains 3 phosphorylation sites, which can be 
phosphorylated by protein kinase C (21) and dephosphorylated by protein phosphatase 
2A (22).  The phosphorylation state may impact agnoprotein localization (19).  
Agnoprotein has been shown to bind to T Ag, down regulating DNA replication (23) and 
enhancing T Ag origin binding (24).  Agnoprotein may also influence viral gene 
expression and splicing of viral transcripts (25).  Loss of agnoprotein expression has 
been associated with loss of early and late mRNA expression (19).  Agnoprotein has 
also been shown to suppress activity of the late promoter (23), and to interact with the 
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transcription factor YB-1, inhibiting its ability to activate the early and late promoters 
(26).   Prevention of agnoprotein expression also has been shown to result in decreased 
levels of T Ag and VP1 protein expression (27).  Viruses lacking agnoprotein are less 
efficient at packaging DNA and virion formation, with infected cells releasing empty 
particles (27, 28).  The agnoprotein may also function as a viroporin, aiding in the 
release of virions from infected cells (29).  These studies have added to our knowledge 
of agnoprotein function in recent years, but the exact mechanisms by which this protein 
influences the viral life cycle remain unclear. 
In addition to agnoprotein function, the DNA of the agnogene has been shown to 
contain 3 host cell factor binding sites.  Deletion of the agnogene DNA has a greater 
effect on replication than prevention of agnoprotein expression by mutation of the start 
codon (30).  In the agnogene deletion present in JCVCPN, 1 of the 3 sites is completely 
deleted, and a second is shortened by 1 nucleotide.   
We hypothesized that the agnogene deletion of JCVCPN allowed the virus to infect 
cortical pyramidal neurons.  We used cell culture models to study the replication of 
JCVCPN compared to the prototype strain JCVMad-1 (31) in different cell types.  We 
generated chimeric viruses of JCVCPN and JCVMad-1, swapping both the agnogene and 
RR, to determine the specific effects of the agnogene deletion and the archetype-like 
RR on viral replication in cell culture.  In these experiments we characterized the 
replication of JCVCPN in different cell types, and determined the relative contributions of 
the agnogene deletion and archetype-like RR to the JCVCPN replication phenotype. 
Studying these novel naturally occurring changes in JCVCPN provided unique insights 
into our understanding of the function of the agnogene and RR form in JCV replication. 
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MATERIALS AND METHODS 
Cell Culture Cos-7 (32), SVG (33) and IMR-32 (34) cells were purchased from the 
ATCC.  Cos-7 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), Penicillin (500 units/mL) and 
Streptomycin (500 µg/mL).  SVG cells were maintained in Minimum Essential Medium 
(MEM) supplemented with Sodium Bicarbonate (1.5 g/L), 10% FBS, Penicillin (500 
units/mL) and Streptomycin (500 µg/mL).  IMR-32 cells were maintained in MEM 
supplemented with Sodium Bicarbonate (1.5 g/L), Sodium Pyruvate (1 mM), Non-
Essential Amino Acids (NEAA) (Invitrogen), 10% FBS, Penicillin (500 units/mL) and 
Streptomycin (500 µg/mL). 
 
Plasmids Construction of the JCVCPN and JCVMad-1 plasmids was previously described 
by Dang et al. (17).  To generate the agnogene chimeric viruses Mad-1 C-Agno and 
CPN M-Agno, the agnogene region was excised using the restriction enzymes ApaI and 
PciI (New England Biolabs), and the digested DNA was run on an agarose gel.  The 
agnogene DNA and the virus minus the agnogene DNA bands were excised and 
purified using the QIAquick Gel Extraction Kit (QIAGEN).  Agnogene DNA segments 
were ligated into the viral backbone using T4 ligase (New England Biolabs).   The 
resulting plasmids were transformed into TOP10 (Invitrogen) or XL1-Blue cells (Agilent).  
Plasmid DNA was maxi prepped (QIAGEN), and plasmids were fully sequenced.  The 
RR chimeras were generated with the same protocol, using the restriction enzymes 
BamHI and PciI (NEB) to excise the RR.  Mad-1 Pt and Mad-1 Del plasmids were 
previously described (30), and obtained as a generous gift from Dr. Safak.  The 
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agnogene from these viruses was introduced into our JCVMad-1 or JCVCPN plasmid using 
the ApaI and PciI restriction sites as previously described.  
 
Transfection Full-length JCV genomes were digested out of the plasmid backbone 
using EcoRI (NEB) and run on a 0.8% agarose gel.  The 5kb virus band was purified 
using the QIAquick Gel Extraction Kit (QIAGEN).  Cells were transfected with 1 µg (for 
IMR-32 and SVG cells) or 2 µg (for Cos-7 cells) of purified JCV DNA using FuGENE6 
transfection reagent (Roche or Promega) in 6 well plates.  3 days post-transfection, 
cells were passaged 1:3 to T25 flasks, and subsequently every 3-4 days 1:4 in T25 
flasks.  At each passage, supernatant was collected and cells were collected, pelleted 
and stored at -80°C until further analysis. 
 
DNA Extraction and Quantitative PCR (QPCR) DNA was extracted from cell pellets 
and supernatant samples using the QIAamp DNA Blood Mini Kit (QIAGEN).  QPCR was 
performed as previously described (15).   An RNAase P primer/probe set (Applied 
Biosystems) was used in a multiplex assay with the JCV primer/probe set on cell lysate 
samples.  Copies RNAse P per reaction was determine and divided by 2 to determine 
the number of input cells for each reaction.  Copies JCV/cell was calculated by dividing 
the copies JCV per reaction by the number of cells per reaction.  All samples were run 
in triplicate. 
 
RNA Extraction and qRT-PCR RNA was extracted using the RNEasy Mini Kit 
(QIAGEN).  RNA samples were digested with rDNAse I (Ambion) to remove any 
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contaminating DNA.  Reverse transcription was done using the High Capacity RNA-to-
cDNA Kit (Applied Biosystems).  QPCR was performed on a 7300 Real-time PCR 
System using Gene Expression Master Mix (Applied Biosystems).  For amplification of 
the early transcript mRNA, a primer probe set spanning the Large T Ag splice site was 
used.  The primers were JCT208F (5’-CATCAGCCTGATTTTGGTACATG-3’, reverse 
complement of position 4784-4806) and JCT 279R (5’-
CCAGGATTCCCATTCATCTGTT-3’, position 4392-4412).  The probe used was JCT-
232p (6FAM-5’-AAT AGT TCA GAG GTG CCA AC-3’-MGB, reverse complement of 
position 4419-4426 and 4771-4482).  For detection of late transcript mRNA we used the 
primers JCVP1-745F (5’-GGTGACAACTTATACTTGTCAGCTGTT-3’, position 2213-
2239) and JCVP1-812R (5’-TGCTGGGAACCAGACCTGTT-3’, reverse complement of 
position 2261-2280) and the probe JCVP1-773p (6FAM-5’-ATG TCT GTG GCA TGT 
TTA-3’-MGB, position 2241-2248).  A TATA-box binding protein (TBP) primer/probe set 
(Invitrogen) was used as the endogenous control for determination of relative quantity 
by the comparative CT method (also known as the ∆∆Ct method) (35).  All samples were 
run in triplicate wells. 
 
Western Blotting Cells were lysed in TNN lysis buffer (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.1% NP40) with 0.2 mM Na-Orthovanadate and 1% protease inhibitor 
cocktail for 30 minutes on ice.  Samples were centrifuged at 8000 rpm for 4 min to 
remove cell debris.  Laemmli Buffer (Bio-Rad) was added to whole cell lysate.  Samples 
were boiled for 10 min and run on a 10% SDS-PAGE gel in Tris/Glycine/SDS running 
buffer (Bio-Rad).  Samples were transferred for 2 hours at 150 mAmps to a nitrocellose 
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membrane in Transfer Buffer (Tris/Glycine with 20% methanol) or to a nitrocellulose 
membrane using the iBlot system (Invitrogen).  Membranes were blocked using 5% milk 
in PBST and incubated overnight at 4⁰C with VP1 antibody pAB597 (1 mg/mL) diluted 
1:1000 or loading control anti-alpha tubulin [DM1A] (abcam) in 2% milk in PBST.  An 
HRP conjugated goat-anti mouse IgG secondary antibody (Bio-Rad) was used and 
detection was done with ECL Plus reagent (Thermo Scientific).  Signal was detected on 
film. 
 
Flow Cytometry Analysis of JCV-Positive Cells Cells were trypsinized, collected and 
washed with 2% FBS in PBS.  Cells were passed through a 30 μm filter (Miltenyi Biotec) 
and incubated for 20 minutes at 4⁰C with Aqua Amine to stain dead cells, and then 
washed with PBS.  Cells were fixed with Cytofix/Cytoperm (BD Biosciences) for 20 
minutes at 4⁰C then washed with PBS.  Staining with the primary antibody PAB597 
(mouse monoclonal anti-VP1) in Perm/Wash Buffer (BD Biosciences) was done for 2 
hours at 4⁰C.  Cells were washed with Perm/Wash Buffer, then PBS and then stained 
with Alexa 488 conjugated Anti-Mouse IgG (Invitrogen) secondary antibody in 
Perm/Wash Buffer for 1 hour at 4⁰C.  Cells were washed, and then analyzed using a BD 
LSR II Flow Cytometer (BD Biosciences). 
 
JCV Infectivity Test Cos-7 cells were plated in 6 well plates at low density and allowed 
to adhere overnight.  Cell free supernatant collected from transfected cells was put on 
the Cos-7 cells, and incubated 2 hours at room temperature with rocking.  The infection 
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was allowed to proceed for 7 days.  Cells were then collected and analyzed for either 
VP1 expression by flow cytometry or JCV DNA by QPCR as previously described. 
 
DNAse Digestion 170 uL of supernatant was digested with 20 units of DNAse I 
(Ambion) in DNAse I Buffer for 1 hour at 37⁰C.  Undigested samples were incubated in 
DNAse I buffer and subject to the sample digestion conditions.  Digestion control 
samples were generated by adding concentrated JCVMad-1 plasmid to supernatant 
collected from JCV negative cells.  After digestion, DNA was extracted using the DNA 
Blood Mini Kit as describe above, or supernatant was used to infect Cos-7 cells in 6 well 
plates as described above. 
 
Statistical Analyses Analyses were done using SAS Software version 9.3.  Data was 
tested for normality before statistical analysis.  P-values for DNA levels were 
determined using the non-parametric Wilcoxon Rank Test.  P-values for mRNA levels 
were done using univariate analysis, and taking the student’s t p value.  Flow cytometry 
p-values were determined using Student’s t test. 
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RESULTS 
JCVCPN has a 143 nucleotide deletion in the agnogene and an archetype-like 
RR.  The JCVCPN1 RR is archetype-like, lacking a duplication of the TATA-box and 
containing 20-bp and 80-bp inserts, which contain portions of the 23-bp and 66-bp 
inserts present in archetype RR (Figure 2.1A) (17).  A 143 nucleotide deletion in the 
agnogene is also present in JCVCPN1 (Figure 2.1B) (17).  This deletion creates a 
premature stop codon, and is predicted to code for a truncated 10 amino acid 
agnoprotein.  Multiple forms of JCVCPN were identified, including JCVCPN1.1 and 
JCVCPN1.2 which both contain the same regulatory region and agnogene deletion.  In 
addition, JCVCPN1.2 contains a 75-bp duplication between the agnogene and the VP2 
gene, encompassing the start of the VP2 gene (Figure 2.1B).  This form is predicted to 
encode for both a truncated and a full length VP2.  Our studies determined that 
JCVCPN1.1 and JCVCPN1.2 are phenotypically equivalent in our cell cultures model (data 
not shown).  Therefore, we chose to conduct the experiments in this study using the 
JCVCPN1.2 strain, because it was the predominant strain in the JCVE patient’s brain.  
JCVCPN1.2 is referred to as JCVCPN for the remainder of this work. 
 
JCVCPN can replicate DNA in cell culture, but at a lower level than JCVMad-1.  
To determine the cellular tropism of JCVCPN, we studied its replication in cell culture.  
We used multiple cell lines to model the replication of the virus in three different types of 
cells, kidney cells, glial cells and neurons.  Cos-7 cells are African Green Monkey 
kidney cells which express SV40 T Ag, and are known to replicate JCV well (32).  SVG 
cells are human fetal glial cells, also transformed with SV40 T Ag (33).  IMR-32 cells are  
52 
 
 
 
 
Figure 2.1 JCVCPN replicates viral DNA, but at lower levels than JCVMad-1. (A) 
JCVCPN RR is archetype-like (adapted from (17)). (B) JCVCPN1.2 (hereafter referred to 
as simply JCVCPN) agnogene contains a 143-bp deletion followed by a 75-bp 
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a human neuroblastoma cell line, derived from a tumor isolated from the abdominal  
cavity of a child, which do not express any polyomavirus T Ag (34).  We first wanted to 
determine if JCVCPN is capable of genome replication.  To do so, linearized genomes of 
JCVCPN and JCVMad-1 were transfected into Cos-7, SVG and IMR-32 cells.  DNA from 
cell lysate, representing JCV DNA replicated in the transfected cells, and supernatant, 
representing DNA released from the transfected cells, was extracted and digested with 
DpnI to remove any remaining input plasmid DNA.  JCV genome copy number was 
determined by QPCR.  We found that JCVCPN replicated DNA after transfection in all 3 
cell lines tested (Figure 2.1C-H).  However, the levels of DNA were not equivalent to 
those seen with the prototype strain JCVMad-1. 
In Cos-7 kidney cells, JCVMad-1 establishes a high level infection that persists over 
3 weeks, as measured by copies JCV DNA in the cell lysate and supernatant (Figure 
2.1C and 2.1D).  JCVCPN has equivalently high levels of JCV genomes present in the 
cell lysate and supernatant during the first week post-transfection, but does not maintain 
such a high viral load, with the copy number decreasing with time.  In SVG glial cells, 
both JCVMad-1 and JCVCPN establish persistent infections (Figure 2.1E and 2.1F).  Levels 
Figure 2.1 (Continued).  duplication at the beginning of the VP2 gene. (C-H) Cos-7, 
SVG and IMR-32 cells were transfected with linearized JCV genomes, or mock 
transfected.  Cells were subcultured every 3-4 days and cell and supernatant samples 
were collected.   DNA was extracted from the samples, digested with DpnI to remove 
input plasmid DNA, and analyzed by QPCR.  Data represents the average of 4-10 
independent experiments.   In Cos-7 cell lysate (C) and supernatant (D) JCVMad-1 but 
not JCVCPN establishes a persistent infection.  In SVG cell lysate (E) and supernatant 
(F) JCVMad-1 and JCVCPN both establish persistent infections.  In IMR-32 cells, JCVMad-1 
infection persists for 21 days, while JCVCPN becomes undetectable in cell lysate (G) 
and in supernatant (H).  Error bars represent standard deviation.  P-values were 
calculated using the Wilcoxon Rank Test.  ND is not detected. 
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of JCVCPN genome copies in cell lysate and supernatant at later time points post-
transfection are significantly lower than those of JCVMad-1, but with a smaller magnitude 
of difference than observed in Cos-7 cells.  In IMR-32 neuronal cells, JCVMad-1 DNA 
decreased over the first 2 weeks after transfection, and then leveled off, remaining 
detectable over 3 weeks (Figure 2.1G and 2.1H).  In contrast, JCVCPN decreased and 
dropped below the limit of detection at 14 days post-transfection in cell lysate and 17 
days post-transfection in the supernatant.  These results indicate that JCVCPN is able to 
replicate its genome after transfection into Cos-7, SVG and IMR-32 cells, but may have 
a decreased capacity to persist and spread within the culture compared to prototype 
JCVMad-1.  Additionally, JCVCPN does not display a replication advantage in the neuronal 
cell culture line tested. 
 
JCVCPN expresses both early and late transcripts, but at decreased levels 
compared to JCVMad-1.  Knowing that JCVCPN is able to replicate viral DNA, but not 
establish a persistent high level infection, we wanted to determine if JCVCPN is able to 
initiate transcription of mRNAs from the early and late promoters.  To do so, we used 
qRT-PCR on RNA from transfected cells using primer and probe sets located in T Ag to 
detect early transcripts, and in VP1 to detect late transcripts. In Cos-7, SVG and IMR-32 
cells, JCVCPN expresses detectable levels of both the early and late transcripts (Figure 
2.2).  In Cos-7 cells, the level of early transcripts is significantly lower than those seen 
with JCVMad-1 3 and 10 days post-transfection (Figure 2.2A).  In SVG cells, the level of 
early transcripts is similar between JCVCPN and JCVMad-1 3 and 7 days post-transfection, 
and significantly lower 10 days post-transfection (Figure 2.2B).  In IMR-32 cells, the  
55 
 
  
Figure 2.2. JCVCPN expresses less early and late mRNA and VP1 protein than 
JCVMad-1.   (A-F) Cos-7, SVG and IMR-32 cells were transfected with JCVMad-1, 
JCVCPN or mock transfected and samples were collected as described in Figure 
2.1.  qRT-PCR was used to determine the levels of early (T Ag) and late (VP1) 
transcripts.  Relative Quantity (RQ) was calculated using the ∆∆Ct method, using 
TATA-Box Binding Protein (TBP) as the endogenous control and JCVMad-1 as the 
calibrator sample.  Data represents the average of 5-6 independent experiments.  
(A and D) In Cos-7 cells, JCVCPN expresses significantly lower levels of T Ag (A) 
and VP1 (D) mRNA.  (B and E) In SVG cells, levels of T Ag (B) mRNA expressed 
by JCVCPN are similar to JCVMad-1, while VP1 (E) mRNA is significantly lower.  (C 
and F) JCVCPN expresses significantly less T Ag (C) and VP1 (F) mRNA in IMR-32 
cells.  Error Bars represent standard deviation.  P values were calculated for 
Student’s t test using univariate analysis. ND is not detected. (G) Western blots  
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level of early transcripts produced by JCVCPN is significantly lower than those of   
JCVMad-1 at 3, 7 and 10 days post-transfection (Figure 2.2C).  In all three cell lines, the 
level of late transcripts is markedly lower in JCVCPN transfected cells compared to 
JCVMad-1 transfected cells (Figure 2.2D-F).  These results indicate that, although both 
the early and late promoter of JCVCPN are transcriptionally active, they function at a level 
lower than JCVMad-1.  The decrease in transcript levels is larger for the late than the 
early promoter.  
 
JCVCPN fails to produce detectable levels of VP1 protein in Cos-7 cells.  We 
then wanted to determine if JCVCPN produces VP1 protein from the late mRNA.  JCVMad-
1 transfected cells produce VP1 protein, with the amount of VP1 present increasing with 
later times post-transfection (Figure 2.2G).  JCVCPN does not produce detectable levels 
of VP1 protein, even with long exposure times (Figure 2.2G). 
To determine if there is VP1 present in a small number of JCVCPN transfected 
cells, which cannot be detected by Western Blot, we developed a protocol to analyze 
transfected Cos-7 cells for VP1 expression using flow cytometry.  JCVMad-1 transfected 
Figure 2.2 (continued) were done with PAB597 (anti-VP1) using cell lysate from 
Cos-7 cells transfected with either JCVMad-1 (Lanes 1-3), JCVCPN (Lanes 7-9) or mock 
transfected cells (Lanes 4-6) collected 7 (Lanes1,4,7), 14 (Lanes 2,5,8) or 21 (Lanes 
3,6,9) days post-transfection.  VP1 can be detected in JCVMad-1 transfected cells at 
all time points, but not at any time with JCVCPN, with either a short (upper panel) or 
long (middle panel) exposure.  Anti-tubulin antibody was used for loading control 
(lower panel). Blots are representative of 3 independent experiments (H) JCVMad-1, 
JCVCPN or mock transfected Cos-7 cells were analyzed for VP1 expression by flow 
cytometry.  JCVMad-1 but not JCVCPN transfected cells have significantly higher levels 
of VP1 positive cells than Mock transfected samples.  Results are the average of 4 
independent experiments.  Error bars represent standard deviation.  P values were 
calculated using students t test, comparing JCVMad-1 and JCVCPN to mock.  
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cells were positive for VP1 expression, with an increase in the percentage of cells 
positive for VP1 over time, with the highest percentage of VP1 positive cells seen 21 
days post-transfection (Figure 2.2H).  The percentage of JCVMad-1 VP1 positive cells is 
significantly higher than the background observed in Mock transfected cells.  JCVCPN 
transfected cells are not positive for VP1 by flow cytometry at a level significantly higher 
than Mock transfected cells (Figure 2.2H).  This supports the results seen using 
Western blotting, that JCVCPN does not express detectable levels of VP1 protein. 
 
JCVCPN produces low levels of infectious virions. Although we could not 
detect VP1 expression by Western Blot or flow cytometry in transfected cells, there may 
be a very low level of expression below our limit of detection.   We therefore wanted to 
determine if JCVCPN transfected cells are producing virions capable of infecting a new 
round of cells.  To do so, supernatant was collected from transfected Cos-7, SVG and 
IMR-32 cells 7, 14 and 21 days post-transfection and was used to infect Cos-7 cells.  
Infection was allowed to proceed for 7 days.  Cells were collected, and analyzed for 
JCV DNA by QPCR or stained for VP1 and analyzed by flow cytometry.  Supernatant 
was not digested with DNAse to remove free JCV DNA, as previous experiments have 
shown that digesting with DNAse does not affect the levels of JCV DNA detected in the 
supernatant by qPCR, or the percentage of cells subsequently infected from the 
supernatant (Figure 2.3).   
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Figure 2.3 DNAse digestion of Supernatant from infected Cos-7 cells.  (A-C) 
Supernatant collected from either JCVMad-1 or JCVCPN transfected Cos-7 cells was 
digested with DNAse, or mock digested by incubating only with Buffer.  (A) qPCR 
was used to quantify the number of JCV genomes/mL Supernatant.  Digestion with 
DNAse does not decrease the amount of DNA detected in either JCVMad-1 or JCVCPN 
containing supernatant.  (B) To determine if the DNAse digestion conditions would 
digest JCV DNA, JCVMad-1 plasmid was added to supernatant from JCV negative 
cells and digested with DNAse.  This digestion caused an almost 4 log drop in 
copies JCV/mL supernatant.  (C) Digested or mock digested Cos-7 supernatant was 
used to infect Cos-7 cells.  The percentage of VP1 positive cells was determined by 
Flow Cytometry.  Digestion did not decreased the amount of observed infection.  
 
59 
 
JCVMad-1 containing supernatant from Cos-7 cells was able to establish an 
infection in the new cells, with the viral load and the percentage of cells infected 
increasing with supernatant collected at later time points post-transfection (Figure 2.4A 
and 2.4B).  The percentage of VP1 positive cells was significantly higher than in the   
samples treated with supernatant from mock transfected cells (Figure 2.4B).  In 
contrast, cells infected with JCVCPN containing supernatant had significantly lower levels 
of viral DNA detected, which decreased over time, becoming undetectable in samples  
infected with supernatant collected 21 days post transfection (Figure 2.4A).   The 
percentage of JCVCPN VP1 positive cells was not significantly higher than observed with 
Mock supernatant (Figure 2.4B), which is most likely due to the lack of detectable 
expression of VP1 protein in JCVCPN transfected cells. 
Similar results were seen using supernatant from transfected SVG and IMR-32 
cells, with low levels JCV DNA detected in cells infected with JCVCPN containing 
supernatant collected 7 days post-transfection, and then decreasing (Figure 2.4C and 
2.4D).  Using supernatant from SVG cells, JCVCPN DNA remains detectable with  
supernatant collected 14, but not 21, days post-transfection and JCVMad-1 infected cells 
had DNA levels that were significantly higher than those observed with JCVCPN at all 
time points (Figure 2.4C).  In contrast to the results observed using Cos-7 supernatant, 
the viral loads in JCVMad-1 infected cells decreased with later collection points using 
SVG supernatant (Figure 2.4C).  Cells infected with supernatant collected 14 and 21 
days post-transfection from IMR-32 cells had undetectable JCVCPN DNA levels (Figure 
2.4D).  JCVMad-1 DNA was detected in cells infected with supernatant collected from 
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IMR-32 cells at 7 and 21 days, but not 14 days, post-transfection (Figure  2.4D).  This is 
most likely due to the levels of JCV DNA being below the limit of detection of our assay. 
 
Figure 2.4 JCVCPN transfected IMR-32, SVG and Cos-7 cells produce low 
levels of infectious virions.  Supernatant from transfected Cos-7, SVG and IMR-
32 cells was collected 7, 14 and 21 days post-transfection, and used to infect naive 
Cos-7 cells. At 7 days post-infection, cells were collected and either analyzed for 
JCV DNA using QPCR (A, C and D) or stained for VP1 and analyzed using flow 
cytometry (B).  Supernatant collected 7 days post-transfection from JCVCPN 
transfected Cos-7 (A), SVG (C) or IMR-32 (D) cells can establish an infection in 
naïve Cos-7 cells, as measured by the presence of JCV DNA 7 days post-infection.  
Levels of DNA detected with JCVCPN infection are significantly lower than with 
JCVMad-1 infection (A, C and D).  (B) VP1 positive cells are detected after infection 
with JCVMad-1, but not JCVCPN containing supernatant.  Data is the average of 3-4 
independent experiments.  Error bars represent standard deviation. P vales were 
calculated using Wilcoxon rank test for QPCR data, comparing JCVCPN to JCVMad-1. 
P-values for flow cytometry data were calculated using students t test, comparing 
JCVMad-1 and JCVCPN to mock at each time point.  ND is not detected. 
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Generation of chimeras and agnogene mutants.  The results of the above 
experiments comparing JCVCPN and JCVMad-1 suggest that JCVCPN has a block 
preventing late gene expression and protein production, as well as in the production and 
release of infectious virions.  The two major regions of difference between JCVCPN and 
JCVMad-1 are the RR and the agnogene.  To determine which area of the virus is the 
major contributor to the phenotype of JCVCPN, we generated chimeric viruses of JCVCPN 
and JCVMad-1 (Figure 2.5).  We swapped the agnogene genes of the two viruses to 
generate Mad-1 C-Agno and CPN M-Agno.  Mad-1 C-RR and CPN M-RR were 
generated by exchanging the RRs of the two viruses.  We obtained two agno deletion 
mutations, Mad-1 Pt, which has a start codon point mutation which prevents the 
expression of agnoprotein, and Mad-1 Del, which has the entire agnogene deleted. 
CPN M-Pt contains the full length agnogene with the start codon point mutation from  
Mad-1 Pt.  We studied these additional mutants in Cos-7 cells, because these cells 
displayed the greatest difference in phenotype between JCVMad-1 and JCVCPN.  
 
The agnogene deletion is the major contributor to the phenotype of JCVCPN.  
To begin characterizing the phenotypes of the viruses shown in Figure 2.5, linearized 
DNA was transfected into Cos-7 cells, and JCV DNA levels in cell lysate and 
supernatant were monitored for 3 weeks using QPCR (Figure 2.6).  Mad-1 C-Agno has 
significantly lower levels of DNA from 10-21 days post-transfection compared to JCVMad-
1, while Mad-1 C-RR has DNA levels similar to JCVMad-1 (Figure 2.6A and 2.6C).  This 
indicates that introducing the agnogene deletion of JCVCPN into JCVMad-1 results in a 
decrease in DNA replication.  In contrast, the introduction of the JCVCPN RR does not.   
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Figure 2.5 JCVMad-1 and JCVCPN chimeras and agno deletion mutants.  This 
diagram shows the various chimeric viruses and deletion mutants generated.  Black 
represents sequences from JCVMad-1 and white represents sequences from JCVCPN.  
Lines represent DNA sequences.  Dotted Lines represent deletions.  Boxes 
represent genes.  An X through ATG represents mutation of the start codon to 
eliminate protein expression.  Mad-1 C-Agno is JCVMad-1 with the JCVCPN agnogene 
introduced.  CPN M-Agno is JCVCPN with a full length agnogene from JCVMad-1 
introduced.  Mad-1 C-RR is JCVMad-1 with the JCVCPN RR and CPN M-RR is JCVCPN 
with the JCVMad-1 RR.  Mad-1 Pt is JCVMad-1 with a mutated start codon which 
prevents the expression of the agnoprotein and Mad-1 Del is JCVMad-1 with the entire 
agnogene deleted.  CPN M-Pt is JCVCPN with the agnogene of Mad-1 Pt. 
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 Figure 2.6 The agnogene deletion of JCVCPN is the primary cause of its 
replication defect.  Linearized JCV DNA of JCVMad-1, Mad-1 C-Agno, Mad-1 C-RR, 
Mad-1 Pt, Mad-1 Del, JCVCPN, CPN M-Agno, CPN M-RR, and CPN M-Pt were  
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This suggests that the major cause of the replication kinetics seen with JCVCPN is the 
agnogene deletion, and the not the archetype-like RR.  When comparing the agno 
deletion viruses to JCVMad-1, Mad-1 Pt has similar DNA levels, while Mad-1 Del had 
decreased levels late in infection similar to JCVCPN (Figure 2.6A and 2.6C).  This 
provides evidence that the gene deletion is more important than the loss of the 
agnoprotein for the observed phenotype. Furthermore, the results seen with the viruses 
on the JCVCPN backbone support these conclusions.  CPN M-Agno, with the full length 
agnogene and agnoprotein, and CPN M-Pt, with just a full length agnogene, have the 
greatest increase of JCV DNA levels compare to JCVCPN, and in both cases the level of 
DNA increase is similar (Figure 2.6B and 2.6D).  This supports the conclusion that the 
deletion in the agnogene causes the decreased replication ability of JCVCPN.  CPN M-
RR, with the JCVMad-1 RR, also show some increase in DNA levels, but to a lesser 
extent than CPN M-Agno (Figure 2.6B and 2.6D). 
 
Deletion in the agnogene prevents expression of VP1 protein.  We then 
sought to determine if the levels of VP1 protein expression would correspond with levels 
of viral DNA in cells transfected with the chimeras and agno deletion mutants.  Western 
Figure 2.6 (Continued).  transfected into Cos-7 cells and DNA levels were 
quantified over 3 weeks, as described in Figure 2.1.  (A and C) Levels of DNA with 
JCVMad-1 and the chimeras and agno deletion viruses on the JCVMad-1 backbone 
were measured in the cell lysate (A) and supernatant (C).  Mad-1 C-Agno and Mad-1 
Del show significantly lower levels of DNA late in infection.  (B and D) Levels of DNA 
with JCVCPN and the chimeras and agno deletion viruses on the JCVCPN backbone 
were measured in the cell lysate (B) and supernatant (D).  Introduction of a full 
length agnogene causes the greatest increase in DNA levels.  Data represents the 
average of 4-10 independent experiments.  Error bars represent standard deviation.  
P-values were calculated with the Wilcoxon Rank Test. ND is not detected. 
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blots were done for VP1 expression in JCV transfected Cos-7 cells.  At 14 days post-
transfection, only JCVMad-1, Mad-1 Pt, Mad-1 C-RR and CPN M-Agno have detectable 
levels of VP1 (Figure 2.7A).  At 21 days post-transfection, all of these viruses and CPN 
M-Pt have detectable VP1 protein expression (Figure 2.7B).  All of these viruses have 
full length agnogenes, but Mad-1 Pt does not have agnoprotein expression.  Compared 
to JCVMad-1, Mad-1 Pt shows some decrease in VP1 expression, while Mad-1 Del has a 
complete lack of VP1 expression.  All of the viruses with the JCVCPN agnogene deletion, 
JCVCPN, Mad-1 C-Agno and CPN M-RR lack VP1 expression (Figure 2.7A and 2.7B). 
Taken together, these results indicate that the deletion in the agnogene results in 
decreased or undetectable levels of VP1 protein expression, and that the levels of DNA 
replication correspond with the presence of VP1 protein expression.  
Figure 2.7 Deletion in the agnogene prevents VP1 expression.  Western blots 
for VP1 were done as described in Figure 2.2.  (A) VP1 levels in Cos-7 cell lysate 
14 days post-transfection.  (B) VP1 levels in Cos-7 cells 21 days post-transfection.  
Levels of VP1 expression are drastically reduced in Mad-1 C-Agno, and expression 
is rescued by the full length agnogene in CPN M-Agno.  Deletion of the agnogene  
in Mad-1 Del results in a greater decrease in VP1 expression than just the 
prevention of the protein expression in Mad-1 Pt.  Blots are representative of 3 or 4 
independent experiments. 
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Deletions in the agnogene reduce the production of infectious virions.  
Finally, we sought to determine if the ability to produce infectious virions of the chimeric 
and agno deletion viruses also corresponds with DNA levels and VP1 protein production 
in these cells.  Supernatant collected from Cos-7 cells 21 days post-transfection was 
used to infect naïve Cos-7 cells, and the DNA levels (Figure 2.8A) and percentage of 
cells expressing VP1 (Figure 2.8B) were determined by QPCR and flow cytometry, 
respectively, at day 7.  Compared to JCVMad-1-infected cells, both Mad-1 C-agno and 
Mad-1 Del infected cells have significantly lower viral loads, showing a 1.5-2 log 
decrease (Figure 2.8A).  Mad-1 Pt and Mad-1 C-RR infected cells also have 
significantly lower viral loads than JCVMad-1 infected cells, but tended to have a smaller 
magnitude of decrease (Figure 2.8A).  Mad-1 C-agno and Mad-1 Del infected cells have 
significantly lower percentages of cells expressing VP1, while Mad-1 Pt and Mad-1 C-
RR infected cells do not (Figure 2.8B).  CPN M-Agno, CPN M-RR and CPN M-Pt-
infected cells all have detectable DNA levels, with significantly higher viral loads 
compared to JCVCPN (Figure 2.8A).  Compared with JCV CPN infected cells, CPN M-
Agno infected cells have a significantly higher percentage cells expressing VP1, and 
CPN M-Pt infected cells tended to have more cells expressing VP1.  Interestingly, 
introduction of only the full length gene without protein expression in CPN M-Pt is 
enough to rescue the DNA levels, and show some increase in percent of cells 
expressing VP1. 
The results of these infection experiments suggest that the deletion in the 
agnogene is the primary cause of the phenotype observed with JCVCPN.  However, CPN 
M-RR, with the JCVMad-1 RR does show some increase in DNA replication and 
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production of infectious virions compare to JCVCPN, which may indicate that the RR 
composition is also affecting replication of the virus, but to a lesser degree than the 
agnogene deletion.  It is likely that the combination of the agnogene deletion together 
with archetype-like RR  is the cause of the overall phenotype of JCVCPN.  Overall, these 
experiments have used the unique naturally occurring JCVCPN agnogene deletion and 
archetype-like RR to clarify the role of the agnogene and RR forms in JCV replication in 
cell culture.  
Figure 2.8 Loss of the agnogene results in decreased production of infectious 
virions. Supernatant was collected from Cos-7 cells 21 days post-transfection and 
used to infect naive Cos-7 cells.  After 7 days, the cells were analyzed for (A) JCV 
DNA by QPCR or (B) VP1 expression by flow cytometry.  Deletions in the agnogene 
in JCVMad-1-infected cells resulted in a significant decrease in JCV genomes/cell and 
percentage of cells expressing VP1, while introduction of a full length agnogene into 
JCVCPN results in a significant increase in the viral load and percentage of cells 
expressing VP1.  Data is the average of 3 independent experiments.  Error bars 
represent standard deviation.  P values were calculated using Wilcoxon rank test for 
QPCR data, comparing each virus to its parent virus, either JCVMad-1 or JCVCPN. P-
vales for flow cytometry data were calculated using students t test using the same 
sets of comparisons.  ND is not detected.
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DISCUSSION 
JCVCPN was isolated from the brain of the first patient to be diagnosed with 
JCVE, a novel syndrome characterized by infection of cortical pyramidal neurons.  
JCVCPN is the first naturally occurring isolate with a large deletion in the agnogene, 
which was originally called agno due to the unknown nature of its function.  While 
studies have begun to shed light on the function of the agnoprotein and agnogene, 
there is still much to be learned.  JCVCPN presents the opportunity to study the function 
of the agnogene and agnoprotein in a naturally occurring pathogenic variant of JCV, 
isolated in association with infection of a new cell type.    
In this study, we compared the replication of JCVCPN to that of the prototype virus 
JCVMad-1. We used Cos-7 cells to model infection in kidney cells and SVG cells as a glial 
cell model.  Both of these cell lines are widely used to study the replication of JCV in 
kidney and glial cells, and it is commonly thought that the results obtained in them are 
applicable to what would occur in these cell types during JCV infection in humans.  
Studying the replication of JCV in cortical pyramidal neurons is challenging, as there are 
no cortical pyramidal neuron cell lines available.  We therefore used IMR-32 
neuroblastoma cells to model neuronal infection.  Using these cell lines allowed us to 
study the replication of JCVCPN in different cell types in cell culture.  We found that 
JCVCPN was capable of replicating its genome in cell culture.  However, it could not 
establish an infection at the same level observed with JCVMad-1 over time and did not 
display any replication advantage over JCVMad-1 in any cell line.  Levels of JCVCPN DNA 
replication in Cos-7 and IMR-32 cells were similar to JCVMad-1 at early time points, and 
then decreased at later time points, indicating that the virus is able to replicate viral DNA 
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after transfection but the infection could not spread and persist in the cell culture at the 
same level as JCVMad-1.  In addition, mRNA and VP1 protein analyses showed some 
decrease in early transcription and a marked decrease in late transcription, with no 
detectable VP1 protein production.  In all three cell lines, low levels of infection were 
observed using supernatant from JCVCPN transfected cells, but only using supernatant 
collected at early times post-transfection, and at levels significantly lower than seen with 
JCVMad-1.  These data indicate that the virus has a block in late gene expression and 
protein production, which results in low levels of infectious virions being released, and 
an inability to sustain a persistent high level infection in cell culture. Furthermore, since 
agnoprotein has been implicated in the late stages of viral maturation, there may be an 
additional block at the level of virion formation and/or release independent of the lack of 
VP1 production. 
JCVCPN and JCVMad-1 are different in two regions, the RR and the agnogene. This 
provided us with the unique opportunity to determine for the first time how each of these 
regions contributed to the phenotype of JCVCPN. We therefore studied a series of 
chimeric viruses of the RR and agnogene.   Interestingly, the agnogene deletion in 
JCVCPN was the predominant cause of its phenotype, not the archetype-like RR.  
Moreover, the loss of the agnogene DNA had a larger effect on the replication of the 
virus than the loss of agnoprotein expression.  Finally, the archetype-like RR also 
showed a detrimental effect on JCVCPN replication, but of a smaller magnitude than that 
of the agnogene deletion.  For these experiments we used Cos-7 cells, because they 
displayed the largest difference in phenotype between JCVCPN and JCVMad-1 and 
allowed us to use the greatest number of techniques to study these viruses.  We believe 
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that the results obtained in these experiments are representative of what would be 
observed with the other cell lines used in this study. 
Previous studies have implied that agnoprotein plays a role in viral DNA 
replication (23, 24).  However, JCVCPN is able to produce levels of DNA similar to 
JCVMad-1 early after transfection, with DNA levels decreasing with time.  These results 
suggest that an agnogene-deletion mutant can indeed replicate DNA, but levels drop off 
due to blocks at later steps in infection, thereby preventing spread within the cell culture.  
Conflicting studies have associated agnoprotein with gene expression, with both the 
loss of agnoprotein (19, 30) or its presence (23, 26) suppressing activity of the late 
promoter of JCV in different experimental systems.  Additionally, deletion of the full 
agnogene causes a greater decrease in VP1 expression than prevention of agnoprotein 
expression without deletion of the agnogene DNA (30).  Our data shows that the 
deletion in the agnogene of JCVCPN results in a block in late gene expression, impairing 
the release of virions capable of infecting new cells and propagating the infection in cell 
culture.  This is consistent with the results of Akan et al (30) and highlights the 
importance of the agnogene DNA in addition to the protein it codes for.  Further studies 
are needed to determine the mechanism of the block in VP1 expression.  One 
possibility is that a host cell factor which binds to one of the sites in the agnogene, 
identified by Akan et al (30), is involved in expression of the late transcript.  Further 
investigations to identify these cellular proteins are warranted to determine the 
mechanism by which they act during JCV replication.  Another potential mechanism is 
that deletions in the agnogene somehow alter the splicing or translation of VP1 from the 
late mRNA.  
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Previous studies of JCV deletion mutants lacking agnoprotein expression have 
implicated the agnoprotein in genome packaging and/or virion formation and release, 
with empty capsids being produced by viruses lacking the agnoprotein (27, 28).  In our 
study however, the agnoprotein start codon point mutant was able to replicate its DNA 
and produce infectious virions at a level similar to JCVMad-1 in Cos-7 cells, which 
suggests that at least in these cells, the agnoprotein is not necessary for formation and 
release of virions containing viral genomes. 
Archetype RR is typically found in the urine, but the JCVCPN RR isolated from the 
brain of the JCVE patient is archetype-like. Studies of the replication of different forms 
of RR have shown that archetype RR form has less active early and late promoters 
(36).  Surprisingly, our study did not find the archetype-like RR of JCVCPN to be the 
primary cause of the decreased levels of late transcription and VP1 protein expression.  
Introducing the archetype-like RR of JCVCPN into JCVMad-1 had little effect on the ability 
of the virus to replicate.  JCVMad-1 RR introduced into JCVCPN partially rescues 
replication, but had a lesser impact than introduction of a full length agnogene.  In fact 
the archetype-like RR only has a significant impact on the virus once it has already 
been impaired by a deletion in the agnogene, indicating that not all archetype-like RR 
forms found in nature lead to lower levels of viral replication.   
While JCVCPN was unable to establish a persistent infection in our cell culture 
model, it was found at high levels in the brain of the JCVE patient.  JCVCPN does 
produce some infectious virions in cell culture, but at much lower levels than JCVMad-1.  
This does not, however, mean that the virus was unable to establish an infection in the 
brain of the JCVE patient.  There are limitations to the cell culture model we utilized in 
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this study.  First, the infection in a person can take place on the timescale of years to 
decades, while our experiments were done over weeks.  Second, this individual was 
also infected with a strain of JCV with a full length agnogene and agnoprotein, which 
may have influenced the replication of JCVCPN.  Third, it may be that having low levels of 
replication in the brain was actually advantageous to the virus while faced with a healthy 
immune system, allowing it to accumulate until the immune system became 
compromised and JCVE developed. 
 After observing the infection of granule cell neurons in JCV GCN and cortical 
pyramidal neurons in JCVE, we conducted studies to determine if infection of neurons 
by JCV was limited to these syndromes, or if it is more widespread.  Based on staining 
of PML brain samples, it is predicted that up to 51% of patients have granule cell 
neurons infected by JCV (37).  Additionally, infection of cortical neurons by JCV in 
classic PML cases has been observed with infection present in the gray white junction 
and gray matter (38). These studies demonstrate that infection of neurons occurs in a 
large number of PML patients, and is not limited to patients with JCV GCN or JCVE.  
Further studies of the molecular composition of JCV in neurons of patients with classic 
PML are needed to determine whether these cells are also infected by JCV-deletion 
mutants. 
The study of unique pathogenic isolates of JCV, such as JCVCPN or JCVGCN 
allows us to decipher the basic biology of JCV replication using mutations that have 
arisen naturally during infection in humans.  Our studies of JCVCPN have provided 
valuable insights into both the function of the agnogene and agnoprotein, as well as a 
naturally occurring variation of the regulatory region, on JCV replication.  Our results 
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have helped clarify the role of the agnogene and agnoprotein in DNA replication, 
transcription and protein expression, demonstrating that a deletion in the agnogene has 
a dramatic effect on the expression of VP1 protein and the production of infectious 
virions.  Further studies of naturally occurring variants of JCV will continue to add clarity 
to our understanding of the biology of JCV replication and pathogenesis. 
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ABSTRACT 
JCV infection of the brain can cause PML, JCV GCN and JCVE.  JCVCPN, 
isolated from the brain of a patient with JCVE, is a naturally occurring strain of JCV 
with a 143 nucleotide deletion in the agnogene.  Cell culture studies of JCVCPN have 
shown that the loss of these nucleotides in the agnogene results in impaired 
expression of VP1 and infectious virion production.  To better understand the role of 
this DNA sequence in JCV replication, we generated a series of deletions in the 
agnogene on the backbone of a virus which has a start codon mutation to prevent 
agnoprotein expression.  We found that deletion of nucleotides 376-396 in the 
agnogene results in decreased levels of viral DNA replication and a lack of VP1 
expression.  These results indicate that these nucleotides play a role in JCV VP1 
expression and replication.  Previous studies have provided evidence of host cell 
factor binding sites in the agnogene.  DNA-Immunoprecipitations were done using 
agnogene DNA to identify candidate host cell binding proteins.  These proteins were 
visualized by SDS-PAGE and individual bands and entire samples were submitted 
for Mass Spectrometry analysis.  Several candidate proteins, including poly (ADP-
ribose) polymerase 1 (PARP-1), Ku70, Replication protein A 70 kDa DNA-binding 
subunit (RPA1) and General transcription factor II-I (GTF2I), were identified, but 
none of these proved to bind specifically to the JCV agnogene DNA. 
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INTRODUCTION 
JCV is the etiological agent of the fatal demyelinating disease PML, as well as 
the more recently described JCV GCN and JCVE (1-3). JCV infection is widespread 
and asymptomatic in healthy individuals (4, 5).  Individuals with immune 
suppression, such as those with AIDS (6), organ transplants (7) and hematological 
malignancies (8), are at risk for developing PML. 
JCV is a polyomavirus with a circlular double stranded DNA genome.  The 
genome has 3 regions, the highly conserved early and late coding regions and the 
hypervariable RR (9).  The regulatory proteins small t ag and large T Ag are encoded 
by the early coding region while the structural proteins VP1, VP2 and VP3 and the 
agnoprotein are encoded by the late coding region (9).  The origin of replication and 
the early and late promoters are contained by the RR (10).  
The agnoprotein of JCV is a 71 amino acid, highly basic protein that is non-
essential for viral infection (11).  It is expressed late in infection, primarily in the 
cytoplasm, and is not incorporated into virions (11, 12).  Recent studies of 
agnoprotein function have begun to shed light on its roles in JCV replication, but 
there is still much to be learned.  The agnoprotein can be phosphorylated (13, 14) 
and form both homodimers and oligomers, an interaction which is mediated by the 
Leu/Ile/Phe rich domain of the protein (15, 16).  The agnoprotein has been 
implicated in a number of different viral processes, including DNA replication (16, 
17), gene expression and splicing of viral transcripts (12, 15, 17, 18), early and late 
protein expression (19) and virion formation and release (19, 20).  It has also been 
reported that agnoprotein may act as a viroporin (21).  While these studies have 
given insights into agnoprotein function, the exact mechanisms of action are still 
unclear.   
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Studies have shown that deleting the agnogene DNA is more detrimental to 
JCV replication than loss of agnoprotein expression without deletion of the DNA 
sequence, indicating that the agnogene may contain a cis-acting regulatory element 
(22, 23).  Additionally, 3 potential host-factor binding sites have been identified in the 
agnogene through nuclease protection and gel shift assays (22).  These binding 
sites are nucleotides 350-411 (binding site III), 442-458 (binding site II) and 458-475 
(binding site I) (22). 
JCVCPN was isolated from the brain of a patient with JCVE, and has an 
archetype-like RR and a 143-bp deletion from nucleotide 300-442 in the agnogene 
(24).  It was named JCVCPN because it causes productive infection in cortical 
pyramidal neurons.  This was the first time a large deletion in the agnogene was 
isolated in a naturally occurring viral isolated.  We have recently studied the 
replication of JCVCPN in cell culture to better understand both the pathogenesis of 
JCVE and the role of the RR and agnogene in JCV replication (23).  Our results 
indicated that, in cell culture, JCVCPN was incapable of establishing a high level 
persistent infection compared to the prototype strain JCVMad-1 and that this was due 
to a lack of VP1 expression and infectious virion release (23, 25).  Further 
experiments identified the deletion in the agnogene, specifically the loss of the 
agnogene DNA more so than the loss of a full length agnoprotein, as the primary 
cause of this phenotype (23).  
To further characterize the role of the agnogene in JCV replication, we 
generated a series of small deletions in the agnogene.  All of the deletions were 
introduced into JCVMad-1 with a mutated agnoprotein start codon (Mad-1 Pt), which 
prevents agnoprotein expression.  This allowed us to study the function of the 
deleted regions in isolation from the functions of the agnoprotein. We compared the 
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replication of these deletion mutants to JCVMad-1 in cell culture by measuring DNA 
replication, early and late mRNA expression and VP1 protein production to identify 
smaller regions of the agnogene which are crucial for viral replication.  We attempted 
to identify the host cell proteins which bind to the agnogene DNA through Mass 
Spectrometry (MS) of proteins from DNA-Immunoprecipitations (DNA-IP) done using 
JCV agnogene DNA.  Candidate proteins were identified, but none have been found 
to bind specifically to the agnogene DNA.  
  
84 
 
MATERIALS AND METHODS 
Cell Lines Cos-7 (26), SVG (27), IMR-32 (28) and 293T cells were purchased from 
the ATCC.  Cos-7 and 293T cells were maintained in DMEM supplemented with 10% 
FBS, 500 units/mL Penicillin and 500 µg/mL Streptomycin.  SVG cells were 
maintained in MEM supplemented with 10% FBS, 500 units/mL Penicillin, 500 µg/mL 
Streptomycin, and 1.5g/L Sodium Bicarbonate.  IMR-32 cells were maintained in 
MEM with 10% FBS, 500 units/mL Penicillin, 500 µg/mL Streptomycin, 1.5g/L 
Sodium Bicarbonate, 1 mM Sodium Pyruvate and Non-Essential Amino Acids 
(Invitrogen). 
 
Plasmids Construction of JCVMad-1 and JCVCPN plasmids was previously described 
by Dang et al. (24).  Construction of Mad-1 Pt, Mad-1 Del and Mad-1 C-Agno was 
previously described by Ellis et al (23).  Additional agnogene deletion mutants were 
introduced using the QuikChange Lightening Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s protocol.  All deletions were made on 
the Mad-1 Pt backbone.  The primer sequences used were: Mad-1 PtDel300-349 
(del300-349F 5’-GGTTCTTCGCCAGCTGTCACGCTCAAAGGATTTTAATTTTTTT-3’ 
and del300-349R 5’- 
AAAAAAATTAAAATCCTTTGAGCGTGACAGCTGGCGAAGAACC-3’), Mad-1 
PtDel350-411 (del350-411F 5’- 
CTGGAGTGGAACTAAAAAAAGAGGTAGACGGGAAAAAAAGAC-3’ and del350-
411R 5’- GTCTTTTTTTCCCGTCTACCTCTTTTTTTAGTTCCACTCCAG-3’), Mad-1 
PtDel442-458 (del442-458F 5’-
AAAAAAAGACAGAGACACAGTATACAGTGCTTTGCCTGAACC-3’ and del442-
458R 5’-GGTTCAGGCAAAGCACTGTATACTGTGTCTCTGTCTTTTTTT-3’), Mad-1 
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PtDel356-376 (del356-376F 5’-
GTGGAACTAAAAAAAGAGCTCAAAAATTTTTGCTGGACTTTTGCACAG-3’ and 
del356-376R 5’-
CTGTGCAAAAGTCCAGCAAAAATTTTTGAGCTCTTTTTTTAGTTCCAC-3’), Mad-1 
PtDel376-396 (del376-396F 5’-
TAAAAAAAGAGCTCAAAGGATTTTAATTTTTTTGTTAACAGGTGAAGACAGTGTA
G-3’ and del376-396R 5’-
CTACACTGTCTTCACCTGTTAACAAAAAAATTAAAATCCTTTGAGCTCTTTTTTTA-
3’), Mad-1 PtDel300-432 (del300-432F 5'-
TTCGCCAGCTGTCACGTAGACACAGTGGTTTG-3' and del300-432R 5'-
CAAACCACTGTGTCTACGTGACAGCTGGCGAA-3'), Mad-1 PtDel310-442 (del310-
442F 5'-GTCACGTAAGGCTTCTGGTTTGACTGAGCAGACA-3' and del310-442R 
5'-TGTCTGCTCAGTCAAACCAGAAGCCTTACGTGAC-3') and Mad-1 PtDel411-442 
(del411-442F 5'-GCACAGGTGAAGACAGGTTTGACTGAGCAGAC-3' and del411-
442R 5'-GTCTGCTCAGTCAAACCTGTCTTCACCTGTGC-3').  Plasmids were 
transformed into TOP10 (Invitrogen) or XL1-Blue cells (Agilent) and plasmid DNA 
was maxi prepped (QIAGEN).  All plasmids were fully sequenced to confirm the 
presence of the desired deletions. 
 
Transfection Full-length JCV genomes were digested out of the plasmid backbone 
using EcoRI (NEB).  Digested DNA was run on a 0.8% agarose gel and the virus 
band (about 5kb) was purified using the QIAquick Gel Extraction Kit (QIAGEN).  
Cells were transfected with 2 µg of purified JCV DNA using FuGENE6 transfection 
reagent (Promega) in 6 well plates.  3 days post-transfection, cells were passaged 
1:3 into T25 flasks, and subsequently every 3-4 days 1:4 in T25 flasks.  Supernatant 
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and cell pellets were collected at each passage and stored at -80°C until further 
analysis. 
 
DNA Extraction and QPCR DNA was extracted from cell pellets and supernatant 
samples using the QIAamp DNA Blood Mini Kit (QIAGEN) according to the 
manufacturer’s protocol.  QPCR was performed as previously described (23).   An 
RNAse P primer/probe set (Applied Biosystems) was used to determine the number 
of input cells for each reaction and the copies JCV/cell as previously described (23).  
All samples were run in triplicate. 
 
RNA Extraction and qRT-PCR RNA was extracted and reverse transcribed as 
previously described (23).  QPCR was performed on a 7300 Real-time PCR System 
using Gene Expression Master Mix (Applied Biosystems).  Primer probe sets 
spanning the Large T Ag splice site and located in the VP1 gene were used as 
previously described (23).  TBP (Invitrogen) was used as the endogenous control to 
determine the relative quantity by the comparative CT method (also known as the 
∆∆Ct method) (29).  All samples were run in triplicate. 
 
Western Blotting Cells were lysed for 30 minutes in TNN lysis buffer (50 mM 
TrisHCl pH 7.5, 150 mM NaCl, 0.1% NP40) with 0.2 mM Na-Orthovanadate and 1% 
protease inhibitor cocktail on ice.  Cell lysate was centrifuged at 8000 rpm for 4 min 
to remove cell debris.  Laemmli Buffer (Bio-Rad) was added and cell lysates were 
boiled for 10 min.  Samples were run on a 10% SDS-PAGE gel in Tris/Glycine/SDS 
running buffer (Bio-Rad) and transferred to a nitrocellulose membrane using the iBlot 
system (Invitrogen) or run on 4-20% Tris-HCl SDS-PAGE gel and transferred to 
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PVDF membrane using the iBlot system.  Membranes were blocked with 5% milk in 
PBST.  Antibodies against VP1 (pAB597 1 mg/mL) diluted 1:1000, PARP-1 (Santa 
Cruz) diluted 1:200, Ku70 (Santa Cruz) diluted 1:200, RPA1 (Santa Cruz) 1:100, 
GTF2I (Santa Cruz) diluted 1:1000 or loading control anti-alpha tubulin [DM1A] 
(Abcam) in 2% milk in PBST was added and incubated overnight at 4⁰C.  
Membranes were washed and incubated with HRP conjugated goat-anti mouse IgG 
secondary antibody (Bio-Rad) for 1 hour at room temperature, followed by detection 
with ECL Plus reagent (Thermo Scientific).  Signal was detected on film.   
 
Generation of Biotinylated JCV agnogene DNA probes.  Biotinylated JCV 
agnogene DNA was generated by PCR amplification of the agnogene from JCVMad-1 
or JCVCPN plasmid using the Phusion High-Fidelity polymerase (NEB) with one 
primer being 5’-biotinylated.  The primers used were agnoPvuIR+biotin (5’-biotin-
TACATTCGATCGCTATGTAGCTTTTGG-3’) and agnoPstI (5’-
AATAACTGCAGATGGTTCTTCGCCAG-3’).  After PCR amplification the MinElute 
PCR purification kit (QIAgen) was used to remove any remaining biotinylated primer.  
Probes were checked by agarose gel electrophoresis to confirm that a fragment of 
the correct size had been generated.  Control DNA fragments were amplified from 
the AmpR gene of the puc18 plasmid backbone.  220-bp and 75-bp regions were 
amplified to generate probes the same size as either the JCVMad-1 or JCVCPN 
agnogene. The primer sets used were AmpR1+biotin (5’-biotin-
AGTCACAGAAAAGCATCTTACGGAT-3’) and AmpR-F1 (5’-
TATCACTCATGGTTATGGCAGCAC-3’) and AmpR-R2+btion (5’-biotin-
GGCGAACTACTTACTCTAGCTTCCC-3’) and AmpR-F2 (5’-
TGACTCCCCGTCGTGTACATAACTA-3’).  
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Isolation of nuclear proteins.  Nuclear proteins were isolated from 293T, IMR-32, 
SVG or Cos-7 cells that were either JCV negative or transfected with JCVMad-1.  Cells 
were grown for 3-4 days.  Nuclear proteins were extracted using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo Scientific) as directed by 
the manufacturer’s protocol. 
 
DNA-Immunoprecipitation Biotinylated DNA was bound to streptavidin conjugated 
magnetic beads (Dynabeads M-280, Invitrogen) by incubating at room temperature 
(RT) for 15 minutes with rocking.  Beads were washed three times with 1X Bind and 
Wash Buffer (BW Buffer) (5 mM Tris-HCl, 0.5 mM EDTA and 0.5 M NaCl).  Nuclear 
proteins were added to the beads with an equal volume of 2X BW Buffer (10 mM 
Tris-HCl, .5 mM EDTA and .5 M NaCl) and incubated overnight at 4⁰C with rocking.  
Beads were washed three times with 1X PBS.  To elute bound proteins, the beads 
were boiled for 5 minutes in .1% SDS and the supernatant containing the proteins 
was removed from the beads.  A magnetic rack was used to separate beads from 
the supernatant. 
 
Gel Analysis 10 µL eluted protein in 10 µL Laemmli Buffer (Bio-Rad) was run on a 
4-20% Tris-HCl gel in Tris/Glycine/SDS buffer.  Alternatively, larger volumes of 
eluted protein were concentrated by Trichloroacetic acid (TCA) precipitation, 
resuspended in 20 µL Laemmli buffer and run on 4-20% or 4-15% Tris-HCl gels.  
Gels were run at 100V for 1-1.5 hours.  Protein was detected either with Coomassie 
Brilliant Blue Stain (Bio-Rad) or Silver Stain (Pierce Silver Stain Kit for Mass 
Spectrometry, Thermo Scientific), as directed by the manufacturer’s protocol.   
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Mass Spectrometry To identify specific protein bands, individual bands stained with 
either Coomassie or Silver Stain were excised from a gel and placed in an eppendorf 
tube containing Milli-Q water.  To identify all the proteins in a sample, the sample 
was run into a gel for 10 minutes, stained with Coomassie Brilliant Blue, and the 
band containing all proteins was excised from the gel and placed in an eppendorf 
tube containing Milli-Q water.  Gel fragments were submitted to the Taplin Mass 
Spectrometry Facility for analysis (https://taplin.med.harvard.edu/).   
 
Statistical analysis P values were calculated using SAS9.3 software.  Before 
analysis, data was tested for normality.  The non-parametric Wilcoxon Rank Test 
was used to determine p values for DNA levels.  Univariate analysis to determine 
student’s t p values was used for mRNA levels. 
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RESULTS 
Generation of agnogene deletion mutants.  Our previous studies have 
indicated that the deletion of nucleotides 300-442 in the agnogene in JCVCPN leads 
to decrease viral replication and a lack of detectable VP1 expression (23).  This 
phenotype is due primarily to the loss of nucleotides in the agnogene and not the 
loss of wild type agnoprotein expression.  To further narrow down the regions of the 
agnogene which are critical for viral replication and VP1 expression, we generated a 
series of additional small agnogene deletion mutants.  All additional deletions were 
introduced onto the Mad-1 Pt backbone, which has a mutated start codon to prevent 
expression of the agnoprotein, in order to investigate only the effects of deletions in 
the agnogene. 
Figure 3.1 shows the locations of the additional mutants that were generated, 
as well as the locations of the predicted host cell protein binding sites (22).  Mad-1 
PtΔ300-349 encompasses the region from the beginning of the JCVCPN deletion to 
the start of binding site III.  Mad-1 PtΔ350-411 and Mad-1 PtΔ442-458 delete binding 
sites III and II, respectively.  Both Mad-1 PtΔ356-376 and Mad-1 PtΔ376-396 are 
located within binding site III. Mad-1 PtΔ356-376 deletes a region predicted to be a 
possible transcription factor binding site by AliBaba 2 software (http://www.gene-
regulation.com/pub/programs.html#alibaba2) (Figure 3.2) and Mad-1 PtΔ376-396 
deletes a region of high homology between JCV, BKV and SV40.  Mad-1 PtΔ300-
432 and Mad-1 PtΔ310-442 encompass the region deleted in JCVCPN (300-432) with 
the last 10 or first 10 nucleotides of the deletion added back, respectively.  Finally, 
Mad-1 PtΔ411-442 is the region between binding sites III and II.  As controls, we 
used the previously characterized viruses Mad-1 Pt, a start codon deletion mutant, 
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Mad-1 Del, a full agnogene deletion mutant (22), and Mad-1 C-Agno JCVMad-1 with 
the JCVCPN agnogene, which has a deletion of nucleotides 300-442 (23). 
  
Figure 3.1 Agnogene deletion mutants.  This diagram shows all of the viruses 
used in this study.  Boxes represent open reading frames.  Lines represent DNA 
sequences.  Dotted lines represent deletions.  ATG with an X through it indicates 
a mutated start codon preventing agnoprotein expression.  Nuclear factor binding 
sites indicate the regions identified by Akan et al. 2006 (22). 
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Figure 3.3 Alignment of the agnogene sequences of JCV, BKV and SV40.  
Nucleotides 376-396 of JCV and the corresponding residues in BKV and SV40 are 
highlighted in red.    
Figure 3.2 Predicted transcription factor binding sites in the agnogene DNA.  
The JCVMad-1 agnogene sequence was analyzed using the AliBaba2.1 transcription 
factor binding site prediction software. 
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Deletion of nucleotides 376-396 decreases levels of viral DNA replication 
at late time points post-transfection.  Linearized JCV genomes were transfected 
into Cos-7 cells and viral DNA was quantified in the supernatant (Figure 3.4A) and 
cell lysate (Figure 3.4B) by qPCR 3, 7, 10, 14, 17 and 21 days post-transfection.  As 
previously reported, Mad-1 C-Agno and Mad-1 Del show lower levels of viral DNA in 
the supernatant and cell lysate from 14-21 days post-transfection compared to 
JCVMad-1 (23).  Most of the new agnogene deletion mutants have replication levels 
similar to JCVMad-1 and Mad-1 Pt.  Interestingly, Mad-1 PtΔ376-396 has drastically 
decreased levels of JCV DNA in the supernatant and cell lysates at later times post-
transfection, similar to Mad-1 C-Agno and Mad-1 Del. Levels of Mad-1 PtΔ376-396 
DNA are significantly lower than JCVMad-1 starting 10 days post-transfection in cell 
lysate and 17 days post-transfection in supernatant.  This indicates that nucleotides 
376-396 are important for JCV replication. 
 
Deletion of nucleotides 376-396 results in decreased levels of late mRNA 
expression.  RNA was extracted from JCV transfected Cos-7 cells 3, 7 and 10 days 
post-transfection.  RNA was reverse transcribed to cDNA and levels of early (T Ag) 
and late (VP1) mRNA were determined using qPCR.  While there was some 
decrease in T Ag mRNA expression 10 days post-transfection with most of the 
deletion mutants, there were no significant decreases observed (Figure 3.5A).  
Greater differences in expression levels were observed for VP1 mRNA, although 
none were statistically significantly lower (Figure 3.5B).  The greatest decrease in 
late mRNA expression was seen with Mad-1 PtΔ376-396, which has levels 
equivalent to Mad-1 Del 7 and 10 days post-transfection.  Additionally, Mad-1 
PtΔ300-432 and Mad-1 PtΔ310-442 also have decreased levels of VP1 mRNA 
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expression 7 and 10 days post-transfection.  These results indicate that nucleotides 
376-396 are involved in the expression of late mRNAs. 
 
 
 
 
Figure 3.4. Deletion of nucleotides 376-396 reduces viral DNA replication. 
Cos-7 cells were transfected with linearized JCV genomes and cells were 
subcultured every 3-4 days.  DNA was extracted from the supernatant and cell 
samples, digested with DpnI to remove input plasmid DNA, and analyzed by 
QPCR.  Data represents the average of 3-5 independent experiments.   In 
supernatant (A) and cell lysate (B) samples, Mad-1 PtΔ376-396 has decreased 
levels of viral DNA compared to JCVMad-1 at 17-21 days post-transfection in 
supernatant and 10-21 in cell lysate. Mock transfected cells remained JCV 
negative.  Error bars represent standard deviation.  P-values were calculated for 
all viruses compared to JCVMad-1 using the Wilcoxon Rank Test.  * indicates 
p<.05 
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Figure 3.5 Deletion of nucleotides 376-396 results in a reduction of late mRNA 
expression.   Cos-7 cells were transfected with linearized JCV genomes.  Cell 
pellets were collect and RNA was extract and reverse transcribed into cDNA.  qPCR 
was used to measure the levels of early (T Ag) and late (VP1) transcripts as well as 
the endogenous control TBP.  Relative Quantity (RQ) was calculated using the ∆∆Ct 
method, with TBP as the endogenous control and JCVMad-1 as the calibrator sample.  
Data represents the average of 3 independent experiments. (A) While some 
decrease in T Ag mRNA is observed 10 days post-transfection, no significant 
differences were observed for any of the viruses tested.  (B)  Mad-1 PtΔ376-396 
expressed decreased levels of VP1 mRNA 7 and 10 days post-transfection, with 
levels similar to Mad-1 Del.  Mad-1 PtΔ300-432 and Mad-1 PtΔ310-442 also have 
some decrease in VP1 mRNA expression.  None of these differences reached 
statistical significance.  Mock transfected samples remained negative for JCV 
mRNAs.  Error Bars represent standard deviation.  P values were calculated for all 
viruses compared to JCVMad-1 with Student’s t test using univariate analysis. 
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Nucleotides 376-396 are critical for VP1 expression.  Western blotting was 
done for VP1 expression in cell lysate collected from Cos-7 cells 14 and 21 days 
post-transfection.  As previously published, JCVMad-1 (Lane 1) and Mad-1 Pt (Lane 
11) express detectable levels of VP1 protein, while Mad-1 C-Agno (Lane 10) and 
Mad-1 Del (Lane 12) do not (Figure 3.6) (23).  Interestingly, all of the additional  
agnogene deletion mutants except Mad-1 PtΔ376-396 (Lane 6) express VP1, 
although at somewhat decreased levels.  Mad-1 PtΔ376-396 does not express  
detectable levels of VP1 14 or 21 days post-transfection.  This indicates that 
nucleotides 376-396 are crucial for VP1 protein expression. 
 
Figure 3.6 Deletion of nucleotides 376-396 prevents VP1 expression. Western 
blots were done with PAB597 (anti-VP1) (upper panels) using cell lysate collected 
from Cos-7 cells (A) 14 and (B) 21 days post-transfected.  VP1 is detectable with 
most of the viruses tested, exept Mad-1 PtΔ376-396 (Lane 6), Mad-1 C-Agno 
(Lane 10) and Mad-1 Del (Lane 12).  Anti-tubulin is used as a loading control 
(lower panels).  Blots are representative of results observed in 3 independent 
experiments. 
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293T cells can be infected with JCV.  Based on these results, we sought to 
identify the host cell proteins which bind to the agnogene of JCV by MS.  Of the cell 
lines used in previous experiments, Cos-7 cells replicate the highest levels of JCV.  
However, this is an African green monkey cell line and is therefore not the ideal cell 
line for use in MS analysis.  We tested 293T cells, a human kidney cell line 
transformed with SV40 T Ag, for the ability to replicate JCV.  293T cells were 
transfected with either JCVMad-1 or JCVCPN.  DNA was extracted from cell lysates and 
supernatant and levels of DNA were determined using qPCR.  We found that JCV 
can infect 293T cells (Figure 3.7).  JCVMad-1 was able to establish a persistent 
infection in these cells.  JCVCPN initially had high levels of JCV DNA present, but 
these levels dropped off at later times post-transfection.  Based on these results, we 
decided to use 293T cells for initial MS studies.  
 
DNA-IP MS to identify candidate agnogene binding proteins.  To identify 
host cell proteins binding to the JCV agnogene DNA we used a DNA-IP approach.  
We generated biotinylated DNA probes of either the JCVMad-1 or JCVCPN agnogene 
through PCR using biotinylated primers.  The biotinylated DNA probes were bound 
to streptavidin conjugated magnetic beads and incubated with nuclear proteins 
extracted from JCVMad-1 positive 293T cells to pull down candidate agnogene binding 
proteins.  Eluted proteins were run on an SDS-PAGE gel, and the bands of interest 
were excised and submitted for MS analysis.  Submitted bands are indicated in 
Figure 3.8. Band 1 was excised from the Coomassie stained gel (Figure 3.8B), Band 
2 from the silver stained gel (Figure 3.8A) and Band 3 from the Coomassie Stained 
gel (Figure 3.8B). Additionally, TCA precipitated samples were run a short distance 
in to the gel, stained with Commassie blue and the section containing 
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all the proteins in the sample was excised and submitted for MS analysis. Results 
were obtained and possible candidate binding proteins were identified. Band 1 was 
identified as poly (ADP-ribose) polymerase 1 (PARP-1), Band 2 as Ku70 and Ku80 
and Band 3 was not definitively identified from the results. Band 3 was resubmitted 
from additional experiments, but we were unable to identify it.  The MS results from  
Figure 3.7 JCVMad-1 and JCVCPN replicate in 293T cells.  239T cells were 
transfected with either JCVMad-1 or JCVCPN as described in Figure 3.3.  DNA was 
extracted from supernatant and cell pellets and JCV DNA levels were quantified 
using qPCR. 
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Figure 3.8 Protein Bands sent for Mass Spectrometry Analysis. A) Silver 
Stain of proteins bound to JCVMad-1 agnogene DNA (Lane 1), JCVCPN agnogene 
DNA (Lane 2) or no DNA control (Lane 3).  Band 2 was excised and submitted of 
Mass Spectrometry (MS) analysis.  B) Coomassie stain of the same samples 
concentrated by TCA precipitation.  Bands 1 and 3 were excised and submitted 
for MS analysis. 
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the total JCVMad-1, JCVCPN and no DNA total samples were compared to identify any 
proteins that were present at higher frequencies in either both JCVMad-1 and JCVCPN r 
in only JCVMad-1 or JCVCPN.  Replication protein A 70 kDa DNA-binding subunit  
(RPA1) and Replication protein A 32 kDa subunit (RPA2) were present in the 
JCVMad-1 but not JCVCPN or no DNA control samples. General transcription factor II-I 
(GTF2I) was present in JCVMad-1 and JCVCPN but not the no DNA control sample. 
 
Testing candidate binding proteins.  Two additional probes were made 
from the Ampicillin Resistance gene of pUC18.  A 220-bp (JCVMad-1 agnogene size)  
and a 75-bp (JCVCPN agnogene size) probe were generated. These DNAs were used 
as controls for proteins binding non-specifically to any DNA fragment. A silver 
stained gel of all proteins bound to each probe is seen in Figure 3.9A. Western Blots 
for specificity of binding of candidate proteins were done.  Despite what was seen 
with silver staining, PARP-1 was not found to bind specifically to JCV agnogene DNA 
in DNA-IPs done using either 293T or IMR-32 nuclear proteins (Figure 3.9B).  We 
also tested Ku70, RPA1 and GTF2I, all of which lacked specific binding to the 
agnogene DNA (Figure 3.9C). 
 
The PARP-1 inhibitor 3-AB does not inhibit JCV replication.  While the 
specificity of binding was being tested, we also tested whether the inhibition of 
PARP-1 enzymatic activity had an effect on JCV replication.  To do so, we used 3-
aminobenzamide (3-AB), an inhibitor of the enzymatic activity of PARP-1.  
Concentrations from 0.1 mM to 5 mM of 3-AB were added to JCVMad-1 transfected 
293T cells and the levels of DNA in the cell lysate and supernatant were monitored 
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(Figure 3.10).  3-AB treatment did no significantly change the levels of JCV DNA 
detected. 
 
 
Figure 3.9 Confirmation of candidate binding proteins. A) Silver Stain of 
proteins bound to JCVMad-1 agnogene DNA (Lane 1), JCVCPN agnogene DNA 
(Lane 2), 220 bp negative control (Lane 3), 75bp negative control (Lane 4) or no 
DNA control (Lane 5).  Band 1 was identified as PARP-1 by MS.  We could not 
identify Band 2.  B) Western blots for PARP1 from agnogene DNA IPs using 293T 
or IMR-32 nuclear proteins. PARP-1 binding to JCV agnogene is non-specific. C) 
Western blots to test binding of Ku70, RPA1 and GTF2I to JCV agnogene DNA 
using 293T nuclear proteins.  Lane 1 contains the total nuclear proteins extracted 
before IP.  Lanes 2-6 contain proteins bound to JCVMad-1 agnogene DNA (Lane 
2), JCVCPN agnogene DNA (Lane 3), 220 bp negative control (Lane 4), 75bp 
negative control (Lane 5) or no DNA control (Lane 6).  None of these were found 
to bind specifically to JCV agnogene DNA. 
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  Figure 3.10 The PARP-1 inhibitor 3-AB does not inhibit JCV replication in 
293T cells.  JCVMad-1 positive 293T cells were treated with increasing 
concentrations of 3-AB.  At 3, 7 and 10 days post-treatment cells were 
subcultured and supernatant and cell samples were collected.  The levels of JCV 
DNA were determined using QPCR. 
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DISCUSSION 
Recent studies of the agnoprotein have identified a number of roles for the 
protein in JCV replication, but the exact mechanisms of action have yet to be worked 
out.  Additionally, a cis-acting regulatory DNA element and host cell binding sites in 
the agnogene have been identified (22), although the mechanism of action is 
unclear.  We have previously studied JCVCPN, a naturally occurring isolate which 
contains a 143 nucleotide deletion, the first large agnogene deletion found in nature 
(23, 24).  The agnogene deletion in JCVCPN was found to impair VP1 expression and 
virion production, and this phenotype was primarily due to the loss of the agnogene 
DNA, rather than lack of a full length agnoprotein.   
In this study, we generated a series of agnogene deletion mutants.  In order to 
rule out any effects of mutations of the agnoprotein, these deletions were introduced 
into Mad-1 Pt, which has a start codon mutation preventing agnoprotein expression.  
We transfected these deletion mutants, along with a number of previously 
characterized control viruses, into Cos-7 cells and studied their replication by 
measuring levels of DNA replication, mRNA expression and VP1 protein production. 
We have previously found that both Mad-1 Del and Mad-1 C-Agno have 
decreased levels of DNA replication at later times post-transfection and lack 
expression of VP1 protein.  Mad-1 Pt has similar levels of DNA detected as JCVMad-1.  
Most of the new deletion mutants have similar phenotypes to Mad-1 Pt and JCVMad-1.  
The most striking phenotype was observed with Mad-1 Pt∆376-396, which had 
decreased levels of DNA replication at later time points post-transfection, and was 
the only new mutant which did not expression VP1.    We initially chose these 
nucleotides to delete because they are highly conserved between JCV, BKV and 
SV40 (Figure 3.3).  This may mean that the function of these nucleotides is 
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conserved among these three related viruses.  Interestingly, some of the larger 
deletions that include these 20 nucleotides do express VP1.  There are a number of 
possible mechanisms which may explain this phenomenon.  Nucleotides 376-396 fall 
within the predicted binding site III for host cell factors.  If there are multiple host cell 
proteins binding to the agnogene, Mad-1 Pt∆376-396 may have lost only one of 
them.  This could change the interactions and effects of other host cell proteins 
binding to the agnogene. Alternatively, this deletion may have created a new binding 
site.  It is also possible that these nucleotides are involved in proper splicing of the 
late mRNA, or that this deletion has created a new RNA secondary structure which 
affects translation of the VP1 protein.  If future studies identify the mechanism of this 
phenotype, it will be of interested to determine if these nucleotides play the same 
role in either BKV or SV40. 
Recently, Saribas et al published a study where they included an agnoprotein 
mutant with amino acids 34-36 deleted, named Mad-1 Agno ∆(34-36) (15).  This 
region is within the deleted region of Mad-1 Pt∆376-396.  In this study, they found 
that these residues are crucial for agnoprotein oligomerization and dimerization.  
They also see reduced viral DNA replication 15 days post-transfection, and 
decreased levels of late transcription and altered relative levels of the M1 and M2 
late transcript splice variants with Mad-1 Agno ∆(34-36).  Our results indicate that 
some of these phenotypes may be due to the loss of the DNA in the agnogene rather 
than expressing an agnoprotein which cannot form dimers and oligomers. 
To further understand the role of the agnogene, we attempted to identify host 
cell proteins binding to the agnogene DNA.  DNA-IPs followed by MS were done and 
the candidate proteins PARP-1, Ku70, RPA1 and GTF2-I were identified as possible 
binding factors.  However, none of these proved to bind specifically to the JCV 
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agnogene.  We can rule out these proteins as the host cell factors which bind the 
agnogene and influence viral replication.  The small band specific to JCVCPN samples 
was seen in multiple experiments (Figure 3.8, Band 3).  Repeated attempts were 
made to determine the identity of this protein, but we were unsuccessful.  Further 
studies of the host cell proteins interacting with the agnogene DNA are warranted.  
Transcription factors predicted to bind to the agnogene through sequence analysis 
could be tested for specific binding.  The agnogene deletion mutants generated here 
could then be used to help narrow down the exact binding sites for any specific 
binding factors. 
Nukuzuma et al. reported that the PARP-1 inhibitor 3-aminobenzamide (3-AB) 
can inhibit JCV replication in IMR-32 cells (30).  We tested the effect of 3-AB on JCV 
replication in 293T cells, and did not see significant changes in the levels of JCV 
DNA detected in either the cell lysate or supernatant.  PARP-1 was a candidate 
protein found bound to the JCV agnogene at high levels.  However, this interaction 
was also found with other DNA sequences, indicating that the interaction was non-
specific.  Given that PARP-1 plays a role in double strand DNA break repair, it is not 
surprising that it was identified in our study but proved non-specific.  While a lack of 
binding to the agnogene does not rule out other mechanisms of action for PARP-1 
inhibition of JCV replication, we did not see an effect of 3-AB treatment in our 
experiments using 203T cells.  The discrepancy between our results and those of 
Nukuzuma et al. may be due to the use of different cell lines and viral strains (30). 
Our study adds to the body of evidence that there is a cis-acting DNA element 
in the agnogene.  Studies to identify these proteins should continue to be carried out.  
Identification of the host cell proteins which bind to the agnogene would be valuable 
in understanding the role of the agnogene in JCV replication, and in the future 
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development of therapeutics for treatment of PML and other brain diseases caused 
by JCV infection. 
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SUMMARY 
 JCV infection of the brain can cause the fatal diseases PML, JCV GCN and 
JCVE.  This list is likely to grow as new diseases continue to be identified.  These 
diseases usually occur in individuals with some form of immune suppression.  In healthy 
individuals, JCV infection remains latent in the kidneys.  The disease pathogenesis and 
mechanisms of viral reactivation are not well understood.  The RR form of the virus 
determines the location, type and number of transcription factor binding sites in the 
early and late promoters, and is thought to play a role in JCV pathogenesis and tropism.  
The agnogene, which encodes the agnoprotein, is located in the late region, and its 
functions are still unclear.  A better understanding of the basic biology of JCV replication 
is crucial for the future development of therapeutics for the treatment of PML, JCV GCN 
and JCVE. 
 In Chapter 2, we studied the replication of JCVCPN in cell culture.  The 143-
nucleotide deletion in the JCVCPN agnogene is the first large deletion in the agnogene 
found in a naturally occurring isolate of JCV.  The RR of JCVCPN is archetype-like, a 
type which is generally found in the kidneys and urine and is considered non-
pathogenic.  We used kidney, glial and neuronal cell lines to compare the replication of 
JCVCPN and JCVMad-1 in different cell types.  We initially hypothesized that JCVCPN would 
have a replication advantage in neuronal cells because it was isolated from the first 
patient found to have JCV infection of cortical pyramidal neurons.  While JCVCPN was 
able to replicate in all cell lines tested, it did not show a replication advantage in the 
neuronal cell line tested.  We found that, while JCVMad-1 was able to establish a 
persistent high level infection, JCVCPN was unable to maintain high levels of DNA in 
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either transfected cell lysate or supernatant.  JCVCPN failed to express detectable levels 
of VP1 capsid protein and produced very low levels of infectious virions only at early 
time points post-transfection.  The agnogene and RR are the two main regions of 
difference between JCVCPN and JCVMad-1.  To determine which region was the main 
cause of the JCVCPN phenotype, we generated a series of chimeras between JCVCPN 
and JCVMad-1 and additional agnogene and agnoprotein deletion mutants.  We found 
that the predominant cause of the lack of VP1 expression and virion production was the 
deletion in the agnogene.  This phenotype was due primarily to the loss of the 
agnogene DNA and not the lack of a full length agnoprotein.  Introduction of a full length 
agnogene with a point mutation preventing agnoprotein expression was able to rescue 
JCVCPN.  These findings support a role for the agnogene DNA in VP1 expression and 
virion production. 
In Chapter 3, we further examined the role of the agnogene DNA in JCV 
replication.  We introduced a series of smaller agnogene deletions on a JCVMad-1 
backbone with the agnoprotein start codon mutated to prevent protein expression.  This 
allowed us to study the role of the agnogene DNA without confounding effects from 
mutations in the agnoprotein.  We characterized the levels of DNA replication, early and 
late mRNA transcription and VP1 protein production of these mutants.  We found that 
the deletion of nucleotides 376-396 resulted in a lack of VP1 capsid protein.  We then 
sought to determine the host cell proteins which bind to the agnogene DNA.  We 
identified a number of candidate proteins, including PARP1, Ku70, GTFII-I and RPA1, 
but none were found to bind specifically to the agnogene. 
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Overall, we have used a naturally occurring, pathogenic isolate of JCV to better 
understand the basic biology of replication of the virus.  We have used a cell culture 
model to study the newly discovered ability of JCV to infect neurons.  The deletion in the 
JCVCPN virus and our additional agnogene deletions have allowed us to better 
characterize the role of the agnogene DNA is JCV replication.  We have also studied 
the effect of the archetype-like RR of JCVCPN, a form more common found in the 
kidneys than the CNS, on replication in cell culture.  
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DISCUSSION 
JCV infection in neurons. 
 Since the isolation of JCV in 1971, it has been thought that JCV can only infect 
oligodendrocytes and astrocytes in the brain.  Over the past decade, the Koralnik 
laboratory has shown that JCV is also able to infect neurons, which results in newly 
discovered diseases other than PML.  This was seen for the first time in a patient with 
PML who also had JCV-infection of granule cell neurons (1). JCV GCN can also occur 
independently from PML and cases have now been identified all over the world (1-5).  
More recently, JCV was found to infect cortical pyramidal neurons in the first patient 
with JCVE (6).  The discoveries of JCV GCN and JCVE indicate a broadened 
pathogenesis of JCV infection in the brain, and we are only beginning to understand the 
prevalence and role in pathogenesis of neuronal infection by JCV.  
Since the identification of JCV GCN and JCVE, histological studies have been 
done to determine the prevalence of JCV infection of neurons.  The Koralnik laboratory 
studied archival brain samples from 49 PML patients and 109 healthy control subjects to 
determine the prevalence of gray matter lesions and JCV infection of cortical pyramidal 
neurons.  96% of the PML patients had demyelinating lesions at the gray-white junction 
and 57% had lesions in the gray matter.  Histological studies revealed that, while most 
JCV infected cells were oligodendrocytes, infected neurons in PML lesions were 
present in 54% and 50% of the gray-white junction and gray matter lesions, 
respectively.  Outside of PML lesions, 11% were found to have isolated cortical neurons 
expressing JCV proteins.  None of the control subjects had detectable JCV-infected 
cells.  This indicates that cerebral cortical neurons  are infected by JCV in a significant 
115 
 
portion of PML patients (7).  A similar study using archival samples from 43 PML 
patients to examine the frequency of JCV infection of cerebral granule cell neurons 
found that, of the 70% of samples in which JCV infected cells were detected, 93% had 
JCV positive cells in the granule cell layer.  19 samples were tested specifically for JCV 
infection of granule cell neurons, and 15 of them were found to be positive for infection.  
Only 1 of 72 control subjects without PML had JCV infection in granule cell neurons.  
This patient was HIV-positive (8).  In both of these studies, infected neurons expressing 
Large T Ag were more frequent than those expressing VP1, suggesting most of these 
neurons are not productively infected (7, 8).  Finally, there is evidence of JCV infection 
of neurons in the brains of individuals without any clinically apparent JCV-associated 
disease.  A study using laser capture microdissection of different cell types in non-PML 
brain samples, followed by PCR amplification found JCV DNA in oligodendrocytes, 
astrocytes and cerebral granule cell neurons, suggesting that JCV may also latently 
infect neurons in individuals without PML (9). 
It is now clear that JCV can infect neurons, both in patients with PML, JCV GCN 
and JCVE, as well as possibly individuals without any apparent JCV-related disease.  
The role of JCV infection of neurons in disease pathogenesis is still being determined.  
One study found JCV DNA in cerebral granule cell neurons of 7 of 17 archival non-PML 
brain samples tested by laser capture microdissection and PCR (9).  Most, but not all, of 
these individuals were HIV-positive or had some other form of immune suppression (9).   
Another only found 1 of 72 archival brain samples from HIV-infected individuals without 
PML had JCV protein expression in cerebral granule cell neurons (8).  This may indicate 
that these cells are a site of latent JCV infection.  This infection could happen with initial 
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infection with JCV, making these infected neurons a possible source of JCV reactivation 
under conditions of immune suppression.  
Studying neuron infection in cell cultures is challenging.  Neurons are difficult to 
grow and differentiate and the brain has a complex architecture that cannot be 
accurately replicated in cell cultures.  Additionally, JCV replicates in very few cell lines, 
most of which express a polyomavirus T Ag, and has a slow replication cycle.  It may be 
possible to address these issues by studying JCV infection ex vivo in cultured brain 
slices.  However, brain samples are generally only available from individuals who either 
have a disease requiring the removal or biopsy of brain tissue or from individuals who 
are deceased, making it difficult to obtain healthy brain tissue for study.  Additionally, 
the long replication cycle of JCV may make it difficult to sustain an infection in a brain 
slice culture long enough to gather sufficient data. 
Another complication to studying JCV infection in neurons is the lack of an 
animal model.  However, SV40 has been shown to sometimes cause a PML like 
disease in immunocompromised rhesus monkeys (10, 11).  When two 
immunocompromised monkeys were inoculated with an SV40 strain isolated from the 
CNS of another monkey with PML-like disease and meningoencephalitis, both 
developed meningoencephalitis and were found to have productive infection of cortical 
neurons (12).  A study of archival brain samples from rhesus monkeys found that 
neuron infection is present in 60% of immunocompromised monkeys with disease in the 
CNS due to SV40 infection (13).  Further studies of SV40 infection in neurons in rhesus 
macaques may add to our understanding of the role of neuronal infection in SV40 and 
JCV neuropathogenesis.  Studying primary infection in rhesus macaques would allow 
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us to determine if neurons are infected with SV40 during primary infection, and then 
latently infected until reactivation associated with immune suppression.  Mutations could 
be introduced into SV40 which equivalent to those seen in the strains of JCV isolated 
from JCV GCN and JCVE patients and these viruses could be used to determine the 
impact of these mutations on SV40 and its cellular tropism. 
 
JCVCPN and JCVE 
JCVCPN was isolated from the brain of a patient with JCVE. We were interested in 
studying this virus due to both the unique agnogene deletion as well as the fact that it 
was isolated in association with the infection of a new cell type, cortical pyramidal 
neurons.  We had initially hypothesized that the mutations in JCVCPN would allow it to 
infect neurons, and that it would have a replication advantage over JCVMad-1 in neurons.  
Our cell culture studies in Chapter 2 did not indicate an increased ability of JCVCPN to 
replicate in the neuronal cell line tested, IMR-32 cells.  However, these cells are a 
neuroblastoma cell line, and the results seen in them may not be representative of what 
occurs in the human brain.  First, they are a neuroblastoma cell line, not cortical 
pyramidal neurons.  JCV cellular tropism is highly dependent on the transcription factors 
present in a cell.  IMR-32 cells may lack the expression of a transcription factor that is 
present in cortical pyramidal neurons that is important for JCVCPN replication.  Second, 
neurons in the brain are surrounded by astrocytes, oligodendrocytes and other types of 
neurons.  These interactions may be important for the replication or spread of the virus, 
and are lacking in a cell culture model.  While we have not found any evidence for an 
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increased ability of JCVCPN to replicate in neuronal cells, we cannot rule out that this 
occurred in the brain of the JCVE patient.   
To date, there have been no additional cases of JCVE reported.  This makes it 
difficult to determine if the agnogene deletion of JCVCPN is the cause of this new 
disease, or if these are two independent phenomena.  JCVCPN was not the only strain of 
JCV present in the brain of the JCVE patient.  This strain co-existed with a strain of JCV 
with an intact agnogene (14).  The strain with the intact agnogene was found in the DNA 
from all parts of the brain tested, as well as in the blood and CSF.  PCR screen 
indicated that the majority of the JCV present was JCVCPN, while the intact-agno strain 
was the minority species.  One possible explanation for the high levels of JCVCPN found 
in the brain of the JCVE patient is that the presence of this strain expressing the full 
length agnoprotein helped the JCVCPN strain replicate.  A second strain of JCV with a 
large deletion in the agnogene has been identified in a PML patient who was not 
diagnosed with JCVE (14).  It may be that JCV variants with deletions occur with some 
regularity during natural infection, just as cortical pyramidal neurons are frequently 
infected in PML patients, as described above.  Further studies are needed to determine 
if this deletion actually plays a role in cortical pyramidal neuron infection in other cases.  
Laser capture microdissection of infected cortical pyramidal neurons from PML patients 
could be used to determine if these cells actually harbor a strain of JCV with a deletion 
in the agnogene, or an intact agnogene.  If they have intact agnogenes, then it is 
unlikely that the JCVCPN deletion is actually giving the virus the ability to infect cortical 
pyramidal neurons.  If additional cases of JCVE are diagnosed in the future, these 
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patients could also be studied to determine whether they also have a deletion in the 
agnogene in the JCV in their brain. 
While it is impossible to know exactly what happened in the JCVE patient, the 
results of our studies allow us to hypothesize about what may have occurred. JCV 
excreted in the urine usually contains an archetype RR, making this the form which is 
most likely to be present during initial infection.  Both the JCV strains with the deleted 
agnogene and the intact agnogene isolated from the brain of the JCVE patient had an 
archetype-like RR.  The sequence of the RR present in the urine of this patient is 
unknown.  It is possible that the JCVCPN archetype-like RR sequence was present in the 
virus which first infected the patient, or that this sequence arose in the virus before it 
infected the brain.  PCR analysis of the JCV present in the CSF and plasma indicated 
that they contained only JCV with a full length agnogene.  Based on these results, it is 
most likely that the brain was infected by JCV with this archetype-like RR and an intact 
agnogene, and the deletion in the agnogene arose in the brain of the patient.  JCV 
typically infects oligodendrocytes, and the infection of cortical pyramidal neurons was 
seen for the first time in the JCVE patient.  Most likely, the JCV with an intact agnogene 
reached the brain, where if first infected a limited number of oligodendrocytes without 
causing clinically apparent PML.  Over the course of time, the deletion in the agnogene 
occurred, and the virus was then able to infect the cortical pyramidal neurons.  In our 
cell culture studies, JCVCPN replicated poorly, and produced only very low levels of 
infectious virions.  While this led to poor replication in cell culture, it may have been 
advantageous in the patient, allowing the viruses to remain undetected and 
accumulated in the neurons over years or decades.  Then, when the JCVE patient was 
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treated with chemotherapy, the right conditions occurred for JCVCPN to cause the patient 
to develop JCVE (14).   
 
JCVCPN biology and the function of the agnogene 
While the cell culture studies of JCVCPN did not confirm our initial hypothesis, we 
were able to use this unique virus to study the functions of both the RR and the 
agnogene and agnoprotein.  Levels of viral DNA in the cell lysate and supernatant were 
not significantly different between JCVCPN and JCVMad-1 until 10-14 days post-
transfection.  Given that one replication cycle takes about 7 days and the initial levels of 
JCV DNA transfected were equal, this indicates that the JCVCPN virus can replicate viral 
DNA normally (15).  The drop in viral DNA after this first round of replication is indicative 
of an inability to produce infectious virions to initiation further rounds of infection in the 
cell culture.  The drastic decrease in late mRNA expression and the lack of detectable 
VP1 protein are evidence that the block in the replication cycle is due to insufficient 
levels of VP1 to produce virions.  Our model is that the low levels of late mRNA 
production leads to very low levels of VP1 production (Figure 4.1).  Although there is 
plenty of viral DNA, the amount of VP1 protein available to form the virion capsid is 
extremely limited, resulting in very few infectious virions being formed and released 
from the JCVCPN transfected cells.  Given the low level of infection observed after 
inoculation of Cos-7 cells with JCVCPN supernatant collected 7 and 14 days post-
transfection, it seems that some virions are produced, but not enough to sustain an 
infection in our cell culture model.  The fact that we can observe some DNA after  
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Figure 4.1 Model of JCVCPN VP1 expression and virion production impairment.  
JCVCPN has lower levels of late transcription, resulting in low VP1 expression.  This 
leads to very low levels of virion formation compared to JCVMad-1. 
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inoculation with this supernatant supports the idea that DNA replication of JCVCPN is not 
affected by the agnogene deletion or archetype-like RR. 
While it has long been thought that the RR of JCV needed to rearrange to allow 
infection of the CNS, there has been increasing evidence that archetype and archetype-
like RR forms can be found in the brain (16).  Based on our studies using chimeric 
viruses, it does not appear that the archetype-like RR of JCVCPN prevents VP1 protein 
expression and the production of infectious virions.  This suggests that the archetype-
like RR of JCVCPN does not impair replication of the virus when compared to the 
prototype rearranged strain, JCVMad-1.  Our results also provide support for the idea that 
archetype and archetype-like RRs are not limited to replication in the kidneys, and can 
be found in the brain. 
The agnoprotein was initially given its name due to the unknown nature of its 
function.  This protein is not essential for replication of JCV, and recent studies have 
begun to determine the role it plays during JCV replication.  Our studies of the chimeric 
viruses indicated that the phenotype of JCVCPN was due to the deletion in the agnogene, 
and more specifically loss of the DNA sequence in the agnogene.  We found that adding 
the full length gene with the start codon mutation preventing agnoprotein expression 
was sufficient to partially rescue the virus.  All of our data together indicate that the JCV 
agnogene plays a role in the expression of VP1 protein. 
It has been previously reported that deletion of the agnogene DNA has a greater 
impact on JCV replication than a start codon mutation preventing expression of the 
agnoprotein, suggesting that a DNA regulatory element is present in the agnogene (17).  
Further experiments indicated the presence of 3 host cell factor binding sites in the 
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agnogene.  This study and the results of our JCVCPN studies led us to generate 
additional small deletions in the agnogene to determine which nucleotides are critical for 
JCV replication.  The most striking finding of these studies was that deleting only 
nucleotides 376-396 prevents VP1 expression, while the viruses with all of the other 
larger deletions expressed VP1 protein.  This region was chosen for deletion because it 
is highly conserved between JCV, BKV and SV40.  This result was surprising given that 
this small deletion was encompassed by a number of larger ones, which had VP1 
expression.  There are many possible explanations for this.  The small deletion may 
disrupt an interaction between two binding factors by deleting the binding site for only 
one of them.  If this is the case, the presence of only one of these binding factors may 
have a different effect than the presence of both together.  If a large complex is being 
formed on the agnogene DNA, this small deletion may alter the proteins which are 
present by deleting one binding site, while larger deletions may lose the binding of 
multiple factors.   It may be altering late mRNA structure or splicing.  Another alternative 
explanation is the creation of a new binding site at the newly formed sequence.  To truly 
understand the mechanism of action of the agnogene, it is necessary to identify the host 
cell proteins which bind to it.  It would then be interesting to see whether these same 
nucleotides play a similar role in BKV and/or SV40. 
 We used a DNA-IP and MS approach to try to identify the host cell proteins which 
bind to the agnogene.  We have so far been unsuccessful in identifying a specific 
agnogene binding protein.  We have ruled out PARP1, Ku70, Ku80, RPA1 and GTFII-I 
as proteins which bind to the agnogene.  Further experiments must be conducted to 
determine the identity of the proteins binding.  Altering the conditions used in the DNA-
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IP may be necessary to successfully pull down the proteins of interest.  Alternatively, a 
different method such as a gel shift followed by MS analysis could be used to identify 
these proteins.  If the binding factors are transcription factors, then these interactions 
may be transient and difficult to pick up with our DNA-IP.  More targeted experiments, 
such as Chromatin Immunoprecipitations, to test for binding of transcription factors 
which are predicted to bind by computer algorithms could be used.  Regardless of 
method, identifying these proteins is an important area of research which will clarify the 
mechanism of the effect of deleting the agnogene. 
 While the list of human polyomaviruses has increased in recent years, decades 
passed between the discovery of JCV and BKV, and the discovery of additional human 
polyomaviruses.  It is interesting to note that of the human polyomaviruses, only JCV 
and BKV have an agnogene and express an agnoprotein.  The presence of an 
agnoprotein may have been advantageous for replication, and subsequent 
identification, of these viruses in cell culture using the techniques available at the time.  
While many of the new polyomaviruses have yet to be associated with a disease, 
MCPyV and TSPyV have been linked to Merkel cell carcinoma and Trichodysplasia 
Spinulosa, respectively.  This indicates that the lack of an agnoprotein does not prevent 
these viruses from causing human disease.  In addition to the JCVCPN strains, BKV with 
deletions of the 5’ end of the agnogene preventing agnoprotein expression have been 
isolated from 2 renal transplant patients (18, 19).  Both of these patients were also 
found to be infected with a BKV strain with an intact agnogene (18, 19).  While it is clear 
that naturally occurring JCV and BKV strains with agnogene deletions exist, it is 
possible that they require the presence of another strain with an intact agnogene.  
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Additional human polyomaviruses encoding agnoproteins may be discovered in the 
future, and aid in our understanding of the roles of the agnoprotein and agnogene in 
JCV replication. 
 
Challenges of studying JCV in cell culture 
Studying JCV in cell culture presents a number of challenges.  First, there are 
few cell lines in which JCV robustly replicates.  Many of the cell lines which are 
available for use are transformed with a polyomavirus, usually SV40, T Ag.  Second, the 
replication cycle of JCV is low, taking approximately 7 days for one replication cycle 
(15).  In our studies, we used Cos-7, SVG and IMR-32 cells.  Cos-7 is an African Green 
Monkey kidney cell line which express SV40 T Ag (20).  SVG is a human fetal glial cell 
line, also transformed with SV40 T Ag (21).  IMR-32 is a cell line derived from a human 
neuroblastoma tumor, and does not express any polyomavirus T Ag (22).  In some 
experiments, we also used the 293T cell line, which is a human kidney cell line which 
expresses SV40 T Ag.  All of these are cell lines which are commonly used to JCV in 
cell culture.  The difficulties of studying neuron infection have been discussed above.   
Understanding JCV replication in glial cells is crucial, as these are the cells which 
are lytically infected in patients with PML.  However, studying infection of glial also 
presents a challenge.  We used the SVG cell line to model glial cell infection.  SVG-A 
cells are also commonly used to study JCV infection.  This cell line is derived from the 
SVG cell line, and expresses the astrocyte specific marker glial fibrillary acidic protein 
(GFAP) (23) These cells are different than oligodendrocytes, the primary target of JCV 
in the brain.  This cell line also has the disadvantage of already expressing SV40 T Ag.  
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U-87 MG glioblastoma cells and TC620 oligodendroma cells have also been used to 
study JCV replication (24-27).  While these cells do not express a polyomavirus T Ag, 
they have the disadvantage of being derived from tumors.  Given the importance of 
transcription factor expression profiles in determining susceptibility to JCV infection, the 
altered cellular environments in these cancer cell lines may not be ideal for the study of 
JCV infection in glial cells. 
It has also been suggested that the used of progenitor derived astrocytes (PDAs) 
would be a better system for the study of JCV replication in glial cells.  These cells are 
derived from human neural progenitor cells (NPCs) from fetal CNS tissue, and do not 
express any polyomavirus T Ag (28-30).  They have been used in multiple studies of 
JCV, including a study of susceptibility factors for JCV infection, and to look at the effect 
of 1-O-hexadecyloxypropyl-cidofovir (CMX001) on JCV replication (28, 29).  One 
advantage to the use of PDAs is that they are more likely to accurately mimic the 
conditions present in the glial cells in the brain.  However, they require the use of fetal 
CNS tissue, and may be more difficult to obtain and culture than transformed cell lines.  
Nevertheless, it may be beneficial to repeat our experiments done in cell lines in PDAs.   
Currently, there is not a single perfect system for studying JCV in cell culture.  
Both the currently available cell lines and PDAs have advantages and disadvantages.  
Cell lines either express T Ag or are derived from tumors, but they grow well in culture 
and provide robust replication of JCV.  PDAs may be difficult to obtain and grow, but are 
more likely to represent the conditions present in glial cells in the brain.  The best 
utilization of these reagents is most likely using a combination of different cell lines and 
PDAs.  A study of the effect of CMX001 on JCV replication used both Cos-7 and PDA 
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cells, and found the results were consistent between the two cell types (29).  It would be 
beneficial to follow up the studies we have done here using cell lines in PDAs and 
possibly also in NPCs which have been differentiated into neuronal cells.  
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CONCLUSION 
 Infection with JCV is prevalent, with 39-91% of the population worldwide being 
seropositive for antibodies against the virus, depending on the population studied and 
assay used (31-35).  Individuals infected with JCV are at risk for the development of 
PML, JCV GCN and JCVE if they develop some form of immunosuppression.  
Additionally, with the use of immunomodulatory monoclonal antibody therapies, more of 
which are being developed for a variety of ailments, the population at risk for the 
development of these diseases is increasing.  Currently, there is no effective therapy for 
PML or other diseases caused by JCV infection in the brain.  The management consists 
of treating the underlying cause of immune suppression to boost the patient’s immune 
response to JCV, or, if possible, discontinuation of immunosuppressive medications.  
The development of a drug which inhibits JCV replication would be extremely valuable 
for the treatment of these patients.  A better understanding of JCV replication and 
pathogenesis may aid in such a breakthrough.  The agnoprotein was given its name 
due to the unknown nature of its function.  While recent research has begun to elucidate 
the functions of the agnoprotein and agnogene, the mechanisms of action remain 
unknown.  Interestingly, of the human polyomaviruses, only JCV and BKV have an 
agnogene.  All of the more recently discovered viruses, including MCPyV, do not have 
an agnogene encoding an agnoprotein.  A better understanding of the role of the 
agnogene in the viral replication cycle will increase our understanding of JCV 
replication, and may help in the development of treatments for PML and other diseases 
caused by JCV infection in the brain. 
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 In this thesis, we have explored the role of the agnogene, agnoprotein and RR in 
JCV replication.  JCVCPN was isolated from the brain of the first patient found to have 
JCV infection of cortical pyramidal neurons.  It is a pathogenic, naturally occurring strain 
of JCV which contains a 143 nucleotide deletion in the agnogene and has an archetype-
like RR.  Although our cell culture studies did not find evidence of a replication 
advantage for JCVCPN in neuronal cells, it is possible that JCVCPN is responsible for the 
broadened pathogenesis of JCV seen in JCVE.  Using JCVCPN to study the agnoprotein 
and agnogene we found that the agnogene DNA is necessary for the expression of VP1 
capsid protein and the successful production of infectious virions.  Additionally, the 
phenotype of JCVCPN can be attributed to the deletion of the nucleotides in the 
agnogene, rather than the loss of a full length agnoprotein.  We generated additional 
deletions in the agnogene and found that nucleotides 376-396 within the agnogene are 
critical for VP1 protein production.  Finally, we attempted to identify host cell proteins 
which bind to the agnogene DNA.  We have not yet identified a specific binding factor, 
but future efforts to identify binding factors and their functions in JCV replication will help 
to clarify the mechanism of action of the agnogene.  Overall, these studies have added 
considerably to our understanding of the role of the agnogene in JCV replication. 
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Abstract
Infection of glial cells by the human polyomavirus JC (JCV) causes progressive multifocal leukoencephalopathy (PML). JCV
Encephalopathy (JCVE) is a newly identified disease characterized by JCV infection of cortical pyramidal neurons. The virus
JCVCPN associated with JCVE contains a unique 143 base pair deletion in the agnogene. Contrary to most JCV brain isolates,
JCVCPN has an archetype-like regulatory region (RR) usually found in kidney strains. This provided us with the unique
opportunity to determine for the first time how each of these regions contributed to the phenotype of JCVCPN. We
characterized the replication of JCVCPN compared to the prototype virus JCVMad-1 in kidney, glial and neuronal cell lines. We
found that JCVCPN is capable of replicating viral DNA in all cell lines tested, but is unable to establish persistent infection
seen with JCVMad-1. JCVCPN does not have an increased ability to replicate in the neuronal cell line tested. To determine
whether this phenotype results from the archetype-like RR or the agnogene deletion, we generated chimeric viruses
between JCVCPN of JCVMad-1. We found that the deletion in the agnogene is the predominant cause of the inability of the
virus to maintain a persistent infection, with the introduction of a full length agnogene, either with or without agnoprotein
expression, rescues the replication of JCVCPN. Studying this naturally occurring pathogenic variant of JCV provides a valuable
tool for understanding the functions of the agnogene and RR form in JCV replication.
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Introduction
The human polyomavirus JC (JCV) has a circular double
stranded DNA genome which can be divided into 3 regions. The
early coding region encodes the regulatory proteins small t antigen
and large T antigen (T Ag). The late coding region encodes the
VP1, VP2 and VP3 structural proteins, and the agnoprotein [1].
The regulatory region (RR) contains the origin of replication, as
well as the early and late promoters [2,3]. While the coding
regions are well conserved, the RR is hypervariable, with different
sequences being isolated from individuals [1]. Archetype RR,
which has one 98-bp element and contains a 23-bp and a 66-bp
insert, is generally found in the kidneys or urine of healthy and
immunosuppressed individuals [4]. RRs from the brain or CSF of
PML patients are generally of the rearranged type, containing two
98-bp tandem repeats with additional mutations, insertions and
deletions [1,2].
JCV is the etiological agent of Progressive Multifocal Leukoen-
cephalopathy (PML), an often fatal demyelinating disease caused
by lytic infection of oligodendrocytes by the virus [5]. Infection
with JCV is widespread in the population, but remains asymp-
tomatic in healthy people [6,7]. Development of PML is associated
with immune suppression, such as in patients with AIDS [8],
organ transplants [9] or hematological malignancies [10]. We
have identified two additional syndromes caused by JCV infection
in the brain, JCV Granule Cell Neuronopathy (JCV GCN)
[11,12,13] and JCV Encephalopathy (JCVE) [14]. The viruses
isolated from patients with these syndromes contain previously
unreported unique mutations. JCV GCN is associated with
deletions in the C-terminus of the VP1 protein [15,16] and JCVE
with a deletion in the agnogene [17]. These naturally occurring
pathogenic variants provide a unique tool for studying the basic
biology of JCV replication and pathogenesis.
JCVE was described in an HIV-negative patient with a history
of lung cancer treated with chemotherapy, who presented with
cortical lesions, aphasia and progressive cognitive decline. Post-
mortem analysis of the brain showed cortical lesions with
productive infection of cortical pyramidal neurons [14]. Isolation
and sequencing of the JCV DNA present in the brain of this
patient identified a virus with an archetype-like RR and a 143 base
pair deletion in the agnogene [17]. This virus was named JCV
Cortical Pyramidal Neuron 1 (JCVCPN1). The deleted agnogene
encodes a 10 amino acid truncated peptide. Further analysis found
that multiple forms of JCVCPN were present, and that these strains
co-existed with a virus containing a full length agnogene.
Immunostaining analysis indicated that the majority of the cortical
cells infected with JCV contained the truncated form of the
agnoprotein [17].
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JCV agnoprotein is a highly basic, 71 amino acid, non-essential
protein that is expressed late in infection, but not incorporated into
virions [18]. It is primarily expressed in the cytoplasm, particularly
in the perinuclear region, with a small amount found in the
nucleus [19]. Agnoprotein has been shown to form homodimers
and oligimers [20]. Agnoprotein contains 3 phosphorylation sites,
which can be phosphorylated by protein kinase C [21] and
dephosphorylated by protein phosphatase 2A [22]. The phos-
phorylation state may impact agnoprotein localization [19].
Agnoprotein has been shown to bind to T Ag, down regulating
DNA replication [23] and enhancing T Ag origin binding [24].
Agnoprotein may also influence viral gene expression and splicing
of viral transcripts [25]. Loss of agnoprotein expression has been
associated with loss of early and late mRNA expression [19].
Agnoprotein has also been shown to suppress activity of the late
promoter [23], and to interact with the transcription factor YB-1,
inhibiting its ability to activate the early and late promoters [26].
Prevention of agnoprotein expression also has been shown to result
in decreased levels of T Ag and VP1 protein expression [27].
Viruses lacking agnoprotein are less efficient at packaging DNA
and virion formation, with infected cells releasing empty particles
[27,28]. The agnoprotein may also function as a viroporin, aiding
in the release of virions from infected cells [29]. These studies have
added to our knowledge of agnoprotein function in recent years,
but the exact mechanisms by which this protein influences the viral
life cycle remain unclear.
In addition to agnoprotein function, the DNA of the agnogene
has been shown to contain 3 host cell factor binding sites. Deletion
of the agnogene DNA has a greater effect on replication than
prevention of agnoprotein expression by mutation of the start
codon [30]. In the agnogene deletion present in JCVCPN, 1 of the
3 sites is completely deleted, and a second is shortened by 1
nucleotide.
We hypothesized that the agnogene deletion of JCVCPN allowed
the virus to infect cortical pyramidal neurons. We used cell culture
models to study the replication of JCVCPN compared to the
prototype strain JCVMad-1 [31] in different cell types. We
generated chimeric viruses of JCVCPN and JCVMad-1, swapping
both the agnogene and RR, to determine the specific effects of the
agnogene deletion and the archetype-like RR on viral replication
in cell culture. In these experiments we characterized the
replication of JCVCPN in different cell types, and determined the
relative contributions of the agnogene deletion and archetype-like
RR to the JCVCPN replication phenotype. Studying these novel
naturally occurring changes in JCVCPN provided unique insights
into our understanding of the function of the agnogene and RR
form in JCV replication.
Materials and Methods
Cell Culture
Cos-7 [32], SVG [33] and IMR-32 [34] cells were purchased
from the ATCC. Cos-7 cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), Penicillin (500 units/mL) and Streptomycin
(500 mg/mL). SVG cells were maintained in Minimum Essential
Medium (MEM) supplemented with Sodium Bicarbonate (1.5 g/
L), 10% FBS, Penicillin (500 units/mL) and Streptomycin
(500 mg/mL). IMR-32 cells were maintained in MEM supple-
mented with Sodium Bicarbonate (1.5 g/L), Sodium Pyruvate
(1 mM), Non-Essential Amino Acids (NEAA) (Invitrogen), 10%
FBS, Penicillin (500 units/mL) and Streptomycin (500 mg/mL).
Plasmids
Construction of the JCVCPN and JCVMad-1 plasmids was
previously described by Dang et al. [17]. To generate the
agnogene chimeric viruses Mad-1 C-Agno and CPN M-Agno,
the agnogene region was excised using the restriction enzymes
ApaI and PciI (New England Biolabs), and the digested DNA was
run on an agarose gel. The agnogene DNA and the virus minus
the agnogene DNA bands were excised and purified using the
QIAquick Gel Extraction Kit (QIAGEN). Agnogene DNA
segments were ligated into the viral backbone using T4 ligase
(New England Biolabs). The resulting plasmids were transformed
into TOP10 (Invitrogen) or XL1-Blue cells (Agilent). Plasmid
DNA was maxi prepped (QIAGEN), and plasmids were fully
sequenced. The RR chimeras were generated with the same
protocol, using the restriction enzymes BamHI and PciI (NEB) to
excise the RR. Mad-1 Pt and Mad-1 Del plasmids were previously
described [30], and obtained as a generous gift from Dr Safak.
The agnogene from these viruses was introduced into our JCVMad-
1 or JCVCPN plasmid using the ApaI and PciI restriction sites as
previously described.
Transfection
Full-length JCV genomes were digested out of the plasmid
backbone using EcoRI (NEB) and run on a 0.8% agarose gel. The
5 kb virus band was purified using the QIAquick Gel Extraction
Kit (QIAGEN). Cells were transfected with 1 mg (for IMR-32 and
SVG cells) or 2 mg (for Cos-7 cells) of purified JCV DNA using
FuGENE6 transfection reagent (Roche or Promega) in 6 well
plates. 3 days post-transfection, cells were passaged 1:3 to T25
flasks, and subsequently every 3–4 days 1:4 in T25 flasks. At each
passage, supernatant was collected and cells were collected,
pelleted and stored at 280uC until further analysis.
DNA Extraction and Quantitative PCR (QPCR)
DNA was extracted from cell pellets and supernatant samples
using the QIAamp DNA Blood Mini Kit (QIAGEN). QPCR was
performed as previously described [15]. An RNAase P primer/
probe set (Applied Biosystems) was used in a multiplex assay with
the JCV primer/probe set on cell lysate samples. Copies RNAse P
per reaction was determine and divided by 2 to determine the
number of input cells for each reaction. Copies JCV/cell was
calculated by dividing the copies JCV per reaction by the number
of cells per reaction. All samples were run in triplicate.
RNA Extraction and qRT-PCR
RNA was extracted using the RNEasy Mini Kit (QIAGEN).
RNA samples were digested with rDNAse I (Ambion) to remove
any contaminating DNA. Reverse transcription was done using
the High Capacity RNA-to-cDNA Kit (Applied Biosystems).
QPCR was performed on a 7300 Real-time PCR System using
Gene Expression Master Mix (Applied Biosystems). For amplifi-
cation of the early transcript mRNA, a primer probe set spanning
the Large T Ag splice site was used. The primers were JCT208F
(59-CATCAGCCTGATTTTGGTACATG-39, reverse comple-
ment of position 4784–4806) and JCT 279R (59-CCAG-
GATTCCCATTCATCTGTT-39, position 4392–4412). The
probe used was JCT-232p (6FAM-59-AAT AGT TCA GAG
GTG CCA AC-39-MGB, reverse complement of position 4419–
4426 and 4771–4482). For detection of late transcript mRNA we
used the primers JCVP1-745F (59-GGTGACAACTTA-
TACTTGTCAGCTGTT-39, position 2213–2239) and JCVP1-
812R (59-TGCTGGGAACCAGACCTGTT-39, reverse comple-
ment of position 2261–2280) and the probe JCVP1-773p (6FAM-
A Novel JC Virus Isolate with an Agnogene Deletion
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59-ATG TCT GTG GCA TGT TTA-39-MGB, position 2241–
2248). A TATA-box binding protein (TBP) primer/probe set
(Invitrogen) was used as the endogenous control for determination
of relative quantity by the comparative CT method (also known as
the DDCt method) [35]. All samples were run in triplicate wells.
Western Blotting
Cells were lysed in TNN lysis buffer (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1% NP40) with 0.2 mM Na-Orthovanadate and
1% protease inhibitor cocktail for 30 minutes on ice. Samples were
centrifuged at 8000 rpm for 4 min to remove cell debris. Laemmli
Buffer (Bio-Rad) was added to whole cell lysate. Samples were
boiled for 10 min and run on a 10% SDS-PAGE gel in Tris/
Glycine/SDS running buffer (Bio-Rad). Samples were transferred
for 2 hours at 150 mAmps to a nitrocellose membrane in Transfer
Buffer (Tris/Glycine with 20% methanol) or to a nitrocellulose
membrane using the iBlot system (Invitrogen). Membranes were
blocked using 5% milk in PBST and incubated overnight at 4uC
with VP1 antibody pAB597 (1 mg/mL) diluted 1:1000 or loading
control anti-alpha tubulin [DM1A] (abcam) in 2% milk in PBST.
An HRP conjugated goat-anti mouse IgG secondary antibody
(Bio-Rad) was used and detection was done with ECL Plus reagent
(Thermo Scientific). Signal was detected on film.
Flow Cytometry Analysis of JCV-Positive Cells
Cells were trypsinized, collected and washed with 2% FBS in
PBS. Cells were passed through a 30 mm filter (Miltenyi Biotec)
and incubated for 20 minutes at 4uC with Aqua Amine to stain
dead cells, and then washed with PBS. Cells were fixed with
Cytofix/Cytoperm (BD Biosciences) for 20 minutes at 4uC then
washed with PBS. Staining with the primary antibody PAB597
(mouse monoclonal anti-VP1) in Perm/Wash Buffer (BD Biosci-
ences) was done for 2 hours at 4uC. Cells were washed with Perm/
Wash Buffer, then PBS and then stained with Alexa 488
conjugated Anti-Mouse IgG (Invitrogen) secondary antibody in
Perm/Wash Buffer for 1 hour at 4uC. Cells were washed, and
then analyzed using a BD LSR II Flow Cytometer (BD
Biosciences).
JCV Infectivity Test
Cos-7 cells were plated in 6 well plates at low density and
allowed to adhere overnight. Cell free supernatant collected from
transfected cells was put on the Cos-7 cells, and incubated 2 hours
at room temperature with rocking. Supernatant was not digested
with DNAse to remove free JCV DNA, as previous experiments
have shown that digesting with DNAse does not affect the levels of
JCV DNA detected in the supernatant by qPCR, or the
percentage of cells subsequently infected from the supernatant
(data not shown). The infection was allowed to proceed for 7 days.
Cells were then collected and analyzed for either VP1 expression
by flow cytometry or JCV DNA by QPCR as previously described.
Statistical Analyses
Analyses were done using SAS Software version 9.3. Data was
tested for normality before statistical analysis. P-values for DNA
levels were determined using the non-parametric Wilcoxon Rank
Test. P-values for mRNA levels were done using univariate
analysis, and taking the student’s t p value. Flow cytometry p-
values were determined using Student’s t test.
Results
JCVCPN has a 143 base pair deletion in the agnogene and
an archetype-like RR
The JCVCPN1 RR is archetype-like, lacking a duplication of the
TATA-box and containing a 66 bp and 80 bp insert, which
contain portions of the 23 bp and 66 bp inserts present in
archetype RR (Fig. 1A) [17]. A 143 bp deletion in the agnogene is
also present in JCVCPN1 (Fig. 1B) [17]. This deletion creates a
premature stop codon, and is predicted to code for a truncated 10
amino acid agnoprotein. Multiple forms of JCVCPN were
identified, including JCVCPN1.1 and JCVCPN1.2 which both
contain the same regulatory region and agnogene deletion. In
addition, JCVCPN1.2 contains a 75 bp duplication between the
agnogene and the VP2 gene, encompassing the start of the VP2
gene (Fig. 1B). This form is predicted to encode for both a
truncated and a full length VP2. Our studies determined that
JCVCPN1.1 and JCVCPN1.2 are phenotypically equivalent in our
cell cultures model (data not shown). Therefore, we chose to
conduct the experiments in this study using the JCVCPN1.2 strain,
because it was the predominant strain in the JCVE patient’s brain.
JCVCPN1.2 is referred to as JCVCPN for the remainder of this work.
JCVCPN can replicate DNA in cell culture, but at a lower
level than JCVMad-1
To determine the cellular tropism of JCVCPN, we studied its
replication in cell culture. We used multiple cell lines to model the
replication of the virus in three different types of cells, kidney cells,
glial cells and neurons. Cos-7 cells are African Green Monkey
kidney cells which express SV40 T Ag, and are known to replicate
JCV well [32]. SVG cells are human fetal glial cells, also
transformed with SV40 T Ag [33]. IMR-32 cells are a human
neuroblastoma cell line, derived from a tumor isolated from the
abdominal cavity of a child, which do not express any
polyomavirus T Ag [34]. We first wanted to determine if JCVCPN
is capable of genome replication. To do so, linearized genomes of
JCVCPN and JCVMad-1 were transfected into Cos-7, SVG and
IMR-32 cells. DNA from cell lysate, representing JCV DNA
replicated in the transfected cells, and supernatant, representing
DNA released from the transfected cells, was extracted and
digested with DpnI to remove any remaining input plasmid DNA.
JCV genome copy number was determined by QPCR. We found
that JCVCPN replicated DNA after transfection in all 3 cell lines
tested (Fig. 1C–H). However, the levels of DNA were not
equivalent to those seen with the prototype strain JCVMad-1.
In Cos-7 kidney cells, JCVMad-1 establishes a high level infection
that persists over 3 weeks, as measured by copies JCV DNA in the
cell lysate and supernatant (Fig. 1C and 1D). JCVCPN has
equivalently high levels of JCV genomes present in the cell lysate
and supernatant during the first week post-transfection, but does
not maintain such a high viral load, with the copy number
decreasing with time. In SVG glial cells, both JCVMad-1 and
JCVCPN establish persistent infections (Fig 1E and 1F). Levels of
JCVCPN genome copies in cell lysate and supernatant at later time
points post-transfection are significantly lower than those of
JCVMad-1, but with a smaller magnitude of difference than
observed in Cos-7 cells. In IMR-32 neuronal cells, JCVMad-1 DNA
decreased over the first 2 weeks after transfection, and then leveled
off, remaining detectable over 3 weeks (Fig. 1G and 1H). In
contrast, JCVCPN decreased and dropped below the limit of
detection at 14 days post-transfection in cell lysate and 17 days
post-transfection in the supernatant. These results indicate that
JCVCPN is able to replicate its genome after transfection into Cos-
7, SVG and IMR-32 cells, but may have a decreased capacity to
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persist and spread within the culture compared to prototype
JCVMad-1. Additionally, JCVCPN does not display a replication
advantage in the neuronal cell culture line tested.
JCVCPN expresses both early and late transcripts, but at
decreased levels compared to JCVMad-1
Knowing that JCVCPN is able to replicate viral DNA, but not
establish a persistent high level infection, we wanted to determine
if JCVCPN is able initiate transcription of mRNAs from the early
and late promoters. To do so, we used qRT-PCR on RNA from
transfected cells using primer and probe sets located in T Ag to
detect early transcripts, and in VP1 to detect late transcripts. In
Cos-7, SVG and IMR-32 cells, JCVCPN expresses detectable levels
of both the early and late transcripts (Fig. 2). In Cos-7 cells, the
level of early transcripts is significantly lower than those seen with
JCVMad-1 3 and 10 days post-transfection (Fig. 2A). In SVG cells,
Figure 1. JCVCPN replicates viral DNA, but at lower levels than JCVMad-1. (A) JCVCPN RR is archetype-like (adapted from (17)). (B) JCVCPN1.2
(hereafter referred to as simply JCVCPN) agnogene contains a 143 base pair deletion followed by a 75 base pair duplication at the beginning of the
VP2 gene. (C–H) Cos-7, SVG and IMR-32 cells were transfected with linearized JCV genomes, or mock transfected. Cells were subcultured every 3–4
days and cell and supernatant samples were collected. DNA was extracted from the samples, digested with DpnI to remove input plasmid DNA, and
analyzed by QPCR. Data represents the average of 4–10 independent experiments. In Cos-7 cell lysate (C) and supernatant (D) JCVMad-1 but not
JCVCPN establishes a persistent infection. In SVG cell lysate (E) and supernatant (F) JCVMad-1 and JCVCPN both establish persistent infections. In IMR-32
cells, JCVMad-1 infection persists for 21 days, while JCVCPN becomes undetectable in cell lysate (G) and in supernatant (H). Error bars represent standard
deviation. P-values were calculated using the Wilcoxon Rank Test. ND is not detected.
doi:10.1371/journal.pone.0080840.g001
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the level of early transcripts is similar between JCVCPN and
JCVMad-1 3 and 7 days post-transfection, and significantly lower 10
days post-transfection (Fig. 2B). In IMR-32 cells, level of early
transcripts produced by JCVCPN is significantly lower than those of
JCVMad-1 at 3, 7 and 10 days post-transfection (Fig. 2C). In all
three cell lines, the level of late transcripts is markedly lower in
JCVCPN transfected cells compared to JCVMad-1 transfected cells
(Fig. 2D–F). These results indicate that, although both the early
and late promoter of JCVCPN are transcriptionally active, they
function at a level lower than JCVMad-1. The decrease in transcript
levels is larger for the late than the early promoter.
JCVCPN fails to produce detectable levels of VP1 protein
in Cos-7 cells
We then wanted to determine if JCVCPN produces VP1 protein
from the late mRNA. JCVMad-1 transfected cells produce VP1
protein, with the amount of VP1 present increasing with later
times post-transfection (Fig. 2G). JCVCPN does not produce
detectable levels of VP1 protein, even with long exposure times
(Fig. 2G).
To determine if there is VP1 present in a small number of
JCVCPN transfected cells, which cannot be detected by Western
Blot, we developed a protocol to analyze transfected Cos-7 cells for
VP1 expression using flow cytometry. JCVMad-1 transfected cells
were positive for VP1 expression, with an increase in the
percentage of cells positive for VP1 over time, with the highest
percentage of VP1 positive cells seen 21 days post-transfection
(Fig. 2H). The percentage of JCVMad-1 VP1 positive cells is
significantly higher than the background observed in Mock
transfected cells. JCVCPN transfected cells are not positive for
VP1 by flow cytometry at a level significantly higher than Mock
transfected cells (Fig 2H). This supports the results seen in using
Western blotting, that JCVCPN does not express detectable levels
of VP1 protein.
JCVCPN produces low levels of infectious virions
Although we could not detect VP1 expression by Western Blot
or flow cytometry in transfected cells, there may be a very low level
of expression below our limit of detection. We therefore wanted to
determine if JCVCPN transfected cells are producing virions
capable of infecting a new round of cells. To do so, supernatant
Figure 2. JCVCPN expresses less early and late mRNA and VP1 protein than JCVMad-1. (A–F) Cos-7, SVG and IMR-32 cells were transfected
with JCVMad-1, JCVCPN or mock transfected and samples collected as described in Figure 1. qRT-PCR was used to determine the levels of early (T Ag)
and late (VP1) transcripts. Relative Quantity (RQ) was calculated using the DDCt method, using TATA-Box Binding Protein (TBP) as the endogenous
control and JCVMad-1 as the calibrator sample. Data represents the average of 5–6 independent experiments. (A and D) In Cos-7 cells, JCVCPN expresses
significantly lower levels of T Ag (A) and VP1 (D) mRNA. (B and E) In SVG cells, levels of T Ag (B) mRNA expressed by JCVCPN are similar to JCVMad-1,
while VP1 (E) mRNA is significantly lower. (C and F) JCVCPN expresses significantly less T Ag (C) and VP1 (F) mRNA in IMR-32 cells. Error Bars represent
standard deviation. P values were calculated for Student’s t test using univariate analysis. ND is not detected. (G) Western blots were done with
PAB597 (anti-VP1) using cell lysate from Cos-7 cells transfected with either JCVMad-1 (Lanes 1–3), JCVCPN (Lanes 7–9) or mock transfected cells (Lanes
4–6) collected 7 (Lanes1,4,7), 14 (Lanes 2,5,8) or 21 (Lanes 3,6,9) days post-transfection. VP1 can be detected in JCVMad-1 transfected cells at all time
points, but not at any time with JCVCPN, with either a short (upper panel) or long (middle panel) exposure. Anti-tubulin antibody was used for loading
control (lower panel). Blots are representative of 3 independent experiments (H) JCVMad-1, JCVCPN or mock transfected Cos-7 cells were analyzed for
VP1 expression by flow cytometry. JCVMad-1 but not JCVCPN transfected cells have significantly higher levels of VP1 positive cells than Mock
transfected samples. Results are the average of 4 independent experiments. Error bars represent standard deviation. P values were calculated using
students t test, comparing JCVMad-1 and JCVCPN to mock.
doi:10.1371/journal.pone.0080840.g002
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was collected from transfected Cos-7, SVG and IMR-32 cells 7, 14
and 21 days post-transfection and was used to infect Cos-7 cells.
Infection was allowed to proceed for 7 days. Cells were collected,
and analyzed for JCV DNA by QPCR or stained for VP1 and
analyzed by flow cytometry.
JCVMad-1 containing supernatant from Cos-7 cells was able to
establish an infection in the new cells, with the viral load and the
percentage of cells infected increasing with supernatant collected
at later time points post-transfection (Fig. 3A and B). The
percentage of VP1 positive cells was significantly higher than in
the samples treated with supernatant from mock transfected cells
(Fig. 3B). In contrast, cells infected with JCVCPN containing
supernatant had significantly lower levels of viral DNA detected,
which decreased over time, becoming undetectable in samples
infected with supernatant collected 21 days post transfection
(Fig. 3A). The percentage of JCVCPN VP1 positive cells was not
significantly higher than observed with Mock supernatant (Fig. 3B),
which is most likely due to the lack of detectable expression of VP1
protein in JCVCPN transfected cells.
Similar results were seen using supernatant from transfected
SVG and IMR-32 cells, with low levels JCV DNA detected in cells
infected with JCVCPN containing supernatant collected 7 days
post-transfection, and then decreasing (Fig. 3C and D). Using
supernatant from SVG cells, JCVCPN DNA remains detectable
with supernatant collected 14, but not 21, days post-transfection
and JCVMad-1 infected cells had DNA levels that were significantly
higher than those observed with JCVCPN at all time points
(Fig. 3C). In contrast to the results observed using Cos-7
supernatant, the viral loads in JCVMad-1 infected cells decreased
with later collection points using SVG supernatant (Fig. 3C). Cells
infected with supernatant collected 14 and 21 days post-
transfection from IMR-32 cells had undetectable JCVCPN DNA
levels (Fig. 3D). JCVMad-1 DNA was detected in cells infected with
supernatant collected from IMR-32 cells at 7 and 21 days, but not
14 days, post-transfection (Fig. 3D). This is most likely due to the
levels of JCV DNA being below the limit of detection of our assay.
Generation of chimeras and agnogene mutants
The results of the above experiments comparing JCVCPN and
JCVMad-1 suggest that JCVCPN has a block preventing late gene
expression and protein production, as well as in the production
and release of infectious virions. The two major regions of
difference between JCVCPN and JCVMad-1 are the RR and the
agnogene. To determine which area of the virus is the major
contributor to the phenotype of JCVCPN, we generated chimeric
viruses of JCVCPN and JCVMad-1 (Fig. 4). We swapped the
agnogene genes of the two viruses to generate Mad-1 C-Agno and
CPN M-Agno. Mad-1 C-RR and CPN M-RR were generated by
exchanging the RRs of the two viruses. We obtained two agno
deletion mutations, Mad-1 Pt, which has a start codon point
mutation which prevents the expression of agnoprotein, and Mad-
1 Del, which has the entire agnogene deleted. CPN M-Pt contains
the full length agnogene with the start codon point mutation from
Figure 3. JCVCPN transfected IMR-32, SVG and Cos-7 cells produce low levels of infectious virions. Supernatant from transfected Cos-7,
SVG and IMR-32 cells was collected 7, 14 and 21 days post-transfection, and used to infect naive Cos-7 cells. At 7 days post-infection, cells were
collected and either analyzed for JCV DNA using QPCR (A, C and D) or stained for VP1 and analyzed using flow cytometry (B). Supernatant collected 7
days post-transfection from JCVCPN transfected Cos-7 (A), SVG (C) or IMR-32 (D) cells can establish an infection in naı¨ve Cos-7 cells, as measured by the
presence of JCV DNA 7 days post-infection. Levels of DNA detected with JCVCPN infection are significantly lower than with JCVMad-1 infection (A, C and
D). (B) VP1 positive cells are detected after infection with JCVMad-1, but not JCVCPN containing supernatant. Data is the average of 3–4 independent
experiments. Error bars represent standard deviation. P vales were calculated using Wilcoxon rank test for QPCR data, comparing JCVCPN to JCVMad-1.
P-values for flow cytometry data were calculated using students t test, comparing JCVMad-1 and JCVCPN to mock at each time point. ND is not
detected.
doi:10.1371/journal.pone.0080840.g003
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Mad-1 Pt. We studied these additional mutants in Cos-7 cells,
because these cells displayed the greatest difference in phenotype
between JCVMad-1 and JCVCPN.
The agnogene deletion is the major contributor to the
phenotype of JCVCPN
To begin characterizing the phenotypes of the viruses shown in
Figure 4, linearized DNA was transfected into Cos-7 cells, and
JCV DNA levels in cell lysate and supernatant were monitored for
3 weeks using QPCR (Fig. 5). Mad-1 C-Agno has significantly
lower levels of DNA from 10–21 days post-transfection compared
to Mad-1, while Mad-1 C-RR has DNA levels similar to Mad-1
(Fig. 5A and 5C). This indicates that introducing the agnogene
deletion of JCVCPN into Mad-1 results in a decrease in DNA
replication. In contrast, the introduction of the JCVCPN RR does
not. This suggests that the major cause of the replication kinetics
seen with JCVCPN are due to the agnogene deletion, and the not
the archetype-like RR. When comparing the agno deletion viruses
to JCVMad-1, Mad-1 Pt has similar DNA levels, while Mad-1 Del
had decreased levels late in infection similar to JCVCPN (Fig. 5A
and 5C). This provides evidence the gene deletion is more
important than the loss of the agnoprotein for the observed
phenotype.
Furthermore, the results seen with the viruses on the JCVCPN
backbone support these conclusions. CPN M-Agno, with the full
length agnogene and agnoprotein, and CPN M-Pt, with just a full
length agnogene, have the greatest increase of JCV DNA levels
compare to JCVCPN, and in both cases the level of DNA increase
is similar (Fig. 5B and 5D). This supports the conclusion that the
deletion in the agnogene causes the decreased replication ability of
JCVCPN. CPN M-RR, with the JCVMad-1 RR, also show some
increase in DNA levels, but to a lesser extent than CPN M-Agno
(Fig. 5B and 5D).
Deletion in the agnogene prevents expression of VP1
protein
We then sought to determine if the levels of VP1 protein
expression would correspond with levels of viral DNA in cells
transfected with the chimeras and agno deletion mutants. Western
blots were done for VP1 expression in JCV transfected Cos-7 cells.
At 14 days post-transfection, only JCVMad-1, Mad-1 Pt, Mad-1 C-
RR and CPN M-Agno have detectable levels of VP1 (Fig. 6A). At
21 days post-transfection, all of these viruses and CPN M-Pt have
detectable VP1 protein expression (Fig. 6B). All of these viruses
have full length agnogenes, but Mad-1 Pt does not have
agnoprotein expression. Compared to JCVMad-1, Mad-1 Pt shows
some decrease in VP1 expression, while Mad-1 Del has a complete
lack of VP1 expression. All of the viruses with the JCVCPN
agnogene deletion, JCVCPN, Mad-1 C-Agno and CPN M-RR lack
VP1 expression (Fig. 6A and 6B). Taken together, these results
indicate that the deletion in the agnogene results in decreased or
undetectable levels of VP1 protein expression, and that the levels
of DNA replication correspond with the presence of VP1 protein
expression.
Deletions in the agnogene reduce the production of
infectious virions
Finally, we sought to determine if the ability to produce
infectious virions of the chimeric and agno deletion viruses also
corresponds with DNA levels and VP1 protein production in these
cells. Supernatant collected from Cos-7 cells 21 days post-
transfection was used to infect naı¨ve Cos-7 cells, and the DNA
levels (Fig. 7A) and percentage of cells expressing VP1 (Fig. 7B)
were determined by QPCR and flow cytometry, respectively, at
day 7. Compared to JCVMad-1-infected cells, both Mad-1 C-agno
and Mad-1 Del –infected cells have significantly lower viral loads,
showing a 1.5–2 log decrease (Fig. 7A). Mad-1 Pt and Mad-1 C-
RR-infected cells also have significantly lower viral loads than
JCVMad-1-infected cells, but tended to have a smaller magnitude of
decrease (Fig. 7A). Mad-1 C-agno and Mad-1 Del-infected cells
have significantly lower percentages of cells expressing VP1, while
Mad-1 Pt and Mad-1 C-RR-infected cells do not (Fig. 7B). CPN
M-Agno, CPN M-RR and CPN M-Pt-infected cells all have
detectable DNA levels, with significantly higher viral loads
compared to JCVCPN (Fig. 7A). Compared with JCV CPN-infected
cells, CPN M-Agno-infected cells have a significantly higher
percentage cells expressing VP1, and CPN M-Pt-infected cells
tended to have more cells expressing VP1. Interestingly,
introduction of only the full length gene without protein expression
in CPN M-Pt is enough to rescue the DNA levels, and show some
increase in percent of cells expressing VP1.
The results of these infection experiments suggest that the
deletion in the agnogene is the primary cause of the phenotype
observed with JCVCPN. However, CPN M-RR, with the JCVMad-1
RR does show some increase in DNA replication and production
of infectious virions compare to JCVCPN, which may indicate that
the RR composition is also affecting replication of the virus, but to
a lesser degree than the agnogene deletion. It is likely that the
combination of the agnogene deletion together with archetype-like
RR is the cause of the overall phenotype of JCVCPN. Overall,
these experiments have used the unique naturally occurring
JCVCPN agnogene deletion and archetype-like RR to clarify the
Figure 4. JCVMad-1 and JCVCPN chimeras and agno deletion
mutants. This diagram shows the various chimeric viruses and deletion
mutants generated. Black represents sequences from JCVMad-1 and
white represents sequences from JCVCPN. Lines represent DNA
sequences. Dotted Lines represent deletions. Boxes represent genes.
An X through ATG represents mutation of the start codon to eliminate
protein expression. Mad-1 C-Agno is JCVMad-1 with the JCVCPN
agnogene introduced. CPN M-Agno is JCVCPN with a full length
agnogene from JCVMad-1 introduced. Mad-1 C-RR is JCVMad-1 with the
JCVCPN RR and CPN M-RR is JCVCPN with the JCVMad-1 RR. Mad-1 Pt is
JCVMad-1 with a mutated start codon which prevents the expression of
the agnoprotein and Mad-1 Del is JCVMad-1 with the entire agnogene
deleted. CPN M-Pt is JCVCPN with the agnogene of Mad-1 Pt.
doi:10.1371/journal.pone.0080840.g004
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role of the agnogene and RR forms in JCV replication in cell
culture.
Discussion
JCVCPN was isolated from the brain of the first patient to be
diagnosed with JCVE, a novel syndrome characterized by
infection of cortical pyramidal neurons. JCVCPN is the first
naturally occurring isolate with a large deletion in the agnogene,
which was originally called agno due to the unknown nature of its
function. While studies have begun to shed light on the function of
the agnoprotein and agnogene, there is still much to be learned.
JCVCPN presents the opportunity to study the function of the
agnogene and agnoprotein in a naturally occurring pathogenic
variant of JCV, isolated in association with infection of a new cell
type.
In this study, we compared the replication of JCVCPN to that of
the prototype virus JCVMad-1. We used Cos-7 cells to model
infection in kidney cells and SVG cells as a glial cell model. Both of
these cell lines are widely used to study the replication of JCV in
kidney and glial cells, and it is commonly thought that the results
obtained in them are applicable to what would occur in these cell
types during JCV infection in humans. Studying the replication of
JCV in cortical pyramidal neurons is challenging, as there are no
cortical pyramidal neuron cell lines available. We therefore used
IMR-32 neuroblastoma cells to model neuronal infection. Using
these cell lines allowed us to study the replication of JCVCPN in
Figure 5. The agnogene deletion of JCVCPN is the primary cause of its replication defect. Linearized JCV DNA of JCVMad-1, Mad-1 C-Agno,
Mad-1 C-RR, Mad-1 Pt, Mad-1 Del, JCVCPN, CPN M-Agno, CPN M-RR, and CPN M-Pt were transfected into Cos-7 cells and DNA levels were quantified
over 3 weeks, as described in Figure 1. (A and C) Levels of DNA with JCVMad-1 and the chimeras and agno deletion viruses on the JCVMad-1 backbone
were measured in the cell lysate (A) and supernatant (C). Mad-1 C-Agno and Mad-1 Del show significantly lower levels of DNA late in infection. (B and
D) Levels of DNA with JCVCPN and the chimeras and agno deletion viruses on the JCVCPN backbone were measured in the cell lysate (B) and
supernatant (D). Introduction of a full length agnogene causes the greatest increase in DNA levels. Data represents the average of 4–10 independent
experiments. Error bars represent standard deviation. P-values were calculated with the Wilcoxon Rank Test. ND is not detected.
doi:10.1371/journal.pone.0080840.g005
A Novel JC Virus Isolate with an Agnogene Deletion
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e80840
142
different cell types in cell culture. We found that JCVCPN was
capable of replicating its genome in cell culture. However, it could
not establish an infection at the same level observed with JCVMad-1
over time and did not display any replication advantage over
JCVMad-1 in any cell line. Levels of JCVCPN DNA replication in
Cos-7 and IMR-32 cells were similar to JCVMad-1 at early time
points, and then decreased at later time points, indicating that the
virus is able to replicate viral DNA after transfection but the
infection could not spread and persist in the cell culture at the
same level as JCVMad-1. In addition, mRNA and VP1 protein
analyses showed some decrease in early transcription and a
marked decrease in late transcription, with no detectable VP1
protein production. In all three cell lines, low levels of infection
were observed using supernatant from JCVCPN transfected cells,
but only using supernatant collected at early times post-transfec-
tion, and at levels significantly lower than seen with JCVMad-1.
These data indicate that the virus has a block in late gene
expression and protein production, which results in low levels of
infectious virions being released, and an inability to sustain a
persistent high level infection in cell culture. Furthermore, since
agnoprotein has been implicated in late stages of viral maturation,
there may be an additional block at the level of virion formation
and/or release independent of the lack of VP1 production.
JCVCPN and JCVMad-1 are different in two regions, the RR and
the agnogene. This provided us with the unique opportunity to
determine for the first time how each of these regions contributed
to the phenotype of JCVCPN. We therefore studied a series of
chimeric viruses of the RR and agnogene. Interestingly, the
agnogene deletion in JCVCPN was the predominant cause of its
phenotype, not the archetype-like RR. Moreover, the loss of the
agnogene DNA had a larger effect on the replication of the virus
than the loss of agnoprotein expression. Finally, the archetype-like
RR also showed a detrimental effect on JCVCPN replication, but of
a smaller magnitude than that of the agnogene deletion. For these
experiments we used Cos-7 cells, because they displayed the
largest difference in phenotype between JCVCPN and JCVMad-1
and allowed us to use the greatest number of techniques to study
these viruses. We believe that the results obtained in these
experiments are representative of what would be observed with the
other cell lines used in this study.
Previous studies have implied that agnoprotein had a role in
viral DNA replication [23,24]. However, JCVCPN is able to
Figure 6. Deletion in the agnogene prevents VP1 expression. Western blots for VP1 were done as described in Figure 2. (A) VP1 levels in Cos-
7 cell lysate 14 days post-transfection. (B) VP1 levels in Cos-7 cells 21 days post-transfection. Levels of VP1 expression are drastically reduced in Mad-1
C-Agno, and expression is rescued by the full length agnogene in CPN M-Agno. Deletion of the agnogene Mad-1 Del results in a greater decrease in
VP1 expression than just the prevention of the protein expression in Mad-1 Pt. Blots are representative of 3 or 4 independent experiments.
doi:10.1371/journal.pone.0080840.g006
Figure 7. Loss of the agnogene results in decreased production of infectious virions. Supernatant was collected from Cos-7 cells 21 days
post-transfection and used to infect naive Cos-7 cells. After 7 days, the cells were analyzed for (A) JCV DNA by QPCR or (B) VP1 expression by flow
cytometry. Deletions in the agnogene in JCVMad-1-infected cells resulted in a significant decrease in JCV genomes/cell and percentage of cells
expressing VP1, while introduction of a full length agnogene into JCVCPN results in a significant increase in the viral load and percentage of cells
expressing VP1. Data is the average of 3 independent experiments. Error bars represent standard deviation. P values were calculated using Wilcoxon
rank test for QPCR data, comparing each virus to its parent virus, either JCVMad-1 or JCVCPN. P-vales for flow cytometry data were calculated using
students t test using the same sets of comparisons. ND is not detected.
doi:10.1371/journal.pone.0080840.g007
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produce levels of DNA similar to JCVMad-1 early after transfection,
with DNA levels decreasing with time. These results suggest that
an agnogene-deletion mutant can indeed replicate DNA, but levels
drop off due to blocks at later steps in infection, thereby preventing
spread within the cell culture. Conflicting studies have associated
agnoprotein with gene expression, with both the loss of
agnoprotein [19,30] or its presence [23,26] suppressing activity
of the late promoter of JCV in different experimental systems.
Additionally, deletion of the full agnogene causes a greater
decrease in VP1 expression than prevention of agnoprotein
expression without deletion of the agnogene DNA [30]. Our data
shows that the deletion in the agnogene of JCVCPN results in a
block in late gene expression, impairing the release of virions
capable of infecting new cells and propagating the infection in cell
culture. This is consistent with the results of Akan et al [30] and
highlights the importance of the agnogene DNA in addition to the
protein it codes for. Further studies are needed to determine the
mechanism of the block in VP1 expression. One possibility is that
a host cell factor which binds to one of the sites in the agnogene,
identified by Akan et al [30], is involved in expression of the late
transcript. Further investigations to identify these cellular proteins
are warranted to determine the mechanism by which they act
during JCV replication. Another potential mechanism is that
deletions in the agnogene somehow alter the splicing or translation
of VP1 from the late mRNA.
Previous studies of JCV deletion mutants lacking agnoprotein
expression have implicated the agnoprotein in genome packaging
and/or virion formation and release, with empty capsids being
produced by viruses lacking the agnoprotein [27,28]. In our study
however, the agnoprotein start codon point mutant was able to
replicate its DNA and produce infectious virions at a level similar
to JCVMad-1in Cos-7 cells, which suggests that at least in these
cells, the agnoprotein is not necessary for formation and release of
virions containing viral genomes.
Archetype RR is typically found in the urine, but the JCVCPN
RR isolated from the brain of the JCVE patient is archetype-like.
Studies of the replication of different forms of RR have shown that
archetype RR form has less active early and late promoters [36].
Surprisingly, our study did not find the archetype-like RR of
JCVCPN to be the primary cause of the decreased levels of late
transcription and VP1 protein expression. Introducing the
archetype-like RR of JCVCPN into JCVMad-1 had little effect on
the ability of the virus to replicate. JCVMad-1 RR introduced into
JCVCPN partially rescues replication, but had a lesser impact than
introduction of a full length agnogene. In fact the archetype-like
RR only has a significant impact on the virus once it has already
been impaired by a deletion in the agnogene, indicating that not
all archetype-like RR forms found in nature lead to lower levels of
viral replication.
While JCVCPN was unable to establish a persistent infection in
our cell culture model, it was found at high levels in the brain of
the JCVE patient. JCVCPN does produce some infectious virions in
cell culture, but at much lower levels than JCVMad-1. This does
not, however, mean that the virus was unable to establish an
infection in the brain of the JCVE patient. There are limitations to
the cell culture model we utilized in this study. First, the infection
in a person can take place on the timescale of years to decades,
while our experiments were done over weeks. Second, this
individual was also infected with a strain of JCV with a full length
agnogene and agnoprotein, which may have influenced the
replication of JCVCPN. Third, it may be that having low levels
of replication in the brain was actually advantageous to the virus
while faced with a healthy immune system, allowing it to
accumulate until the immune system became compromised and
JCVE developed.
After observing the infection of granule cell neurons in JCV
GCN and cortical pyramidal neurons in JCVE, we conducted
studies to determine if infection of neurons by JCV was limited to
these syndromes, or if it is more widespread. Based on staining of
PML brain samples, it is predicted that up to 51% of patients have
granule cell neurons infected by JCV [37]. Additionally, infection
of cortical neurons by JCV in classic PML cases has been observed
with infection present in the gray white junction and gray matter
[38]. These studies demonstrate that infection of neurons occurs in
a large number of PML patients, and is not limited to patients with
JCV GCN or JCVE. Further studies of the molecular composition
of JCV in neurons of patients with classic PML are needed to
determine whether these cells are also infected by JCV-deletion
mutants.
The study of unique pathogenic isolates of JCV, such as
JCVCPN or JCVGCN allows us to decipher the basic biology of JCV
replication using mutations that have arisen naturally during
infection in humans. Our studies of JCVCPN have provided
valuable insights into both the function of the agnogene and
agnoprotein, as well as a naturally occurring variation of the
regulatory region, on JCV replication. Our results have helped
clarify the role of the agnogene and agnoprotein in DNA
replication, transcription and protein expression, demonstrating
that a deletion in the agnogene has a dramatic effect on the
expression of VP1 protein and the production of infectious virions.
Further studies of naturally occurring variants of JCV will
continue to add clarity to our understanding of the biology of
JCV replication and pathogenesis.
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JC virus (JCV) is latent in the kidneys and lymphoid organs of healthy individuals, and its reactivation in
the context of immunosuppression may lead to progressive multifocal leukoencephalopathy (PML). Whether
JCV is present in the brains or other organs of healthy people and in immunosuppressed patients without PML
has been a matter of debate. We detected JCV large T DNA by quantitative PCR of archival brain samples of
9/24 (38%) HIV-positive PML patients, 5/18 (28%) HIV-positive individuals, and 5/19 (26%) HIV-negative
individuals. In the same samples, we detected JCV regulatory region DNA by nested PCR in 6/19 (32%)
HIV-positive PML patients, 2/11 (18%) HIV-positive individuals, and 3/17 (18%) HIV-negative individuals. In
addition, JCV DNA was detected in some spleen, lymph node, bone, and kidney samples from the same groups.
In situ hybridization data confirmed the presence of JCV DNA in the brains of patients without PML. However,
JCV proteins (VP1 or T antigen) were detected mainly in the brains of 23/24 HIV-positive PML patients, in only
a few kidney samples of HIV-positive patients, with or without PML, and rarely in the bones of HIV-positive
patients with PML. JCV proteins were not detected in the spleen or lymph nodes in any study group.
Furthermore, analysis of the JCV regulatory region sequences showed both rearranged and archetype forms in
brain and extraneural organs in all three study groups. Regulatory regions contained increased variations of
rearrangements correlating with immunosuppression. These results provide evidence of JCV latency in the
brain prior to severe immunosuppression and suggest new paradigms in JCV latency, compartmentalization,
and reactivation.
JC virus (JCV) is the etiologic agent of the often fatal brain-
demyelinating disease progressive multifocal leukoencepha-
lopathy (PML) (23a). JCV remains latent in the kidneys, lymph
nodes, and bone marrow of healthy and immunosuppressed
individuals without PML (2, 21, 24) and, upon reactivation, can
cause a lytic infection of oligodendrocytes in the brain, leading
to PML (14). Although JCV is often found in the urine of
healthy individuals (12, 18), it is not usually detected in the
blood of patients without PML (15). The pathway leading to
viral reactivation and replication in the brains of immunosup-
pressed individuals is not well defined. Molecular analysis of
JCV has prompted hypotheses on how the virus emerges from
latency and becomes pathogenic. JCV has a double-stranded,
circular DNA of 5,130 bp. While the coding region is well
conserved, the noncoding regulatory region (RR) of JCV is
hypervariable. The kidneys and urine usually contain JCV with
a well-conserved, nonpathogenic RR which is called the “ar-
chetype” (30). The JCV RR detected in the brains and the
cerebrospinal fluid (CSF) of PML patients usually has dupli-
cations, tandem repeats, and deletions and has been called
“rearranged” compared to the archetype. Although it is not
clear which form of JCV RR is propagated at the time of
primary infection, it has been hypothesized that JCV with the
archetype RR remains confined in the kidneys of most healthy
individuals and that rearrangements which confer neurotro-
pism need to occur prior to viral migration to the brain to
destroy the myelin-producing glial cells. Whether JCV can
reach the brain and establish latency in the central nervous
systems (CNS) of otherwise-healthy individuals are matters of
debate. While some investigators detected JCV DNA in 28 to
68% of frozen (8, 27) and 18 to 71% of formalin-fixed, paraf-
fin-embedded (FFPE) (4, 7, 20) brain samples of patients with-
out PML, others reported negative results (3, 6, 10, 23).
Clearly, characterizing JCV sites of latency is imperative in the
prevention of viral reactivation and PML. Recently, a group of
PML patients has emerged among those treated with mono-
clonal antibodies, including natalizumab (13, 17, 26), efali-
zumab (16, 19a), and rituximab (5), for multiple sclerosis,
psoriasis, hematological malignancies, and rheumatologic
diseases. Mechanisms of JCV reactivation in these patients has
yet to be defined. To better understand JCV organ tropism and
characterize the types of JCV RRs in different compartments,
we used archival pathology samples to detect JCV DNA and
proteins and to analyze JCV RRs in various organ systems in
HIV-positive individuals with and without PML and in HIV-
negative subjects.
MATERIALS AND METHODS
Specimens. Formalin-fixed, paraffin-embedded (FFPE) samples of brain, kid-
ney, vertebral bone, spleen, and lymph nodes from HIV-positive patients with or
without PML and HIV-negative patients without PML were obtained from the
National NeuroAIDS Tissue Consortium (NNTC). All brain samples in the
HIV-positive and HIV-negative groups were sections from the cerebrum. Brain
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Medical Center, E/CLS 1005, 330 Brookline Ave., Boston, MA 02215.
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sections containing PML lesions were studied from the HIV-positive PML
group. Of the 24 samples, 13 were from the cerebellum and 11 from the cere-
brum.
Samples of brain, brain stem, kidney, spleen, and lymph nodes from a PML
patient were obtained at autopsy. Half of the tissues were frozen for further
analysis, and the other half were fixed in formalin and paraffin embedded for
further analysis. Prior consent was obtained for the study protocol, approved by
the Beth Israel Deaconess Medical Center Institutional Review Board of Human
Studies.
DNA extraction from formalin-fixed, paraffin-embedded samples. Ten 5-m-
thick slices from FFPE blocks were collected into an Eppendorf tube, and a new
microtome blade was used for each block. DNA was extracted after deparaf-
finization in 100% xylene for 10 min and then in 50% xylene and 50% ethanol for
10 min, followed by 100% ethanol for 10 min twice, all performed at 56°C. The
dried sample was dissolved in 200 l of tissue lysis solution, part of the Qiagen
DNeasy blood and tissue kit (Qiagen). DNA was extracted by following the
instructions of the manufacturer.
DNA extraction from frozen samples. Freshly frozen autopsy samples were
kept frozen at 80°C until use. DNA extraction was performed with a Qiagen
DNeasy blood and tissue kit (Qiagen).
qPCR. We used quantitative JCV PCR (qPCR) to detect and quantify JCV
DNA in all samples as previously described (22). The limit of detection of the
assay was 10 copies of JCV/g of cellular DNA. All samples underwent two
qPCR analyses with the same primers and conditions. The amount of DNA used
per reaction ranged from 6 to 500 ng, and the results are expressed in numbers
of copies of JCV/g of cellular DNA. In the first qPCR analysis, we tested all
samples in duplicate, and a sample was considered positive if at least one of the
two wells had detectable DNA. In the second qPCR analysis, we tested the same
samples in triplicate and considered positive those for which at least two of the
three wells had detectable DNA. We then combined data from both analyses and
considered positive those samples where JCV DNA could be detected in both
the duplicate- and the triplicate-qPCR analysis.
Cloning and sequencing of the JCV RR. We amplified the JCV RR sequences
by nested PCR using outer primers JRE1 (nucleotides [nt] 4989 to 5009) and
LP2 (nt 537 to 518) and inner primers RREV (nt 310 to 291) and RFOR (nt 5085
to 5104) as described elsewhere (19). For each PCR, 20 pmol of primers was used
in 30 cycles of amplification, with an annealing temperature of 63°C. The amount
of DNA used in the reaction mixture ranged from 2 to 789 ng. The PCR products
corresponding to the expected size were cloned with a TOPO-TA cloning kit
(Invitrogen, Carlsbad, CA). Up to 10 clones for each PCR product were analyzed
by restriction enzyme digestion and electrophoresis. We sequenced up to 10
clones of amplified fragments with the expected length. The DNA sequence was
obtained on an ABI 3730xl sequencer (Applied Biosystems). Sequence analyses
were performed using the Lasergene software MegAlign 7.1 (DNAStar, Madi-
son, WI).
IHC. The expression of JCV proteins was determined by immunohistochem-
istry (IHC) staining using the anti-JCV antibody VP1 PAB597 (a generous gift
from Walter Atwood) and the anti-large T antigen (T Ag) (simian virus 40
[SV40] Tag v-300; Santa Cruz Biotechnology), which cross-reacts with JCV, as
previously described (28).
ISH. The presence of JCV DNA was determined by in situ hybridization
(ISH), using a biotinylated JCV DNA probe (Enzo Life Sciences) as described
previously (29), with modifications of the tissue preparation with antigen-re-
trieval solution (Dako) at 95°C for 20 minutes, followed by a 0.3% hydrogen
peroxidase wash (Sigma) at room temperature for 60 minutes and then by
proteinase K (50 ng/ml; Enzo Life Sciences) digestion at room temperature for
5 min. GenPoint (Dako), a catalyzed-signal amplification system, was used for
staining.
Histological examination. All slides were stained with hematoxylin and Luxol
fast blue solution to determine cellular structures and PML lesions. After depar-
affinization and hydration in up to 95% ethanol, slides were placed in Luxol fast
blue solution at 56°C overnight.
Statistical analysis. Correlation between JCV DNA detection in each patient
and organ group was determined using Fisher’s two-tailed exact test.
RESULTS
JCV DNA detection in FFPE tissues compared to frozen
tissues. To determine the sensitivity of qPCR in detecting JCV
large T DNA in formalin-fixed, paraffin-embedded (FFPE)
tissues, we analyzed several organs from a PML patient that
were either FFPE or frozen at 80°C (Table 1). All of the
organs tested, including the brain, brain stem, kidney, spleen,
and lymph nodes of this PML patient, contained detectable
JCV DNA in samples obtained from both types of tissue prep-
arations. Brain stem, spleen, and lymph node extractions had
comparable quantities of detected JCV DNA in both prepa-
rations. However, the JCV DNA extracted from brain and
kidney of FFPE tissues had 6-log- and 2-log-smaller viral loads,
respectively, than their frozen counterparts. These results in-
dicate that while FFPE tissues can be used for qualitative
assessment of JCV DNA in tissues, quantitative measures may
underestimate the actual viral burden in these specimens.
JCV DNA detection in brain and other organs. To deter-
mine the prevalence of JCV in different body compartments,
we first performed qPCR detection of JCV large T DNA in the
brain tissue of HIV-positive PML patients, as well as of HIV-
positive and HIV-negative subjects (Table 2). We detected
JCV large T DNA in 9/24 (38%) of the HIV-positive PML
group, compared to 5/18 (28%) of the HIV-positive and 5/19
TABLE 1. Quantification of JCV DNA by qPCR in the
brain, brain stem, kidney, spleen, and lymph node
extracted from a PML patient
Sample
typea
No. of JCV copies/g of DNA in:
Brain Brain stem Kidney Spleen Lymphnode
FFPE 194 6  108 249 725 1.41  103
Frozen 1.00 108 4.70  109 1.10  104 8,309 1.57  103
a Frozen, frozen at 80°C; FFPE, formalin fixed, paraffin embedded.
TABLE 2. Detection of JCV DNA in the large T and regulatory regions (RR) of HIV-positive PML, HIV-positive, and HIV-negative
patients’ brains, kidneys, bones, spleens, and lymph nodes
DNA type Group
No. positive/total no. of specimens tested (%)
Brain Kidney Bone Spleen Lymphnode
Large T Ag HIV positive/PML 9/24 (38) 1/11 (9) 0/15 4/10 (40) 1/4 (25)
HIV positive 5/18 (28) 0/11 2/11 (18) 1/9 (11) 3/7 (43)
HIV negative 5/19 (26) 0/12 1/12 (8) 2/9 (22) NAa
RR HIV positive/PML 6/19 (32) 2/5 (40) 3/4 (75) 4/10 (40) 2/2 (100)
HIV positive 2/11 (18) 0/3 3/4 (75) 7/7 (100) 4/6 (67)
HIV negative 3/17 (18) 0/1 0/5 3/9 (33) NA
a NA, not available.
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(26%) of the HIV-negative groups (P  0.78). The JC viral
loads ranged between 38 and 3,464 (mean, 910) copies/g of
DNA in the HIV-positive PML group, 111 and 9,254 (mean,
3,033) copies/g in the HIV-positive group, and 377 and 1,457
(mean, 768) copies/g in the HIV-negative group.
Among the five HIV-positive patients who had detectable
JCV large T DNA in their brain by qPCR, four had normal
brain histology and one had a poorly differentiated metastatic
tumor on pathological examination. Three of these patients
had plasma HIV loads of 54,439,75,000, and400 copies/ml
and corresponding CD4 counts of 8, 13, and 663 cells/l. One
other patient had a CD4 count of 25 cells/l. Among the five
HIV-negative subjects with detectable JCV DNA, three had
amyotrophic lateral sclerosis (ALS) and the other two did not
have any brain pathology on examination.
JCV large T DNA was detected in the kidney of only one
HIV-positive PML patient and in the bone samples of one
HIV-positive and one HIV-negative subject. JCV DNA was
detected in the spleen and lymph nodes of few individuals in all
available study groups. To further clarify JCV DNA detection
in these FFPE tissues, we also amplified the JCV RR by nested
PCR with available samples (Table 2). Detection of the am-
plified RR product by gel electrophoresis was confirmed by
cloning and sequencing. In the brain tissues, detection of the
JCV RR was comparable to detection of JCV large T, with
prevalences of 6/19 (32%) in HIV-positive PML patients and
2/11 (18%) and 3/17 (18%) in HIV-positive and HV-negative
patients, respectively (P  0.67), but in the kidney, bone,
spleen, and lymph nodes, RR detection by nested PCR ex-
ceeded that of large T DNA. However, only 1/11 brain, 1/5
kidney, 2/6 bone, and 1/26 spleen samples with detectable RRs
by nested PCR had no large T detection by qPCR in any of the
runs. The rest of the samples had at least one qPCR run that
was positive for large T but did not meet the criteria for a
positive qPCR result.
In a separate analysis, the large T and RR DNA detections
showed no significant differences in the rates of detection of
JCV DNA in the brains of HIV-positive PML patients com-
pared to the HIV-positive and HIV-negative groups. Detec-
tion of large T DNA in the brain was not significantly more
frequent than in the extraneural organs combined for any of
the three groups (P  0.07, 0.26, and 0.12). Similarly, the
detection of regulatory region DNA in the brains of HIV-
positive patients with PML and HIV-negative patients was also
not significantly more frequent than in the extraneural organs
combined (P  0.22 and 1). In the HIV-positive group, how-
ever, the JCV regulatory region DNA was more frequently
found in the combined extraneural organs than in the brain
(P 0.009). These results showed that JCV DNA is detectable
in multiple organs and that JCV DNA is present in the brains
of patients both with and without immunosuppression.
JCV VP1 and T Ag protein detection in brain and other
organs. We performed IHC on all available tissues. We found
that JCV large T antigen (T Ag), a regulatory protein ex-
pressed early in the viral life cycle, was detected in the brains
of 21 of the 24 HIV-positive PML patients (Table 3) and that
the major capsid protein VP1, indicating the presence of ma-
ture viral particles, was expressed in the lesions of 20/24 (83%)
HIV-positive PML patient brain samples. All together, 23 of
the 24 HIV-positive PML brain samples expressed either one
or both of the JCV proteins tested. One brain sample showed
extensive demyelination but did not stain for VP1 or T Ag
protein. We also found T Ag in one brain sample each from the
HIV-positive and -negative control groups. As expected, JCV
proteins were significantly more frequently expressed in the
brains of PML patients than in the HIV-positive and HIV-
negative groups (P  0.001). Furthermore, T Ag were de-
tected at low levels in kidney samples from the HIV-positive
PML and HIV-positive groups. T Ag and VP1 were rarely
detected in the bone samples of the HIV-positive PML group
only. T Ag was not detected in the extraneural organs of the
TABLE 3. Detection of JCV large T Ag and capsid protein VP1 in brain, kidney, bone, spleen, and lymph node FFPE samples from
HIV-positive PML, HIV-positive, and HIV-negative individuals
Sample type Group
No. positive/total no. of samples tested (%)a
Large T Ag Capsid protein VP1 T Ag or VP1
Brain HIV positive/PML 21/24 (88) 20/24 (83) 23/24 (96)
HIV positive 1/18 (6) 0/18 1/18 (6)
HIV negative 1/19 (5) 0/19 1/19 (5)
Kidney HIV positive/PML 1/11 (9) 0/11 1/11 (9)
HIV positive 3/11 (27) 0/11 3/11 (27)
HIV negative 0/12 0/12 0/12
Bone HIV positive/PML 1/13 (8) 1/13 (8) 2/13 (15)
HIV positive 0/11 0/11 0/11
HIV negative 0/12 0/12 0/12
Spleen HIV positive/PML 0/9 0/9 0/9
HIV positive 0/9 0/9 0/9
HIV negative 0/9 0/9 0/9
Lymph node HIV positive/PML NA NA NA
HIV positive 0/7 0/7 0/7
HIV negative NA NA NA
a NA, not available.
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HIV-negative group, and VP1 protein was not detected in any
organs of this group (Fig. 1).
All five HIV-positive patients with detectable JCV DNA in
the brain had negative staining for VP1, and the patient with
an undifferentiated tumor had a brain sample which stained
positive for T Ag. All five HIV-negative patients with detect-
able JCV DNA in the brain showed no expression of VP1
protein, and one of the five with normal brain pathology had
rare cells expressing T Ag.
In situ hybridization of JCV DNA. To further clarify the
discrepant results between JCV DNA detection by qPCR and
JCV protein detection by IHC, we performed in situ hybrid-
ization (ISH) for JCV DNA on a subset of the FFPE tissue
sections (Fig. 2). In the HIV-positive control group, the brain
tissue sections of 3 of the 5 patients who were positive for JCV
by qPCR exhibited rare cells (1 to 2 cells per tissue section)
which also stained JCV positive by ISH. As described above,
only 1 of these 5 patients had rare cortical cells expressing T
Ag, and the ISH was also positive in this case. Serving as
controls, 5 of 5 other HIV-positive patients with negative
qPCR and IHC results also showed negative ISH results (data
not shown). In the HIV-negative control group, 3 of the 5
patients with positive qPCR results also had 1 to 10 cells per
tissue section that stained positive by ISH, including one with
positive IHC T Ag staining in the same distribution. Further-
more, three additional HIV-negative control patients with un-
detectable JCV DNA by qPCR and proteins detected by IHC
also had negative ISH results (data not shown). In HIV-posi-
FIG. 1. Immunohistochemical staining of JCV proteins Vp1 and T Ag in brain, kidney, and bone in HIV-positive PML patients. Numerous cells
(arrows) in the brain stained positive for VP1 (A) and TAg (B). While no VP1 protein was detected in the kidney (C), JCV-infected kidney tubular
epithelium cells (arrows) stained positive for T Ag (D). In the bone, rare cells (arrows) stained positive for both VP1 (E) and T Ag (F). All the
images are magnified 40-fold, and the scale bar is 100 m.
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tive patients with PML, samples that had detectable JCV DNA
by qPCR and JCV proteins by IHC all had positive ISH results.
Finally, there were 15/24 brain samples in this group with
discrepant results; each sample had at least one cell staining
positive for JCV protein by IHC staining but did not meet the
criteria for qPCR positivity. Of those 15 samples, 8 were pos-
itive for JCV DNA by ISH; therefore, compared to that of
IHC, the sensitivity of ISH to detect JCV in PML lesions was
8/15 (53%). The one HIV-positive PML patient brain sample
with demyelinated lesions, but no VP1 or T Ag IHC staining
and undetectable JCV DNA, was positive by ISH. Lastly, in all
ISH-positive cases, JCV-infected cells were located in the
brain parenchyma and not inside identifiable blood vessels.
JCV regulatory region analysis. Samples that were positive
for JCV DNA on the first duplicate analysis by qPCR were
selected to be tested for the JCV regulatory region (RR) in a
nested PCR assay (Table 4). We obtained RR sequences from
39 samples (11 brains, 14 spleens, 6 bones, 6 lymph nodes, 2
kidneys) from 27 patients (12 PML, 10 HIV-positive, and 5
HIV-negative). Whenever possible, 10 clones from each nest-
ed-PCR-positive RR sample were sequenced, with an average
of 8 clones per sample (311 clones total).
The RR forms were classified into four types as previously
described (11). Type I-S has a single 98-base-pair unit, and
type I-R has repeats of this 98-base-pair unit, with various
deletions, as seen in the JCV Mad-1 and Mad-4 strains; both of
FIG. 2. In situ hybridization (ISH) detection of JCV-positive cells in the brain samples of HIV-positive PML, HIV-positive, and HIV-negative
individuals compared to the immunohistochemical staining detection of JCV VP1 proteins in the same patients. Positive VP1 protein staining in
JCV-infected cells (arrows) in an HIV-positive PML individual (A) corresponds to positive ISH for JCV DNA (arrows) in the same individual (B).
(C) JCV VP1 protein is not detected in the brain of an HIV-positive individual. (D) However, ISH detected rare cells harboring JCV DNA (arrow)
in this patient. (E) JCV VP1 protein is not detected in an HIV-negative individual. (F) However, ISH showed rare JCV DNA-positive cells (arrow).
The images are magnified 40-fold, and the insets are magnified 100-fold. Scale bar  100 m.
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these types have no inserts. Conversely, type II-S has a single
98-base-pair unit and one 23- and one 66-base-pair insert, as
seen in the archetype, and type II-R has repeats of this 98-
base-pair unit and inserts with various mutations, also called
rearranged RRs. In the brains of HIV-positive PML patients,
the RRs were significantly more frequently of the types I-R
and II-S (P  0.007) (Fig. 3). All the RRs from the kidneys of
two HIV-positive PML patients were of type I-R. While the
bone RRs were of all four types, the greatest numbers of
patients and clones were obtained from the spleen. Finally, in
the HIV-negative group, only one sequence representation was
detected in each of the three RR types (I-S, I-R, II-S), whereas
in both the HIV-positive PML and HIV-positive groups, both
type I-R and type II-S clones with several different sequence
rearrangements were detected. This indicates that JCV RR
rearrangements occur more frequently with increased immu-
nosuppression.
In 9 of the 27 patients, we were able to obtain RR sequences
from more than one organ. We cloned and sequenced the RRs
from three organs in three patients; in an HIV-positive patient
with PML, we detected the I-S type in the brain and bone, the
I-R type in the brain, and the II-S type in the lymph node. In
an HIV-positive patient, we found type II-S in the bone and a
mixture of types I-S and I-R in both the spleen and lymph
node. Another HIV-positive individual had type II-R in the
bone and both types I-R and II-S in the spleen and lymph
nodes. We obtained sequences from two organs in six patients,
including three HIV-positive PML patients. In one HIV-pos-
itive patient with PML, we found type I-R in both the brain and
kidney. In two other HIV-positive PML cases, we detected RR
sequences in the brain and spleen, including types I-R and II-S
in the brain and type II-S in the spleen in one of them and type
I-R in the brain and types I-S and I-R in the spleen in the
other. We obtained sequences from two organs in two HIV-
positive control patients. In both cases, we found JCV RRs in
spleen and lymph node, with one patient having types I-R and
II-S in both organs and the other having types I-R and I-S in
both organs. Finally, RR sequences from two organs in one
HIV-negative control patient showed types I-S and I-R in the
brain and type II-S in the spleen. In all cases where both spleen
and lymph node sequences were obtained from the same pa-
tient, the same types of RRs were present in both organs.
DISCUSSION
Our results suggest that JCV can spread throughout the
body in immunosuppressed and immunocompetent individuals
alike and that it is present in the brains of individuals without
PML. Using FFPE tissues allowed us access to archival mate-
rial from PML patients suitable for our study. However, to
estimate the yields of JCV DNA extracted from FFPE sam-
ples, we first compared JCV DNA detection in freshly frozen
tissues to that in FFPE tissues obtained at autopsy from the
same PML patient seen at our institution. These experiments
indicated that although the PCR results were concordant, JC
viral load was 1 to 6 logs lower in FFPE tissues than in freshly
frozen tissues. However, the main demyelinating lesions were
located in the brain stem of this PML patient. The FFPE
tissues from the brain stem showed only a 1-log decrease in JC
virus load from that in the frozen sample, whereas the FFPE
tissues from the brain had a 6-log decrease compared with the
viral load in the frozen sample. This may be due to inhomo-
geneous spread of the virus within the brain areas sampled for
frozen and FFPE tissue analysis.
Although the availability of FFPE tissues allowed us to test
a large number of cases, the frequency of DNA detection was
likely underestimated. This was demonstrated by finding either
JCV large T Ag or RR DNA in only 50% of PML cases, while
JCV proteins could be detected in 96% of them. The archival
samples used in the study groups were available autopsy sam-
ples from patients with various lengths of survival after the
diagnosis of PML. Therefore, the lower frequency of JCV
TABLE 4. Types of JCV RRs found in brain, kidney, bone, spleen, and lymph node FFPE samples from
HIV-positive PML, HIV-positive, and HIV-negative individuals
Sample type Group No. ofpatients
No. of
clones
No. of RRs of the indicated type/no. of clones sequenced (%)a
I-S I-R II-S II-R
Brain HIV positive/PML 6 28 3/28 (11) 13/28 (46) 12/28 (43) 0
HIV positive 2 19 4/19 (21) 15/19 (79) 0 0
HIV negative 3 21 9/21 (43) 12/21 (57) 0 0
Kidney HIV positive/PML 2 19 0 19/19 (100) 0 0
HIV positive 0 0 NA NA NA NA
HIV negative 0 0 NA NA NA NA
Bone HIV positive/PML 3 20 10/20 (50) 10/20 (50) 0 0
HIV positive 3 25 0 6/25 (24) 9/25 (36) 10/25 (40)
HIV negative 0 0 NA NA NA NA
Spleen HIV positive/PML 4 32 2/32 (6) 16/32 (50) 14/32 (44) 0
HIV positive 7 65 10/65 (15) 43/65 (66) 12/65 (18) 0
HIV negative 3 30 0 0 30/30 (100) 0
Lymph node HIV positive/PML 2 19 0 9/19 (47) 10/19 (53) 0
HIV positive 4 33 3/33 (9) 26/33 (79) 4/33 (12) 0
HIV negative NA NA NA NA NA NA
a NA, not available.
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DNA detection by PCR can be due to the fact that the viral
burden in the lesions decreased in time, commensurate with
the destruction of glial cells and demyelination. Another pos-
sibility is that many of these autopsy samples had been in
storage for as long as 13 years and had been incubated for
extended periods of time in formalin prior to being embed-
ded, which affects the integrity and quality of the extracted
DNA. Using archival samples is not ideal, but it was the only
way to study a rare and deadly disease such as PML.
The samplings of tissues used in our study represent a small
portion of the organ, thus subjecting our analysis to sampling
bias. Specifically, prior studies demonstrated detection of JCV
DNA in the urine of up to 30% of healthy individuals (12, 18),
far greater than the detection of JCV DNA in the kidneys (9%
in the HIV-positive group with PML and none in the HIV-
positive and HIV-negative groups without PML) in our study.
This discrepancy is due to the fact that urine represents a
sampling of the entire kidney instead of focal sites, as demon-
strated by others (21). However, this bias is balanced by com-
paring only focal samples in all organs. Future studies should
determine whether JCV spread is homogeneous in each organ.
We took several measures to ensure the integrity of our data
and to eliminate the possibility of contaminations. All labora-
tory procedures were performed only after working surfaces
were cleaned with DNase. DNA extractions from all specimens
were performed in laboratory space entirely separate from
areas of PCR amplification. All samples were deidentified and
processed in batches by researchers. We also performed two
separate qPCR experiments on each sample. In the first qPCR
experiment, we analyzed the samples in duplicate. Samples
were considered positive if one out of two tubes had detectable
JCV DNA. We then repeated the qPCR experiment, analyzing
all of the same samples in triplicate. In this experiment, sam-
ples were considered positive if two out of the three tubes had
detectable JCV DNA. Combining the results of two separate
qPCR experiments, we set the stringent criteria that a sample
was considered to have detectable JCV DNA only if it was
considered positive in both qPCR experiments and thus had
JCV DNA in at least 3 of 5 replicates. These criteria may have
contributed to a lower qPCR sensitivity. Furthermore, several
PML patient lesions had extensive demyelination and only a
few remaining JCV-infected cells, which may explain some of
the negative PCR results. In these cases, ISH seemed to be a
more robust method than PCR to demonstrate the presence of
rare cells harboring JCV DNA in FFPE specimens from PML
patient lesions. We therefore employed ISH as an additional
technique to help us decipher JCV DNA detection in these
tissues. Our data showed that stringent qPCR criteria for the
detection of JCV DNA may have in some cases assigned neg-
ative results to samples. It is also likely that the JCV DNA
from rare positive cells detected by ISH was diluted within
genomic DNA and dropped below the detection level of the
qPCR assay.
While ISH confirmed the results for all the qPCR-positive
samples in the HIV-positive PML group, only 3 of the 5 large
T DNA-positive brains from the HIV-positive and HIV-nega-
tive groups were positive by ISH staining. As shown in Fig. 2,
ISH detected rare positive cells in the latter two groups. In the
brains of PML patients, the higher sensitivity of ISH may have
been due to the fact that JCV DNA was more abundant in
these samples and could readily be detected by ISH. In the
brain of non-PML patients, some qPCR-positive cases were
ISH negative. Since the piece of tissue used to extract DNA for
qPCR is not the same as the sections used for ISH, this ap-
parent discrepancy may be caused by sampling in areas of low
JCV burden. This most likely contributed to the lower sensi-
tivity of ISH in the HIV-positive and HIV-negative groups
than in the HIV-positive PML group.
We did not expect to detect JCV DNA in the brains of a
third of the HIV-positive and negative patients without PML
and therefore performed ISH to verify these findings. ISH
confirmed the presence of rare JCV-infected cells in most of
these cases. However, only one subject in each HIV-positive
and HIV-negative group without PML had expression of JCV
T Ag, but not VP1, in the brain. These results suggest that JCV
DNA may remain latent in a limited number of cells in many
immunocompetent and immunosuppressed individuals alike,
which may lead to an abortive infection with occasional expres-
sion of the T Ag only, without the virus undergoing a full
replicative cycle. We have recently reported 38 cases of PML
occurring in individuals with minimal or occult immunosup-
pression (9). It is therefore possible that in those patients, JCV
was already latent and reactivated from within the brain.
The similar prevalences of JCV DNA in the brains of all
three study groups indicate that the presence of JCV DNA in
the brain is not associated with immunosuppression. A prior
study has also shown that JCV DNA is present in 44% of brain
samples of HIV-positive patients without PML and 33% of
brain samples of HIV-negative patients without PML (25).
To determine the extent of JCV spread in the body, we also
tested kidney, bone, spleen, and lymph node samples. PCR
analysis, including detection of JCV large T and RR DNA,
indicated that JC virus may spread throughout the body in both
immunocompetent and immunosuppressed individuals with
and without PML. However, JCV protein expression was sel-
dom found in the kidneys of HIV-positive patients, with or
without PML, and only occasionally in bone samples from
HIV-positive PML patients. Taken together, these data dem-
onstrate that although JCV DNA is present in various organs,
FIG. 3. Sequencing results of the JCV RRs from the brains, kidneys, bones, spleens, and lymph nodes of HIV-positive patients with PML (A),
HIV-positive patients (B), and HIV-negative patients (C). The nucleotide numbers are based on the prototype MAD-1 sequence. Each 98-bp unit
is represented by an open box. The TATA box is represented by TATA. The 23-bp insert and 66-bp insert characteristic of archetype (II-S)
sequences are represented as open boxes labeled “23 bp” and “66 bp,” respectively. Gray lines represent the region downstream of the 98-bp units.
Dotted lines represent deletions or regions not present. Asterisks represent single nucleotide point mutations or deletions. Letters indicate
nucleotides. MAD-1 contains an adenine at positions 85 and 183, compared with all other sequences, which contain guanine at these positions.
The types of RRs are indicated. These numbers represent total numbers of clones from all patients in the category and may include multiple clones
of the type from a single patient. ori, origin of replication. The black triangles indicate the locations of the drawn fragment insert sites.
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active JCV replication and protein expression occur preferen-
tially in the brains of patients who develop PML.
Lastly, the sequencing of JCV RR from all groups contained
multiple types and mutations, which further support isolation
and amplification of real physiological samples and not labo-
ratory strains. The RR of JCV, containing transcription control
factor binding sites, is closely associated with pathogenesis.
Although the exact mechanism of rearranging and the effects
of rearrangements on pathogenesis have yet to be fully delin-
eated, our data showed that both the archetypal and rear-
ranged forms can be detected in both the brain and kidney. We
describe novel detection of the I-S, II-S, and I-R types of RRs
in the spleens of patients in all categories. Overall, the HIV-
negative group had only one I-R variant and one II-S variant,
while the HIV-positive group without PML had three I-R
variants, three II-S variants, and one II-R variant, and the
HIV-positive group with PML had three I-R variants and two
II-S variants. These results suggest that active replication of
JCV in immunosuppressed patients contributed to the multi-
ple forms of the RR present in all organs. These results invite
us to reappraise the classic assignment of the rearranged I-R
type of RR of JCV in the brain and the archetype II-S type in
the kidney. Multiple types of RRs can be detected in all organs
in PML patients as well as in HIV-positive and HIV-negative
patients without PML. However, HIV-negative patients had
fewer RR variations detected in only two organs, indicating
that immunosuppression most likely enhanced the rearrange-
ments in the RR variations detected in multiple organs in the
HIV-positive groups both with and without PML.
Our results confirm and expand the results of previous stud-
ies showing the presence of JCV DNA in the brains of indi-
viduals without PML (4, 8, 25, 27). We have performed a
comprehensive study of a large number of HIV-positive PML
patients as well as HIV-positive and -negative individuals using
several techniques to detect the presence of JCV DNA and
protein in several organs. The JCV RRs in the brains of HIV-
negative patients are of the I-S and I-R types, while spleens
had the II-S type. Therefore, it is possible that primary infec-
tion with JCV is carried out with a mixture of virions harboring
a variety of RR types. Thereafter, JCV with the II-S type of RR
may preferentially establish latency in kidney epithelium cells,
while JCV with the I-R and II-R RR types establishes latency
in the brain. In the context of immunosuppression, JCV reac-
tivates both in the brain and in the kidney, producing multiple
forms of RRs in all organs.
Our findings of both JCV large T DNA and regulatory
region DNA in the brains of individuals without PML demon-
strate that JCV is latent in the brains of patients without HIV
or PML. In these people, the large T Ag is sometimes ex-
pressed but the viral capsid protein VP1 is not. It is not clear
if JCV first enters the central nervous system during primary
infection. Further studies are needed to show whether the
latent JCV strains present in the brain can reactivate under
immunosuppression and cause PML. Alternatively, PML may
also result from reactivated extraneural JCV strains, which
then cross the blood-brain barrier. In conclusion, by demon-
strating the presence of JCV DNA in the brains of patients
without PML, we have gained new insights into JCV latency,
compartmentalization, and reactivation. A better understand-
ing of JCV latency in the brain will help in devising strategies
to prevent its reactivation in HIV-infected patients and those
treated with immunomodulatory medications.
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